UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)



ý	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June~~September 30, 2017



¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-31719

MOLINA HEALTHCARE, INC.

(Exact name of registrant as specified in its charter)



Delaware		13-4204626
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

200 Oceangate, Suite 100 Long Beach, California		90802
(Address of principal executive offices)		(Zip Code)

(562) 435-3666

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ý No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer	ý	Accelerated filer	¨

Non-accelerated filer	¨ (Do not check if a smaller reporting company)	Smaller reporting company	¨
		Emerging growth company	¨



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act.
	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ¨ No ý

The number of shares of the issuer’s Common Stock, $0.001 par value, outstanding as of ~~July 28,~~October 27, 2017, was approximately ~~57,118,000.~~57,094,000.

MOLINA HEALTHCARE, INC. FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED ~~June~~September 30, 2017

TABLE OF CONTENTS



	Page
Financial Statements	3
Management’s Discussion and Analysis of Financial Condition and Results of Operations	3739
Controls and Procedures	5763
Legal Proceedings	5965
Risk Factors	5965
Unregistered Sales of Equity Securities and Use of Proceeds	6065
Exhibits	6166
Signatures	6267

CROSS-REFERENCE INDEX


ITEM NUMBER	ITEM NUMBER	Page	ITEM NUMBER	Page

PART I - Financial Information	PART I - Financial Information		PART I - Financial Information

1.	Financial Statements	3	Financial Statements	3

2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	37	Management’s Discussion and Analysis of Financial Condition and Results of Operations	39

3.	Quantitative and Qualitative Disclosures About Market Risk	52	Quantitative and Qualitative Disclosures About Market Risk	57

4.	Controls and Procedures	57	Controls and Procedures	63

Part II - Other Information	Part II - Other Information		Part II - Other Information

1.	Legal Proceedings	59	Legal Proceedings	65

1A.	Risk Factors	59	Risk Factors	65

2.	Unregistered Sales of Equity Securities and Use of Proceeds	60	Unregistered Sales of Equity Securities and Use of Proceeds	65

3.	Defaults Upon Senior Securities	Not Applicable.	Defaults Upon Senior Securities	Not Applicable.

4.	Mine Safety Disclosures	Not Applicable.	Mine Safety Disclosures	Not Applicable.

5.	Other Information	Not Applicable.	Other Information	Not Applicable.

6.	Exhibits	61	Exhibits	66

	Signatures	62	Signatures	67

FINANCIAL STATEMENTS

MOLINA HEALTHCARE, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS


	Three Months Ended June 30,					Six Months Ended June 30,					Three Months Ended September 30,					Nine Months Ended September 30,
	2017			2016		2017			2016		2017			2016		2017			2016
	(In millions, except per-share data) (Unaudited)										(In millions, except per-share data) (Unaudited)
Revenue:
Premium revenue	$	4,740		$	4,029	$	9,388		$	8,024	$	4,777		$	4,191	$	14,165		$	12,215
Service revenue	129			135		260			275		130			133		390			408
Premium tax revenue	114			109		225			218		106			127		331			345
Health insurer fee revenue	—			76		—			166		—			85		—			251
Investment income and other revenue	16			10		30			19		18			10		48			29
Total revenue	4,999			4,359		9,903			8,702		5,031			4,546		14,934			13,248
Operating expenses:
Medical care costs	4,491			3,594		8,602			7,182		4,220			3,748		12,822			10,930
Cost of service revenue	124			116		246			243		123			119		369			362
General and administrative expenses	405			351		844			691		383			343		1,227			1,034
Premium tax expenses	114			109		225			218		106			127		331			345
Health insurer fee expenses	—			50		—			108		—			55		—			163
Depreciation and amortization	37			34		76			66		33			36		109			102
Impairment losses	72			—		72			—		129			—		201			—
Restructuring and separation costs	43			—		43			—		118			—		161			—
Total operating expenses	5,286			4,254		10,108			8,508		5,112			4,428		15,220			12,936
Operating (loss) income	(287		)	105		(205		)	194		(81		)	118		(286		)	312
Other expenses (income), net:
Other expenses, net:
Interest expense	27			25		53			50		32			26		85			76
Other income, net	—			—		(75		)	—		—			—		(75		)	—
Total other expenses (income), net	27			25		(22		)	50
Total other expenses, net											32			26		10			76
(Loss) income before income tax (benefit) expense	(314		)	80		(183		)	144		(113		)	92		(296		)	236
Income tax (benefit) expense	(84		)	47		(30		)	87		(16		)	50		(46		)	137
Net (loss) income	$	(230	)	$	33	$	(153	)	$	57	$	(97	)	$	42	$	(250	)	$	99

Net (loss) income per share:
Basic	$	(4.10	)	$	0.58	$	(2.74	)	$	1.02	$	(1.70	)	$	0.77	$	(4.44	)	$	1.79
Diluted	$	(4.10	)	$	0.58	$	(2.74	)	$	1.01	$	(1.70	)	$	0.76	$	(4.44	)	$	1.77

CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME


	Three Months Ended June 30,					Six Months Ended June 30,					Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016		2017			2016		2017			2016			2017			2016
	(Amounts in millions) (Unaudited)										(Amounts in millions) (Unaudited)
Net (loss) income	$	(230	)	$	33	$	(153	)	$	57	$	(97	)	$	42		$	(250	)	$	99
Other comprehensive income:
Unrealized investment gain	—			4		1			13
Unrealized investment gain (loss)											1			(3		)	2			10
Less: effect of income taxes	—			2		—			5		1			(2		)	1			3
Other comprehensive income, net of tax	—			2		1			8
Other comprehensive (loss) income, net of tax											—			(1		)	1			7
Comprehensive (loss) income	$	(230	)	$	35	$	(152	)	$	65	$	(97	)	$	41		$	(249	)	$	106

See accompanying notes.

MOLINA HEALTHCARE, INC.

CONSOLIDATED BALANCE SHEETS


	June 30, 2017			December 31, 2016			September 30, 2017			December 31, 2016
	(Amounts in millions, except per-share data)						(Amounts in millions, except per-share data)
	(Unaudited)						(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	2,979		$	2,819		$	3,934		$	2,819
Investments	2,192			1,758			1,787			1,758
Restricted investments	325			—			326			—
Receivables	1,006			974			1,002			974
Income taxes refundable	68			39			60			39
Prepaid expenses and other current assets	159			131			174			131
Derivative asset	440			267			425			267
Total current assets	7,169			5,988			7,708			5,988
Property, equipment, and capitalized software, net	449			454			397			454
Deferred contract costs	93			86			97			86
Intangible assets, net	112			140			101			140
Goodwill	559			620			430			620
Restricted investments	118			110			117			110
Deferred income taxes	36			10			62			10
Other assets	47			41			42			41
	$	8,583		$	7,449		$	8,954		$	7,449

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Medical claims and benefits payable	$	2,077		$	1,929		$	2,478		$	1,929
Amounts due government agencies	1,844			1,202			1,324			1,202
Accounts payable and accrued liabilities	375			385			485			385
Deferred revenue	284			315			468			315
Current portion of long-term debt	773			472			782			472
Derivative liability	440			267			425			267
Total current liabilities	5,793			4,570			5,962			4,570
Senior notes	1,017			975
Long-term debt							1,317			975
Lease financing obligations	198			198			198			198
Deferred income taxes	—			15			—			15
Other long-term liabilities	54			42			48			42
Total liabilities	7,062			5,800			7,525			5,800

Stockholders’ equity:
Common stock, $0.001 par value; 150 shares authorized; outstanding: 57 shares at June 30, 2017 and at December 31, 2016	—			—
Common stock, $0.001 par value; 150 shares authorized; outstanding: 57 shares at September 30, 2017 and at December 31, 2016							—			—
Preferred stock, $0.001 par value; 20 shares authorized, no shares issued and outstanding	—			—			—			—
Additional paid-in capital	865			841			870			841
Accumulated other comprehensive loss	(1		)	(2		)	(1		)	(2		)
Retained earnings	657			810			560			810
Total stockholders’ equity	1,521			1,649			1,429			1,649
	$	8,583		$	7,449		$	8,954		$	7,449

See accompanying notes.

MOLINA HEALTHCARE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS


	Six Months Ended June 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
	(Amounts in millions) (Unaudited)						(Amounts in millions) (Unaudited)
Operating activities:
Net (loss) income	$	(153	)	$	57		$	(250	)	$	99
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	96			89			139			135
Impairment losses	72			—			201			—
Deferred income taxes	(41		)	39			(68		)	20
Share-based compensation, including accelerated share-based compensation	35			16			38			24
Non-cash restructuring charges							49			—
Amortization of convertible senior notes and lease financing obligations	16			15			24			23
Other, net	7			11			13			14
Changes in operating assets and liabilities:
Receivables	(32		)	(415		)	(28		)	(427		)
Prepaid expenses and other assets	(38		)	(143		)	(53		)	(116		)
Medical claims and benefits payable	148			82			549			168
Amounts due government agencies	642			509			122			503
Accounts payable and accrued liabilities	(18		)	147			90			1
Deferred revenue	(32		)	(119		)	153			157
Income taxes	(30		)	(10		)	(22		)	32
Net cash provided by operating activities	672			278			957			633
Investing activities:
Purchases of investments	(1,636		)	(974		)	(1,896		)	(1,444		)
Proceeds from sales and maturities of investments	874			812			1,538			1,512
Purchases of property, equipment and capitalized software	(60		)	(102		)	(85		)	(143		)
(Increase) decrease in restricted investments held-to-maturity	(10		)	5			(10		)	4
Net cash paid in business combinations	—			(8		)	—			(48		)
Other, net	(13		)	(6		)	(21		)	(12		)
Net cash used in investing activities	(845		)	(273		)	(474		)	(131		)
Financing activities:
Proceeds from senior notes offering, net of issuance costs	325			—			325			—
Proceeds from borrowings under credit facility							300			—
Proceeds from employee stock plans	11			10			11			10
Other, net	(3		)	1			(4		)	1
Net cash provided by financing activities	333			11			632			11
Net increase in cash and cash equivalents	160			16			1,115			513
Cash and cash equivalents at beginning of period	2,819			2,329			2,819			2,329
Cash and cash equivalents at end of period	$	2,979		$	2,345		$	3,934		$	2,842

MOLINA HEALTHCARE, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(continued)


	Six Months Ended June 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
	(Amounts in millions) (Unaudited)						(Amounts in millions) (Unaudited)
Supplemental cash flow information:

Schedule of non-cash investing and financing activities:
Common stock used for share-based compensation	$	(21	)	$	(7	)	$	(21	)	$	(8	)

Details of change in fair value of derivatives, net:
Gain (loss) on 1.125% Call Option	$	173		$	(148	)	$	158		$	(60	)
(Loss) gain on 1.125% Conversion Option	(173		)	148			(158		)	60
Change in fair value of derivatives, net	$	—		$	—		$	—		$	—

Details of business combinations:
Fair value of assets acquired	$	—		$	(131	)	$	—		$	(186	)
Fair value of liabilities assumed							—			28
Purchase price amounts accrued/received	—			21			—			8
Reversal of amounts advanced to sellers in prior year	—			102			—			102
Net cash paid in business combinations	$	—		$	(8	)	$	—		$	(48	)

See accompanying notes.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

~~June~~September 30, 2017

1. Basis of Presentation

Organization and Operations

Molina Healthcare, Inc. provides quality managed health care to people receiving government assistance. We offer cost-effective Medicaid-related solutions to meet the health care needs of low-income families and individuals, and to assist government agencies in their administration of the Medicaid program. We have three reportable segments. These segments consist of our Health Plans segment, which constitutes the vast majority of our operations; our Molina Medicaid Solutions segment; and our Other segment.

The Health Plans segment consists of health plans operating in 12 states and the Commonwealth of Puerto ~~Rico, and includes our direct delivery business.~~Rico. As of ~~June~~September 30, 2017, these health plans served approximately ~~4.7~~4.5 million members eligible for Medicaid, Medicare, and other government-sponsored health care programs for low-income families and individuals. This membership includes Affordable Care Act Marketplace (Marketplace) members, most of whom receive government premium subsidies. The health plans are operated by our respective wholly owned subsidiaries in those states, each of which is licensed as a health maintenance organization (HMO). ~~Our direct delivery business consists primarily of the operation of primary care clinics in several states in which we operate.~~

Our health plans’ state Medicaid contracts generally have terms of three to four years. These contracts typically contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Our health plan subsidiaries have generally been successful in retaining their contracts, but such contracts are subject to risk of loss when a state issues a new request for proposal (RFP) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may be subject to non-renewal.

In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled (ABD); and regions or service areas.

The Molina Medicaid Solutions segment provides support to state government agencies in the administration of their Medicaid programs, including business processing, information technology development and administrative services.

The Other segment includes primarily our Pathways behavioral health and social services provider, and corporate amounts not allocated to other reportable segments.

~~Restructuring Plan~~

We recorded $43 million in restructuring and separation costs in the second quarter of 2017 related primarily to contractually required termination benefits paid to our former chief executive officer (CEO) and chief financial officer (CFO). Also included in these costs are consulting fees incurred for the development and implementation of our corporate restructuring initiatives. See Note 11, “Restructuring and Separation Costs.”

Recent Developments — Health Plans Segment

~~Direct Delivery.~~Illinois Health Plan. OnIn August 2, 2017, ~~we announced plans~~Molina Healthcare of Illinois, Inc. was awarded a statewide Medicaid managed care contract by the Illinois Department of Healthcare and Family Services. This Medicaid contract further integrates behavioral health and physical health by combining the State’s three current managed care programs into one program. The contract begins January 1, 2018, for four years with options to ~~restructure our direct delivery operations.~~renew annually for up to four additional years.

Mississippi Health Plan. In June 2017, Molina Healthcare of Mississippi, Inc. was awarded a Medicaid Coordinated Care Contract for the statewide administration of the Mississippi Coordinated Access Network (MississippiCAN). The operational start date for the program is currently scheduled for October 1, 2018, pending the completion of a readiness review. The initial term of the contract ~~begins July 1, 2017, for three years~~is through June 2020, with options to renew annually for up to two additional years. ~~The operational start date for the program is currently scheduled for July 1, 2018, pending the completion of a readiness review.~~

Washington Health Plan. In May 2017, Molina Healthcare of Washington, Inc. was selected by the Washington State Health Care Authority to negotiate and enter into managed care contracts for the North Central region of the state’s Apple Health Integrated Managed Care Program. The start date for the new contract is scheduled for January 1, 2018.

Terminated Medicare Acquisition. In August 2016, we entered into agreements with each of Aetna Inc. and Humana Inc. to acquire certain assets related to their Medicare Advantage business. The transaction was subject to closing

conditions including the completion of the proposed acquisition of Humana by Aetna (the Aetna-Humana Merger). In January 2017, the U.S. District Court for the District of Columbia granted the request for relief made by the U.S. Department of Justice in its civil antitrust lawsuit against Aetna and Humana, to prohibit the Aetna-Humana Merger. In February 2017, our agreements with each of Aetna and Humana were terminated by the parties pursuant to the terms of the agreements. Under the termination agreements, we received an aggregate termination fee of $75 million from Aetna and Humana in the first quarter of 2017, which is reported in “Other income, ~~net.”~~ net” in the accompanying consolidated statements of operations.

New York Health Plan. In August 2016, we closed on our acquisition of the outstanding equity interests of Today’s Options of New York, Inc., which now operates as Molina Healthcare of New York, Inc. The purchase price allocation was completed, and the final purchase price adjustments were recorded, in the first quarter of 2017. Such adjustments were insignificant, and the final cash purchase price was $38 million.

~~Recent Developments — Other Segment~~Impairment Losses

Molina Medicaid Solutions segment. In the third quarter of 2017, we recorded a non-cash goodwill impairment loss of $28 million.See Note 10, “Impairment Losses.”

Other segment. In the third quarter of 2017, we recorded a non-cash goodwill impairment loss of $101 million for our Pathways subsidiary. In the second quarter of 2017, we recorded non-cash goodwill and intangible assets impairment losses of $72 million, ~~related~~ primarily tofor our Pathways subsidiary. See Note 10, “Impairment Losses.”

Consolidation and Interim Financial Information

The consolidated financial statements include the accounts of Molina Healthcare, Inc., its subsidiaries, and variable interest entities (VIEs) in which Molina Healthcare, Inc. is considered to be the primary beneficiary. Such VIEs are insignificant to our consolidated financial position and results of operations. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the interim periods presented have been included; such adjustments consist of normal recurring adjustments. All significant intercompany balances and transactions have been eliminated. The consolidated results of operations for the current interim period are not necessarily indicative of the results for the entire year ending December 31, 2017.

The unaudited consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either read or have access to our audited consolidated financial statements for the fiscal year ended December 31, 2016. Accordingly, certain disclosures that would substantially duplicate the disclosures contained in the December 31, 2016 audited consolidated financial statements have been omitted. These unaudited consolidated interim financial statements should be read in conjunction with our December 31, 2016 audited consolidated financial statements.

2. Significant Accounting Policies

Certain of our significant accounting policies are discussed within the note to which they specifically relate.

Revenue Recognition – Health Plans Segment

Premium revenue is fixed in advance of the periods covered and, except as described below, is not generally subject to significant accounting estimates. Premium revenues are recognized in the month that members are entitled to receive health care services, and premiums collected in advance are deferred. Certain components of premium revenue are subject to accounting estimates and fall into two broad categories discussed in further detail below: 1) “Contractual Provisions That May Adjust or Limit Revenue or Profit;” and 2) “Quality Incentives.”

Contractual Provisions That May Adjust or Limit Revenue or Profit

Medicaid

Medical Cost Floors (Minimums), and Medical Cost Corridors: A portion of our premium revenue may be returned if certain minimum amounts are not spent on defined medical care costs. In the aggregate, we recorded a liability under the terms of such contract provisions of ~~$136~~$119 million and $272 million at ~~June~~September 30, 2017 and December 31, 2016, respectively, to “Amounts due government agencies.” Approximately ~~$114~~$82 million and $244 million of the liability accrued at ~~June~~September 30, 2017 and December 31, 2016, respectively, relates to our participation in Medicaid Expansion programs.

In certain circumstances, our health plans may receive additional premiums if amounts spent on medical care costs exceed a defined maximum threshold. Receivables relating to such provisions were insignificant at ~~June~~September 30, 2017 and December 31, 2016.

Profit Sharing and Profit Ceiling: Our contracts with certain states contain profit-sharing or profit ceiling provisions under which we refund amounts to the states if our health plans generate profit above a certain specified percentage. In some cases, we are limited in the amount of administrative costs that we may deduct in calculating the refund, if any. Liabilities for profits in excess of the amount we are allowed to retain under these provisions were insignificant at ~~June~~September 30, 2017 and December 31, 2016.

Retroactive Premium Adjustments: State Medicaid programs periodically adjust premium rates on a retroactive basis. In these cases, we must adjust our premium revenue in the period in which we learn of the adjustment, rather than in the months of service to which the retroactive adjustment applies.

Medicare

Risk Adjustment: Our Medicare premiums are subject to retroactive increase or decrease based on the health status of our Medicare members (measured as a member risk score). We estimate our members’ risk scores and the related amount of Medicare revenue that will ultimately be realized for the periods presented based on our knowledge of our members’ health status, risk scores and the Centers for Medicare & Medicaid Services (CMS) practices. Consolidated balance sheet amounts related to anticipated Medicare risk adjustment premiums and Medicare Part D settlements were insignificant at ~~June~~September 30, 2017 and December 31, 2016.

Minimum MLR: Additionally, federal regulations have established a minimum annual medical loss ratio (Minimum MLR) of 85% for Medicare. The medical loss ratio represents medical costs as a percentage of premium revenue. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to the federal government. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of operations.

Marketplace

Premium Stabilization Programs: The Affordable Care Act (ACA) established Marketplace premium stabilization programs effective January 1, 2014. These programs, commonly referred to as the “3R’s,” include a permanent risk adjustment program, a transitional reinsurance program, and a temporary risk corridor program. We record receivables or payables related to the 3R programs and the Minimum MLR when the amounts are reasonably estimable as described below, and, for receivables, when collection is reasonably assured. Our receivables (payables) for each of these programs, as of the dates indicated, were as follows:


	June 30, 2017									December 31, 2016			September 30, 2017								December 31, 2016
	Current Benefit Year			Prior Benefit Years			Total						Current Benefit Year			Prior Benefit Years		Total

	(In millions)												(In millions)
Risk adjustment	$	(502	)	$	(546	)	$	(1,048	)	$	(522	)	$	(655	)	$	—	$	(655	)	$	(522	)
Reinsurance	—			57			57			55			—			10		10			55
Risk corridor	—			(1		)	(1		)	(1		)	—			—		—			(1		)
Minimum MLR	(3		)	(2		)	(5		)	(1		)	(27		)	—		(27		)	(1		)

Risk adjustment: Under this permanent program, our health plans’ composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk transfer payment into the pool if their composite risk scores are below the average risk score, and will receive a risk transfer payment from the pool if their composite risk scores are above the average risk score. We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of operations.

Reinsurance: This program was designed to provide reimbursement to insurers for high cost members and ended December 31, 2016; we expect to settle the outstanding receivable balance in 2017.

Risk corridor: This program was intended to limit gains and losses of insurers by comparing allowable costs to a target amount as defined by CMS, and ended December 31, 2016; ~~we expect to settle the~~all outstanding ~~payable balance in~~balances were settled as of September 30, 2017.

Additionally, the ACA established a Minimum MLR of 80% for the Marketplace. The medical loss ratio represents medical costs as a percentage of premium revenue. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to our Marketplace policyholders. Each of the 3R programs is taken into consideration when computing the Minimum MLR. We

recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of operations.

Quality Incentives

At several of our health plans, revenue ranging from approximately 1% to 3% of certain health plan premiums is earned only if certain performance measures are met.

The following table quantifies the quality incentive premium revenue recognized for the periods presented, including the amounts earned in the periods presented and prior periods. Although the reasonably possible effects of a change in estimate related to quality incentive premium revenue as of ~~June~~September 30, 2017 are not known, we have no reason to believe that the adjustments to prior years noted below are not indicative of the potential future changes in our estimates as of ~~June~~September 30, 2017.


	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016			2017			2016			2017			2016
	(Dollars in millions)												(Dollars in millions)
Maximum available quality incentive premium - current period	$	39		$	41		$	77		$	81		$	36		$	33		$	113		$	114
Quality incentive premium revenue recognized in current period:
Earned current period	$	29		$	36		$	48		$	54		$	24		$	26		$	72		$	80
Earned prior periods	1			49			6			54			3			—			9			54
Total	$	30		$	85		$	54		108			$	27		$	26		$	81		134

Quality incentive premium revenue recognized as a percentage of total premium revenue	0.6		%	2.1		%	0.6		%	1.3		%	0.6		%	0.6		%	0.6		%	1.1		%

Income Taxes

The provision for income taxes is determined using an estimated annual effective tax rate, which generally differs from the U.S. federal statutory rate primarily because of state taxes, nondeductible expenses such as the Health Insurer Fee (HIF), goodwill impairment, certain compensation, and other general and administrative expenses. The effective tax rate was not impacted by HIF in 2017 given the 2017 HIF moratorium.

The effective tax rate may be subject to fluctuations during the year, particularly as a result of the level of pretax earnings, and also as new information is obtained. Such information may affect the assumptions used to estimate the annual effective tax rate, including factors such as the mix of pretax earnings in the various tax jurisdictions in which we operate, valuation allowances against deferred tax assets, the recognition or the reversal of the recognition of tax benefits related to uncertain tax positions, and changes in or the interpretation of tax laws in jurisdictions where we conduct business. We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our assets and liabilities, along with net operating loss and tax credit carryovers.

Premium Deficiency Reserves on Loss Contracts

We assess the profitability of our medical care policies to identify groups of contracts where current operating results or forecasts indicate probable future losses. If anticipated future variable costs exceed anticipated future premiums and investment income, a premium deficiency reserve is recognized. We assume a full-year CSR reconciliation (see further information below) in the premium deficiency reserve calculation for the Marketplace program. We recorded a premium deficiency reserve to “Medical claims and benefits payable” on our accompanying consolidated balance sheets relating to our Marketplace program of $30 million as of December 31, 2016, which increased to $100 million as of June 30, 2017, and then decreased to $70 million as of September 30, 2017. If a nine-month CSR reconciliation had been included in the computation rather than a full year, the premium deficiency reserve would have increased by $55 million, to $125 million as of September 30, 2017. The theoretical $55 million increase to the premium deficiency reserve is less than the potential fourth quarter 2017 impact described below, or $85 million, because such adjustment only recognizes the potential CSR impact to the extent it would have created a deficiency in premiums at September 30, 2017.

Marketplace Cost Share Reduction (CSR) Update

Our third quarter results do not include any potential impact from the October 12, 2017, direction to Centers for Medicare and Medicaid Services (CMS) from Acting Department of Health and Human Services Secretary Hargan to cease payment of Marketplace CSR subsidies. At September 30, 2017, we had a total of approximately $220 million in excess CSR subsidies, recorded as a payable to CMS. This payable represents the extent to which payments received by us from CMS exceeded our estimate of the actual cost of member subsidies incurred by us through September 30, 2017.

We expect to incur approximately $85 million in unreimbursed expense associated with the cessation of CSR subsidies in the fourth quarter of 2017. It has been the practice of CMS to perform a reconciliation on an annual basis of CSR subsidies paid to all health plans against the actual costs incurred by the health plans. Were such a reconciliation to be performed for the full calendar year of 2017—consistent with past practice—we would be able to offset nearly all of the $85 million expense incurred in the fourth quarter against the excess amounts received prior to September 30, 2017. However, should CMS transition to a nine month reconciliation period ending September 30, 2017—the last month for which CSR subsidies have been paid—the absence of CSR subsidy reimbursement would reduce income before income tax expense by approximately $85 million in the fourth quarter of 2017.

Recent Accounting Pronouncements

Goodwill Impairment. In January 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-04, Simplifying the Test for Goodwill Impairment, which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment loss. Instead, an impairment loss is measured as the excess of the carrying amount of the reporting unit, including goodwill, over the fair value of the reporting unit. ASU 2017-04 is effective beginning January 1, 2020; we ~~have~~ early adopted ASU 2017-04 as of June 30, 2017, in connection with the interim assessment of our Pathways subsidiary. See further discussion at Note 10, “Impairment Losses.”

Restricted Cash. In November 2016, the FASB issued ASU 2016-18, Restricted Cash, which will require us to include in our consolidated statements of cash flows the balances of cash, cash equivalents, restricted cash and

restricted cash equivalents. When these items are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet. Transfers between cash and cash equivalents and restricted cash and restricted cash equivalents will no longer be presented in the statement of cash flows. ASU 2016-18 is effective beginning January 1, 2018; early adoption is permitted. We ~~intend to early adopt ASU 2016-18 as of December 31, 2017, and~~ are currently evaluating the ~~effect to~~changes that will be required in our consolidated statements of cash flows.

Stock Compensation. In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting, which amends ASC Topic 718, Compensation – Stock Compensation. ASU 2016-09 simplifies several aspects of accounting for employee share-based payment transactions, including the accounting for income taxes, forfeitures, statutory tax and classification in the statement of cash flows. We adopted ASU 2016-09 in the first quarter of 2017; such adoption did not significantly impact our consolidated financial statements. In addition, the prior period presentation in the statement of cash flows was not adjusted because such adjustments were insignificant.

Leases. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), as modified by ASU 2017-03, Transition and Open Effective Date Information. Under ASU 2016-02, an entity will be required to recognize assets and liabilities for the rights and obligations created by leases on the entity’s balance sheet for both finance and operating leases. For leases with a term of 12 months or less, an entity can elect to not recognize lease assets and lease liabilities and expense the lease over a straight-line basis for the term of the lease. ASU 2016-02 will require new disclosures that depict the amount, timing, and uncertainty of cash flows pertaining to an entity’s leases. ASU 2016-02 is effective for us beginning January 1, 2019, and must be adopted using a modified retrospective approach for annual and interim periods beginning after December 15, 2018. Early adoption is permitted. Under this guidance, we will record assets and liabilities relating primarily to our long-term office ~~leases, and~~leases. We are ~~currently~~ evaluating the effect to our consolidated financial statements.

Revenue Recognition. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). We intend to adopt this standard and the related modifications on January 1, 2018, using the modified retrospective approach. Under this approach, the cumulative effect of initially applying the guidance will be reflected as an adjustment to beginning retained earnings.

We have determined that the insurance contracts of our Health Plans segment, which ~~comprises~~segment constitutes the vast majority of our operations, are excluded from the scope of ~~ASU 2014-09~~Topic 606 because the recognition of revenue under these contracts is dictated by other accounting standards governing insurance contracts.

For our Molina Medicaid Solutions segment, we have reevaluated our earlier assessment and determined that ~~certain~~revenue for contracts that include design, development and implementation of Medicaid managed care systems shall be deferred until the system ‘go-live’ date, and then generally recognized on a straight-line basis over the hosting period. This approach is consistent with the FASB/IASB Joint Transition Resource Group for Revenue Recognition view for entities that provide software as a service solution, and similar to our historical revenue recognition methodology. We are continuing to evaluate the existence of customers’ rights with regard to renewal options and whether such rights may constitute separate performance obligations. We expect that cost of service revenue will ~~no longer be deferred and recognized over the service delivery period. Rather, service revenue will~~generally be recognized ~~based on~~in a manner consistent with the ~~expected cost plus gross margin method, and cost of service~~corresponding revenue ~~will be recognized as incurred. As of June 30, 2017, we expect~~recognition.

We believe the cumulative adjustment ~~for historical periods through June 30, 2017~~ to ~~increase~~ retained earnings ~~by no more than $50 million. This estimate~~associated with the adoption of Topic 606 effective January 1, 2018, will be ~~updated in each quarterly~~insignificant for both our Molina Medicaid Solutions and ~~annual report until adoption. We expect the cumulative adjustment, if any, relating to our~~ Other ~~segment to be insignificant.~~segments.

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (SEC) did not have, or are not believed by management to have, a significant impact on our present or future consolidated financial statements.

3. Net (Loss) Income per Share

The following table sets forth the calculation of basic and diluted net (loss) income per share:


	Three Months Ended June 30,					Six Months Ended June 30,					Three Months Ended September 30,					Nine Months Ended September 30,
	2017			2016		2017			2016		2017			2016		2017			2016
	(In millions, except net income per share)										(In millions, except net income per share)
Numerator:
Net (loss) income	$	(230	)	$	33	$	(153	)	$	57	$	(97	)	$	42	$	(250	)	$	99
Denominator:
Denominator for basic net (loss) income per share	56			55		56			55		57			56		56			55
Effect of dilutive securities:
1.125% Warrants ⁽¹⁾	—			—		—			1		—			—		—			1
Denominator for diluted net (loss) income per share	56			55		56			56		57			56		56			56

Net (loss) income per share: ⁽²⁾
Basic	$	(4.10	)	$	0.58	$	(2.74	)	$	1.02	$	(1.70	)	$	0.77	$	(4.44	)	$	1.79
Diluted	$	(4.10	)	$	0.58	$	(2.74	)	$	1.01	$	(1.70	)	$	0.76	$	(4.44	)	$	1.77

Potentially dilutive common shares excluded from calculations:
1.125% Warrants⁽¹⁾	2			—		1			—		2			—		2			—
1.625% Notes⁽¹⁾											1			—		—			—

(1)

For more information regarding the 1.125% Warrants, refer to Note 9, “Stockholders' Equity.” For more information regarding the 1.625% Notes, refer to Note 7, “Debt.” The dilutive effect of all potentially dilutive common shares is calculated using the ~~treasury-stock~~treasury stock method. ~~Certain potentially~~Potentially dilutive common shares ~~issuable are~~were not included in the computation of diluted net ~~(loss) income~~loss per share ~~because to do so would be anti-dilutive. For~~in the three and ~~six~~nine months ended ~~June~~September 30, 2017, ~~the 1.125% Warrants were excluded from diluted shares outstanding~~ because to do so would have been anti-dilutive.


(2)	Source data for calculations in thousands.

4. Fair Value Measurements

We consider the carrying amounts of cash, ~~and~~ cash equivalents and other current assets and current liabilities (not including derivatives and the current portion of long-term debt) to approximate their fair values because of the

relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to athe three-tier fair value ~~hierarchy defined by GAAP.~~hierarchy. For a description of the methods and assumptions that we use to a) estimate the fair value; and b) determine the classification according to the fair value hierarchy for each financial instrument, see Note 5, “Fair Value Measurements,” in our 2016 Annual Report on Form 10-K.

Derivative financial instruments include the 1.125% Call Option derivative asset and the 1.125% Conversion Option derivative liability. These derivatives are not actively traded and are valued based on an option pricing model that uses observable and unobservable market data for inputs. Significant market data inputs used to determine fair value as of ~~June~~September 30, 2017, included the price of our common stock, the time to maturity of the derivative instruments, the risk-free interest rate, and the implied volatility of our common stock. As described further in Note 8, “Derivatives,” the 1.125% Call Option asset and the 1.125% Conversion Option liability were designed such that changes in their fair values would offset, with minimal impact to the consolidated statements of operations. Therefore, the sensitivity of changes in the unobservable inputs to the option pricing model for such instruments is mitigated.

The net changes in fair value of Level 3 financial instruments were insignificant to our results of operations for the ~~six~~nine months ended ~~June~~September 30, 2017.

Our financial instruments measured at fair value on a recurring basis at ~~June~~September 30, 2017, were as follows:


	Total		Quoted Market Prices (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total		Quoted Market Prices (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	(In millions)								(In millions)
Corporate debt securities	$	1,386	$	—	$	1,386	$	—	$	1,162	$	—	$	1,162	$	—
U.S. treasury notes	263		263		—		—
Government-sponsored enterprise securities (GSEs)	241		241		—		—		220		220		—		—
Municipal securities	140		—		140		—		131		—		131		—
Asset-backed securities	128		—		128		—		125		—		125		—
U.S. treasury notes									121		121		—		—
Certificates of deposit	34		—		34		—		28		—		28		—
Subtotal - current investments	2,192		504		1,688		—		1,787		341		1,446		—
Corporate debt securities	228		—		228		—		229		—		229		—
U.S. treasury notes	97		97		—		—		97		97		—		—
Subtotal - current restricted investments	325		97		228		—		326		97		229		—
1.125% Call Option derivative asset	440		—		—		440		425		—		—		425
Total assets	$	2,957	$	601	$	1,916	$	440	$	2,538	$	438	$	1,675	$	425

1.125% Conversion Option derivative liability	$	440	$	—	$	—	$	440	$	425	$	—	$	—	$	425
Total liabilities	$	440	$	—	$	—	$	440	$	425	$	—	$	—	$	425

Our financial instruments measured at fair value on a recurring basis at December 31, 2016, were as follows:


	Total		Quoted Market Prices (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total		Quoted Market Prices (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	(In millions)								(In millions)
Corporate debt securities	$	1,179	$	—	$	1,179	$	—	$	1,179	$	—	$	1,179	$	—
U.S. treasury notes	84		84		—		—
GSEs	231		231		—		—		231		231		—		—
Municipal securities	142		—		142		—		142		—		142		—
Asset-backed securities	69		—		69		—		69		—		69		—
U.S. treasury notes									84		84		—		—
Certificates of deposit	53		—		53		—		53		—		53		—
Subtotal - current investments	1,758		315		1,443		—		1,758		315		1,443		—
1.125% Call Option derivative asset	267		—		—		267		267		—		—		267
Total assets	$	2,025	$	315	$	1,443	$	267	$	2,025	$	315	$	1,443	$	267

1.125% Conversion Option derivative liability	$	267	$	—	$	—	$	267	$	267	$	—	$	—	$	267
Total liabilities	$	267	$	—	$	—	$	267	$	267	$	—	$	—	$	267

There were no current restricted investments as of December 31, 2016.

Fair Value Measurements – Disclosure Only

The carrying amounts and estimated fair values of our senior notes ~~which~~ are classified as Level 2 financial ~~instruments,~~instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets. The carrying amount and estimated fair value of the amount due under our Credit Facility is classified as a Level 3 financial instrument, because certain inputs used to determine its fair value are ~~indicated in~~not observable. As of September 30, 2017, the ~~following table.~~carrying value of the amount due under the Credit Facility approximates it fair value because of the recency of this borrowing during the third quarter of 2017.


	June 30, 2017				December 31, 2016				September 30, 2017				December 31, 2016
	Carrying Value		Fair Value		Carrying Value		Fair Value		Carrying Value		Fair Value		Carrying Value		Fair Value
	(In millions)								(In millions)
5.375% Notes	$	692	$	745	$	691	$	714	$	692	$	726	$	691	$	714
1.125% Convertible Notes	483		976		471		792		489		927		471		792
4.875% Notes	325		333		—		—		325		324		—		—
Credit Facility									300		300		—		—
1.625% Convertible Notes	289		386		284		344		292		373		284		344
	$	1,789	$	2,440	$	1,446	$	1,850	$	2,098	$	2,650	$	1,446	$	1,850

5. Investments

Available-for-Sale Investments

We consider all of our investments classified as current assets (including restricted investments) to be available-for-sale. Certain of our senior notes, as further discussed in Note 7, “Debt,” contain a limitation on the use of proceeds which required us to deposit the net proceeds from their issuance into a segregated deposit account, a current asset reported as “Restricted investments” in the accompanying consolidated balance sheets. Such proceeds, while restricted as to their use and held in a segregated deposit account, are available-for-sale based upon our contractual liquidity requirements.

The following tables summarize our investments as of the dates indicated:


	June 30, 2017								September 30, 2017
	Amortized		Gross Unrealized				Estimated Fair		Amortized		Gross Unrealized				Estimated Fair
	Cost		Gains		Losses		Value		Cost		Gains		Losses		Value
	(In millions)								(In millions)
Corporate debt securities	$	1,387	$	1	$	2	$	1,386	$	1,162	$	1	$	1	$	1,162
U.S. treasury notes	263		—		—		263
GSEs	242		—		1		241		221		—		1		220
Municipal securities	140		—		—		140		132		—		1		131
Asset-backed securities	128		—		—		128		125		—		—		125
U.S. treasury notes									121		—		—		121
Certificates of deposit	34		—		—		34		28		—		—		28
Subtotal - current investments	2,194		1		3		2,192		1,789		1		3		1,787
Corporate debt securities	227		1		—		228		229		—		—		229
U.S. treasury notes	97		—		—		97		97		—		—		97
Subtotal - current restricted investments	324		1		—		325		326		—		—		326
Total	$	2,518	$	2	$	3	$	2,517
									$	2,115	$	1	$	3	$	2,113


	December 31, 2016								December 31, 2016
	Amortized		Gross Unrealized				Estimated Fair		Amortized		Gross Unrealized				Estimated Fair
	Cost		Gains		Losses		Value		Cost		Gains		Losses		Value
	(In millions)								(In millions)
Corporate debt securities	$	1,180	$	1	$	2	$	1,179	$	1,180	$	1	$	2	$	1,179
U.S. treasury notes	84		—		—		84
GSEs	232		—		1		231		232		—		1		231
Municipal securities	143		—		1		142		143		—		1		142
Asset-backed securities	69		—		—		69		69		—		—		69
U.S. treasury notes									84		—		—		84
Certificates of deposit	53		—		—		53		53		—		—		53
Total - current investments	$	1,761	$	1	$	4	$	1,758
									$	1,761	$	1	$	4	$	1,758

There were no current restricted investments as of December 31, 2016.

The contractual maturities of our available-for-sale investments as of ~~June~~September 30, 2017 are summarized below:


	Amortized Cost		Estimated Fair Value		Amortized Cost		Estimated Fair Value
	(In millions)				(In millions)
Due in one year or less	$	1,301	$	1,301	$	1,154	$	1,153
Due after one year through five years	1,194		1,193		944		943
Due after five years through ten years	23		23		17		17
Total	$	2,518	$	2,517
					$	2,115	$	2,113

Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains and losses for the three and ~~six~~nine months ended ~~June~~September 30, 2017 and 2016 were insignificant.

We have determined that unrealized losses at ~~June~~September 30, 2017 and December 31, 2016, are temporary in nature, because the change in market value for these securities has resulted from fluctuating interest rates, rather than a deterioration of the ~~credit worthiness~~creditworthiness of the issuers. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.

The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a loss position for 12 months or more as of June 30, 2017:

In a Continuous Loss Position
for Less than 12 Months

In a Continuous Loss Position
for 12 Months or More

Estimated
Fair
Value

Unrealized
Losses

Total
Number of
Positions

Estimated
Fair
Value

Unrealized
Losses

Total
Number of
Positions
(Dollars in millions)
Corporate debt securities $ 913
$ 2
418
$ —
$ —
—
GSEs 247
1
101
—
—
—
Total - current investments $ 1,160
$ 3
519
$ —
$ —
—

The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of September 30, 2017:



	In a Continuous Loss Position for Less than 12 Months					In a Continuous Loss Position for 12 Months or More
	Estimated Fair Value		Unrealized Losses		Total Number of Positions	Estimated Fair Value		Unrealized Losses		Total Number of Positions
	(Dollars in millions)
Corporate debt securities	$	783	$	1	314	$	—	$	—	—
GSEs	—		—		—	58		1		20
Municipal securities	97		1		116	—		—		—
	$	880	$	2	430	$	58	$	1	20


	In a Continuous Loss Position for Less than 12 Months					In a Continuous Loss Position for 12 Months or More					In a Continuous Loss Position for Less than 12 Months					In a Continuous Loss Position for 12 Months or More
	Estimated Fair Value		Unrealized Losses		Total Number of Positions	Estimated Fair Value		Unrealized Losses		Total Number of Positions	Estimated Fair Value		Unrealized Losses		Total Number of Positions	Estimated Fair Value		Unrealized Losses		Total Number of Positions
	(Dollars in millions)										(Dollars in millions)
Corporate debt securities	$	542	$	2	378	$	—	$	—	—	$	542	$	2	378	$	—	$	—	—
GSEs	198		1		73	—		—		—	198		1		73	—		—		—
Municipal securities	101		1		129	—		—		—	101		1		129	—		—		—
Total - current investments	$	841	$	4	580	$	—	$	—	—
											$	841	$	4	580	$	—	$	—	—

Held-to-Maturity Investments

Pursuant to the regulations governing our Health Plans segment subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in certificates of deposit and U.S. treasury securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulation in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as non-current “Restricted investments” in the accompanying consolidated balance ~~sheet.~~sheets. We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates.

The contractual maturities of our held-to-maturity restricted investments, which are carried at amortized cost, which approximates fair value, as of ~~June~~September 30, 2017 are summarized below:


	Amortized Cost		Estimated Fair Value		Amortized Cost		Estimated Fair Value
	(In millions)				(In millions)
Due in one year or less	$	100	$	100	$	100	$	100
Due after one year through five years	18		17		17		17
	$	118	$	117	$	117	$	117

6. Medical Claims and Benefits Payable

The following table provides the details of our medical claims and benefits payable (including amounts payable for the provision of long-term services and supports, or LTSS) as of the dates ~~indicated.~~indicated:


	June 30, 2017		December 31, 2016		September 30, 2017		December 31, 2016
	(In millions)				(In millions)
Fee-for-service claims incurred but not paid (IBNP)	$	1,478	$	1,352	$	1,681	$	1,352
Pharmacy payable	121		112		125		112
Capitation payable	45		37		57		37
Other	433		428		615		428
	$	2,077	$	1,929	$	2,478	$	1,929

“Other” medical claims and benefits payable include amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of operations. Non-risk provider payables amounted to ~~$111~~$403 million and $225 million as of ~~June~~September 30, 2017 and December 31, 2016, respectively.

Reinsurance recoverables of ~~$65~~$16 million and ~~$83~~$72 million as of ~~June~~September 30, 2017 and 2016, respectively, are included in “Receivables” in the accompanying consolidated balance sheets.

The following table presents the components of the change in our medical claims and benefits payable for the periods indicated. The amounts presented for “Components of medical care costs related to: Prior periods” represent the ~~amount~~amounts by which our original estimate of medical claims and benefits payable at the beginning of the period were ~~more~~less (more) than the actual amount of the liability based on information (principally the payment of claims) developed since that liability was first reported.


	Six Months Ended June 30,						Nine Months Ended September 30,
	2017			2016			2017			2016
	(Dollars in millions)						(Dollars in millions)
Medical claims and benefits payable, beginning balance	$	1,929		$	1,685		$	1,929		$	1,685
Components of medical care costs related to:
Current period	8,633			7,371			12,813			11,120
Prior periods	(31		)	(189		)	9			(190		)
Total medical care costs	8,602			7,182			12,822			10,930

Change in non-risk provider payables	(114		)	24			172			70

Payments for medical care costs related to:
Current period	6,883			5,885			10,944			9,536
Prior periods	1,457			1,240			1,501			1,278
Total paid	8,340			7,125			12,445			10,814
Medical claims and benefits payable, ending balance	$	2,077		$	1,766		$	2,478		$	1,871
Benefit from prior period as a percentage of:
Balance at beginning of period	1.6		%	11.3		%	(0.5		)%	11.3		%
Premium revenue, trailing twelve months	0.2		%	1.3		%	—		%	1.2		%
Medical care costs, trailing twelve months	0.2		%	1.4		%	(0.1		)%	1.3		%

Assuming that our initial estimate of IBNP is accurate, we believe that amounts ultimately paid would generally be between 8% and 10% less than the IBNP liability recorded at the end of the period as a result of the inclusion in that liability of the provision for adverse claims deviation and the accrued cost of settling those claims. Because the amount of our initial liability is merely an estimate (and therefore not perfectly accurate), we will always experience variability in that estimate as new information becomes available with the passage of time. Therefore, there can be no assurance that amounts ultimately paid out will fall within the range of 8% to 10% lower than the liability that was initially recorded. Furthermore, because our initial estimate of IBNP is derived from many factors, some of which are qualitative in nature rather than quantitative, we are seldom able to assign specific values to the reasons for a change in estimate—we only know when the circumstances for any one or more factors are out of the ordinary.

As indicated in the table above, the amounts ultimately paid out on our medical claims and benefits payable liabilities in fiscal years 2017 and 2016 were less than what we had expected when we had established those liabilities. The differences between our original estimates and the amounts ultimately paid out (or now expected to be ultimately paid out) for the most part related to IBNP. While many related factors working in conjunction with one another serve to determine the accuracy of our estimates, we are seldom able to quantify the impact that any single

factor has on a change in estimate. In addition, given the variability inherent in the reserving process, we will only be able to identify specific factors if they represent a significant departure from expectations. As a result, we do not expect to be able to fully quantify the impact of individual factors on changes in estimates.

~~While prior~~Prior period development of our estimate as of December 31, 2016, through ~~June~~September 30, 2017, was ~~favorable~~unfavorable by ~~$31~~$9 million, ~~that amount~~which is substantially less than the favorable prior period development of ~~$189~~$190 million we recognized for the same period in the prior year. Further, ~~favorable~~the unfavorable development through ~~June~~September 30, 2017, was less than the 8% to 10% favorable development we typically expect.

We believe that the most significant uncertainties surrounding our IBNP estimates at ~~June~~September 30, 2017 are as follows:

In the first half of 2017, our Marketplace enrollment across all health plans increased by over 400,000 members. Due to limited insight into the cost patterns associated with this large number of new Marketplace members, our liability estimates for these members are subject to more than the usual amount of uncertainty.

At our Florida health plan, the inventory of unpaid claims ~~receipts~~ increased significantly ~~over~~during the ~~last few months due to an increase~~first two quarters of 2017, and then dropped in the ~~receipt of secondary claims, many of which are not our liability. These claims will either be denied or will have very small paid amounts.~~third quarter. For this reason, the timing between the dates of service and the dates claims ~~denial rates, amounts~~are paid ~~per claim and other claims indicators~~ will be impacted, making our liability estimates subject to more than the usual amount of uncertainty.

At our Illinois health plan, in 2017 we paid a large number of claims ~~in the first half of 2017~~ that had previously been denied and were subsequently disputed by providers. We have also established a liability for additional expected claims resulting from provider disputes. This has created some distortion in the claims payment patterns, making our liability estimates subject to more than the usual amount of uncertainty.

At our California health plan, we adjusted our inpatient authorization process. As a result, due to the expected increase in authorized inpatient stays, our liability estimates are subject to more than the usual amount of uncertainty.

At our Illinois and New ~~Mexico~~York health ~~plan,~~plans, we implemented a ~~fee schedule reduction~~new process for increased quality review of claims payments. While we do not anticipate this new process will impact the percentage of claims paid within the timely turnaround requirements, we believe it will have a ~~large provider has created~~minor impact on the timing of some ~~distortion in the claims payment patterns, making~~paid claims. For this reason, our liability estimates in these two health plans are subject to more than the usual amount of uncertainty.

At our Puerto Rico health plan, Hurricane Maria had a significant impact on both utilization of services and our ability to process claims payments in Puerto Rico. For these reasons, we believe our liability estimates are subject to more than the usual amount of uncertainty.

7. Debt

Substantially all of our debt is held at the parent, which is reported in the Other segment. The following table summarizes our outstanding debt obligations and their classification in the accompanying consolidated balance sheets (in millions):


	June 30, 2017			December 31, 2016			September 30, 2017			December 31, 2016
Current portion of long-term debt:
1.125% Convertible Notes, net of unamortized discount	$	488		$	477		$	494		$	477
1.625% Convertible Notes, net of unamortized premium and discount	291			—			293			—
Lease financing obligations	1			1			1			1
Debt issuance costs	(7		)	(6		)	(6		)	(6		)
	773			472			782			472
Non-current portion of long-term debt, reported as “Senior notes”:
Non-current portion of long-term debt:
5.375% Notes	700			700			700			700
4.875% Notes	330			—			330			—
Credit Facility							300			—
1.625% Convertible Notes, net of unamortized premium and discount	—			286			—			286
Debt issuance costs	(13		)	(11		)	(13		)	(11		)
	1,017			975			1,317			975
Lease financing obligations	198			198			198			198
	$	1,988		$	1,645		$	2,297		$	1,645

4.875% Notes due 2025

On June 6, 2017, we completed the private offering of $330 million aggregate principal amount of senior notes (4.875% Notes) due June 15, 2025, unless earlier redeemed. Interest on the 4.875% Notes is payable semiannually in arrears on June 15 and December 15. According to their terms, the guarantees under the 4.875% Notes mirror those of the Credit Facility, defined and described below. See Note 16, “Supplemental Condensed Consolidating Financial Information,” for more information on the guarantors. The 4.875% Notes contain customary non-financial covenants and change of control provisions.

The 4.875% Notes contain a limitation on the use of proceeds which required us to deposit the net proceeds from their issuance into a segregated deposit account, a current asset reported as “Restricted investments” in our consolidated balance sheets. These funds may be used by us as follows:

On or prior to August 20, 2018, to:


◦	Redeem, repurchase, repay, tender for, or acquire for value all or any portion of our 1.625% Convertible Notes, defined and discussed further below, or to satisfy the cash portion of any consideration due upon any conversion of the 1.625% Convertible Notes; and/or


◦	Pay any interest due on all or any portion of the 4.875% Notes.

On or after August 20, 2018, to repurchase all or any portion of the 1.625% Convertible Notes that we are obligated to repurchase; and

Subsequent to August 20, 2018 (or such earlier date in the event that there are no longer any 1.625% Convertible Notes outstanding), in any other manner not otherwise prohibited in the indenture governing the 4.875% Notes.

5.375% Notes due 2022

We have outstanding $700 million aggregate principal amount of senior notes (5.375% Notes) due November 15, 2022, unless earlier redeemed. According to their terms, the guarantees under the 5.375% Notes mirror those of the Credit Facility, defined and described below. See Note 16, “Supplemental Condensed Consolidating Financial Information,” for more information on the guarantors.

Credit Facility

In January 2017, we entered into an amended unsecured $500 million revolving credit facility (Credit Facility), referred to as the First Amendment. ~~As of June 30, 2017, outstanding letters of credit amounting to $6 million reduced our borrowing capacity under the Credit Facility to $494 million.~~ The Credit Facility has a term of five years and all amounts outstanding will be due and payable on January 31, 2022. As of ~~June~~September 30, 2017, ~~no amounts were~~$300 million was outstanding under the Credit Facility, and we were in compliance with all financial and non-financial covenants under the Credit Facility. Also as of September 30, 2017, outstanding letters of credit amounting to $6 million reduced our remaining borrowing capacity under the Credit Facility to $194 million.

In addition to increasing amounts available to borrow under the Credit Facility and extending its term, the First Amendment provided that all guarantors immediately prior to January 3, 2017, other than Molina Information Systems, LLC, d/b/a Molina Medicaid Solutions, Molina Pathways, LLC, and Pathways Health and Community Support LLC, were automatically and unconditionally released from their obligations as guarantors of the Credit Facility and the 5.375% Notes.

The Credit Facility contains customary non-financial and financial covenants, including a net leverage ratio and an interest coverage ratio. In February 2017, we entered into a second amendment to the Credit Facility (the Second Amendment) which modified the Credit Facility’s definition of the earnings measure used in the financial covenant computations to a) allow us to receive credit for risk corridor payments owed to, but not received or accrued by us during 2016; and b) account for the difference between the amount of actual risk transfer payments made or accrued by us during 2016, and the amount of risk transfer payments that would have been due under the federal government’s proposed 2018 risk adjustment payment transfer formula.

In May 2017, we entered into a third amendment to the Credit Facility (the Third Amendment) which modified the Credit Facility’s definition of specified cash, to permit cash that is either subject to customary escrow arrangements or held in a segregated account to be netted from the Credit Facility’s consolidated net leverage ratio if the use of the cash is limited to the repayment of other indebtedness. The Third Amendment also adds a carve-out to the Credit Facility’s negative pledge covenant to allow for the escrow arrangements and segregated accounts. ~~At June 30,~~

In August 2017, we ~~were in compliance with all financial and non-financial covenants under~~entered into a fourth amendment to the Credit ~~Facility.~~Facility (the Fourth Amendment). The Fourth Amendment modified the definition of consolidated adjusted EBITDA to permit the add-back of certain restructuring charges and cost savings subject to certain limitations, and modified the definition of the consolidated interest coverage ratio to include, when calculating such ratio, consolidated interest expense “paid in cash” only.

Convertible Senior Notes

We have outstanding $550 million aggregate principal amount of 1.125% cash convertible senior notes due January 15, 2020 (1.125% Convertible Notes), unless earlier repurchased or converted. ~~We refer to these notes as our 1.125% Convertible Notes.~~ We also have outstanding $302 million aggregate principal amount of 1.625% convertible senior notes due August 14, 2044 (1.625% Convertible Notes), unless earlier repurchased, redeemed, or converted. ~~We refer to these notes as our 1.625% Convertible Notes.~~ The 1.125% Convertible Notes are convertible entirely tointo cash, and the 1.625% Convertible Notes are convertible partially tointo cash, each prior to their respective maturity dates under certain circumstances, one of which relates to the closing price of our common stock over a specified period. We refer to this conversion trigger as the stock price trigger.

The stock price trigger for the 1.125% Convertible Notes is $53.00 per share. The 1.125% Convertible Notes met this trigger in the quarter ended ~~June~~September 30, 2017; therefore, they are convertible into cash and are reported in current portion of long-term debt as of ~~June~~September 30, 2017.

The stock price trigger for the 1.625% Convertible Notes is $75.51 per share. The 1.625% Convertible Notes did not meet this stock price trigger in the quarter ended ~~June~~September 30, 2017. OnHowever, on contractually specified dates beginning in 2018, holders of the 1.625% Convertible Notes may require us to repurchase some or all of such notes. In addition, beginning May 15, 2018 until August 19, 2018, holders may convert some or all of the 1.625% Convertible Notes. Because of ~~this~~these put and conversion ~~feature,~~features, the 1.625% Convertible Notes are reported in current portion of long-term debt as of ~~June~~September 30, 2017. As noted above, because the proceeds from the 4.875% Notes are initially restricted to payments upon conversion or redemption of the 1.625% Convertible Notes, such restricted investments are also classified as current in the accompanying consolidated balance sheets.

Cross-Default Provisions

The terms of our 4.875% Notes, 5.375% Notes and each of the 1.125% and 1.625% Convertible Notes contain cross-default provisions with the Credit Facility that are triggered upon an event of default under the Credit Facility, and when borrowings under the Credit Facility equal or exceed certain amounts as defined in the related indentures.

Debt Commitment Letter

In connection with the ~~Terminated~~terminated Medicare Acquisition, we entered into a debt commitment letter with Barclays Bank PLC (Barclays) in August 2016. Under this debt commitment letter, Barclays agreed to lend us up to $400 million, subject to satisfaction of certain conditions, including consummation of the ~~Terminated~~terminated Medicare Acquisition. The debt commitment letter automatically terminated in February 2017 as a result of the termination of this transaction. The costs associated with the debt commitment letter and its termination were reimbursed as described in Note 1, “Basis of Presentation–Health Plans Segment Recent Developments.”

8. Derivatives

The following table summarizes the fair values and the presentation of our derivative financial instruments (defined and discussed individually below) in the accompanying consolidated balance sheets:


	Balance Sheet Location	June 30, 2017		December 31, 2016		Balance Sheet Location	September 30, 2017		December 31, 2016
		(In millions)					(In millions)
Derivative asset:
1.125% Call Option	Current assets: Derivative asset	$	440	$	267	Current assets: Derivative asset	$	425	$	267
Derivative liability:
1.125% Conversion Option	Current liabilities: Derivative liability	$	440	$	267	Current liabilities: Derivative liability	$	425	$	267

Our derivative financial instruments do not qualify for hedge treatment; therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations, and reported in “Other income, net.” Gains and losses for our derivative financial instruments are presented individually in the accompanying consolidated statements of cash flows, “Supplemental cash flow information.”

1.125% Notes Call Spread Overlay. Concurrent with the issuance of the 1.125% Convertible Notes in 2013, we entered into privately negotiated hedge transactions (collectively, the 1.125% Call Option) and warrant transactions (collectively, the 1.125% Warrants), with certain of the initial purchasers of the 1.125% Convertible Notes (the Counterparties). We refer to these transactions collectively as the Call Spread Overlay. Under the Call Spread Overlay, the cost of the 1.125% Call Option we purchased to cover the cash outlay upon conversion of the 1.125% Convertible Notes was reduced by proceeds from the sale of the 1.125% Warrants. Assuming full performance by the Counterparties (and 1.125% Warrants strike prices in excess of the conversion price of the 1.125% Convertible Notes), these transactions are intended to offset cash payments in excess of the principal amount of the 1.125% Convertible Notes due upon any conversion of such ~~Notes.~~notes.

1.125% Call Option. The 1.125% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment due to cash settlement features until the 1.125% Call Option settles or expires. For further discussion of the inputs used to determine the fair value of the 1.125% Call Option, refer to Note 4, “Fair Value Measurements.”

1.125% Conversion Option. The embedded cash conversion option within the 1.125% Convertible Notes is accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations until the cash conversion option settles or expires. For further discussion of the inputs used to determine the fair value of the 1.125% Conversion Option, refer to Note 4, “Fair Value Measurements.”

As of ~~June~~September 30, 2017, the 1.125% Call Option and the 1.125% Conversion Option were classified as a current asset and current liability, respectively, because the 1.125% Convertible Notes may be converted within 12twelve months of ~~June~~September 30, 2017, as described in Note 7, “Debt.”

9. Stockholders' Equity

Stockholders’ equity decreased $~~128~~220 million during the ~~six~~nine months ended ~~June~~September 30, 2017 compared with stockholders’ equity at December 31, 2016. The decrease was due primarily to the net loss of $~~153~~250 million, partially offset by ~~$24~~$29 million related to employee stock transactions in the ~~six~~nine months ended ~~June~~September 30, ~~2017, which are described further below.~~2017.

1.125% Warrants

In connection with the Call Spread Overlay transaction described in Note 8, “Derivatives,” in 2013, we issued 13,490,236 warrants with a strike price of $53.8475 per share. Under certain circumstances, beginning in April 2020, when the price of our common stock exceeds the strike price of the 1.125% Warrants, we will be obligated to issue shares of our common stock subject to a share delivery cap. The 1.125% Warrants could separately have a dilutive effect to the extent that the market value per share of our common stock exceeds the applicable strike price of the 1.125% Warrants. Refer to Note 3, “Net (Loss) Income per Share,” for dilution information for the periods presented. We will not receive any additional proceeds if the 1.125% Warrants are exercised.

Stock Incentive Plans

In connection with our equity incentive plans and employee stock purchase plan, approximately ~~692,000~~702,000 shares of common stock vested or were purchased, net of shares used to settle employees’ income tax obligations, during the ~~six~~nine months ended ~~June~~September 30, 2017.

Except as noted below, we record share-based compensation as “General and administrative expenses” in the accompanying consolidated statements of operations. Restricted stock awards (RSAs), performance stock awards (PSAs) and performance stock units (PSUs) activity for the ~~six~~nine months ended ~~June~~September 30, 2017 is summarized below:


	Restricted Stock Awards		Performance Stock Awards		Performance Stock Units		Total		Weighted Average Grant Date Fair Value		Restricted Stock Awards		Performance Stock Awards		Performance Stock Units		Total		Weighted Average Grant Date Fair Value
Unvested balance, December 31, 2016	577,244		345,656		—		922,900		$	58.15	577,244		345,656		—		922,900		$	58.15
Granted	377,076		—		231,100		608,176		56.98		386,273		—		231,100		617,373		57.16
Vested	(380,812	)	(260,894	)	(139,272	)	(780,978	)	57.63		(391,680	)	(260,894	)	(139,272	)	(791,846	)	57.78
Forfeited	(58,643	)	—		—		(58,643	)	54.48		(69,346	)	—		—		(69,346	)	54.37
Unvested balance, June 30, 2017	514,865		84,762		91,828		691,455		57.57
Unvested balance, September 30, 2017											502,491		84,762		91,828		679,081		57.61

The total fair value of RSAs granted during the ~~six~~nine months ended ~~June~~September 30, 2017 and 2016 was $19 million and ~~$17~~$18 million, respectively. The total fair value of RSAs which vested during the ~~six~~nine months ended ~~June~~September 30, 2017 and 2016 was ~~$20~~$21 million and ~~$21~~$22 million, respectively.

No PSAs were granted during the ~~six~~nine months ended ~~June~~September 30, 2017. The total fair value of PSAs granted during the ~~six~~nine months ended ~~June~~September 30, 2016 was $15 million. The total fair value of PSAs which vested during the ~~six~~nine months ended ~~June~~September 30, 2017 was $15 million. No PSAs vested during the ~~six~~nine months ended ~~June~~September 30, 2016.

The total fair value of PSUs granted during the ~~six~~nine months ended ~~June~~September 30, 2017 was $16 million. The total fair value of PSUs which vested during the ~~six~~nine months ended ~~June~~September 30, 2017 was $9 million. There were no PSUs granted or vested in 2016.

During the ~~six~~nine months ended ~~June~~September 30, 2017, the vesting of 133,957 RSAs, 153,574 PSAs and 139,272 PSUs was accelerated in connection with the termination of our former Chief Executive Officer (CEO) and former Chief Financial Officer (CFO) in May 2017. Share-based compensation expense of ~~$35~~$38 million was recorded during the ~~six~~nine months ended ~~June~~September 30, 2017, of which $23 million was recorded to “Restructuring and separation costs” in the accompanying consolidated statements of operations. See Note 11, “Restructuring and Separation Costs” for further discussion. ~~Share-based~~We recorded share-based compensation expense of ~~$16~~$24 million ~~was recorded to “General and administrative expenses”~~ in the ~~six~~nine months ended ~~June~~September 30, 2016.

As of ~~June~~September 30, 2017, there was ~~$32~~$27 million of total unrecognized compensation expense related to unvested RSAs, ~~including those with market~~PSAs, and ~~performance conditions, and unvested~~ PSUs, which we expect to recognize over a remaining weighted-average period of ~~2.5~~2.2 years and ~~2.1~~1.9 years, respectively. This unrecognized compensation cost assumes an estimated forfeiture rate of ~~3.3%~~4.5% for non-executive employees as of ~~June~~September 30, 2017.

10. Impairment Losses

Goodwill represents the excess of the purchase price over the fair value of net assets acquired in business combinations. Goodwill is not amortized, but is subject to an annual impairment test. ~~Refer to Note 2, “Significant Accounting Policies,” for a discussion of our adoption of ASU 2017-04,~~ ~~Simplifying the Test for Goodwill Impairment.~~ We are required to test at least annually for impairment, or more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. When testing goodwill for impairment, we may first assess qualitative factors, such as industry and market factors, cost factors, and changes in overall performance, to determine if it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value. If our qualitative assessment indicates that goodwill impairment is more likely than not, we perform additional quantitative analysis. We may also elect to skip the qualitative testing and proceed directly to the quantitative testing.

An impairment loss is measured as the excess of the carrying amount of the reporting unit, including goodwill, over the fair value of the reporting unit. We estimate the fair values of our reporting units using discounted cash flows. We apply our weighted average cost of capital (WACC) as the best estimate to discount future estimated cash flows to present value. The WACC is based on externally available data considering market participants’ cost of equity and debt, and capital structure. In addition, we apply a terminal growth rate that corresponds to the reporting unit’s long-term growth prospects.

In the discounted cash flow analyses, we must make assumptions about a wide variety of internal and external factors, and consider the price that would be received to sell the reporting unit as a whole in an orderly transaction between market participants at the measurement date. Significant assumptions include financial projections of free cash flow (including significant assumptions about operations, capital requirements and income taxes), long-term growth rates for determining terminal value beyond the discretely forecasted periods, and discount rates.

~~In the course of developing our restructuring and profitability improvement plan, discussed further~~Molina Medicaid Solutions Segment

As described in Note 11, “Restructuring and Separation Costs,” in the third quarter of 2017 we wrote off certain costs capitalized at our Molina Medicaid Solutions segment that supported our Health Plans segment provider information management processes to be re-designed. Although the intercompany revenues recorded by Molina Medicaid Solutions under this arrangement were insignificant on a consolidated basis, the termination of such revenue resulted in a triggering event for an interim goodwill impairment analysis of this segment in the third quarter of 2017. In the Molina Medicaid Solutions’ discounted cash flow model, we incorporated significant estimates and assumptions related to future periods, such as intercompany business support opportunities and prospects for new Medicaid management information systems contracts. Because management has determined that Molina Medicaid Solutions will provide fewer future benefits for its support of the Health Plans segment, the test resulted in a fair value less than Molina Medicaid Solutions’ carrying amount; therefore, we recorded a goodwill impairment loss for the difference, or $28 million, in the third quarter of 2017.

Other Segment

In the course of developing the Restructuring Plan in the second quarter of 2017, we determined that future benefits to be derived from our Pathways subsidiary, including the integration of its operations with our ~~health plans,~~Health Plans segment, would be less than previously anticipated. In addition, poorer than expected year-to-date operating results, ~~and~~as well as lower projections of operating results for periods in the near term at our Pathways subsidiary, led us to conclude that a triggering event for an interim impairment analysis had occurred in the second quarter of 2017.

In the third quarter of 2017, management determined that Pathways will not provide future benefits relating to the integration of its operations with the Health Plans segment to the extent previously expected. Therefore, we conducted an additional interim impairment analysis.

Intangible ~~Assets.~~assets. ~~We first~~In the second quarter of 2017, we evaluated Pathways’ finite-lived intangible assets (customer relationships and contract licenses) for impairment, using undiscounted cash flows expected over the longest remaining useful life of the assets tested. ~~See below for a description of the estimates and assumptions used in the cash flow model.~~ Because the undiscounted cash flows over the remaining useful life were less than Pathways’ carrying amount, the intangible assets were impaired. We recorded an impairment loss for the carrying amount of the intangible assets, or $11 million, in the second quarter of 2017.

Goodwill. ~~We next tested Pathways’ goodwill for impairment.~~ As ~~described~~noted above, we estimated Pathways’ fair value using discounted cash flows, incorporating significant estimates and assumptions related to future periods. Such estimates included anticipated client census which drives service revenue; ~~management’s determination that~~the likelihood of future benefits to be derived from Pathways (including integration with our health plans) ~~will be less than previously anticipated;~~; current prospects relating to the behavioral services labor market which drives cost of service revenue; and anticipated capital expenditures. ~~In addition, we applied our weighted average cost~~The tests in each of ~~capital (WACC) as~~ the ~~best estimate to discount future estimated cash flows to present value. The WACC was based on externally available data considering market participants’ cost of equity~~three months ended June 30, 2017, and ~~debt, and capital structure. We applied a terminal growth rate that corresponds to Pathways’ long-term growth prospects. The test~~September 30, 2017, resulted in a fair value less than Pathways’ carrying amount; therefore, we recorded an

impairment loss for the ~~difference, or~~difference. The Pathways goodwill impairment losses amounted to $101 million in the third quarter of 2017, and $59 million in the second quarter of 2017. In ~~addition to~~ the ~~Pathways impairment loss,~~second quarter of 2017, we also recorded ana goodwill impairment loss of $2 million for a separate ~~subsidiary’s goodwill~~subsidiary in the Other segment that did not pass ~~the~~its impairment test. ~~Both impairment losses were recorded to the Other segment, and reported as “Impairment losses” in the accompanying consolidated statements of operations.~~

There were no impairments of intangible assets or goodwill during 2016.

The goodwill impairment losses are recorded to the segments as indicated in following table, ~~presents~~and reported as “Impairment losses” in the ~~balances~~accompanying consolidated statements of ~~goodwill as of June 30, 2017 and December 31, 2016:~~operations.


	Health Plans			Molina Medicaid Solutions		Other			Total			Health Plans			Molina Medicaid Solutions			Other			Total
	(In millions)											(In millions)
Historical goodwill	$	445		$	71	$	162		$	678		$	445		$	71		$	162		$	678
Accumulated impairment losses at December 31, 2016	(58		)	—		—			(58		)	(58		)	—			—			(58		)
Balance, December 31, 2016	387			71		162			620			387			71			162			620
Impairment losses	—			—		(61		)	(61		)
Balance, June 30, 2017	$	387		$	71	$	101		$	559
Accumulated impairment losses at June 30, 2017	$	(58	)	$	—	$	(61	)	$	(119	)
Impairment losses, three months ended June 30, 2017												—			—			(61		)	(61		)
Impairment losses, three months ended September 30, 2017												—			(28		)	(101		)	(129		)
Balance, September 30, 2017												$	387		$	43		$	—		$	430
Accumulated impairment losses at September 30, 2017												$	58		$	28		$	162		$	248

11. Restructuring and Separation Costs

Following a management-initiated, broad operational assessment in early 2017, designed to improve our profitability and expand our core Medicaid business, in June 2017, we accelerated the implementation of a comprehensive restructuring and profitability improvement plan (the Restructuring Plan). Under the Restructuring Plan, we are taking the following actions:


1.	We ~~are streamlining~~have streamlined our organizational structure, including the elimination of redundant layers of management, the consolidation of regional support services, and other reductions to our workforce, to improve efficiency as well as the speed and quality of our decision-making.


2.	We are re-designing core operating processes such as provider payment, utilization management, quality monitoring and improvement, and information technology to achieve more effective and cost efficient outcomes.


3.	We are remediating high cost provider contracts and building around high quality, cost-effective networks.


4.	We are restructuring our existing direct delivery operations.


5.	We are reviewing our vendor base to ensure that we are partnering with the lowest-cost, most-effective vendors.


6.	Throughout this process, we are taking precautions to ensure that our actions do not impede our ability to continue to deliver quality health care, retain existing managed care contracts, and to secure new managed care contracts.

In addition to costs incurred under the Restructuring Plan, ~~in the second quarter of 2017~~ we have recorded costs associated with the separation of our former CEO and former CFO, described in further detail below.

~~All~~Expected Costs

We estimate that total pre-tax costs associated with the restructuring plan will be approximately $70 million to $90 million in the fourth quarter of 2017, with an additional $20 million to $40 million to be incurred in 2018. Since the initiation of our Restructuring Plan in the second quarter of 2017, the range of total estimated costs have increased by approximately $50 million due primarily to non-cash write-offs of certain capitalized software in connection with the re-design of core processes. Such write-offs were not included in our initial total cost estimates, but as our evaluation of core operating processes proceeded in the third quarter, we determined that certain projects were inconsistent with our future operating goals and ~~separation~~were therefore written off.

In addition, in the second quarter of 2017, we reported that we expected restructuring costs to relate only to the Health Plans and Other segments. In the third quarter of 2017, however, we wrote off certain costs capitalized at our Molina Medicaid Solutions segment that supported our Health Plans segment provider information management

processes to be re-designed. In addition, we now expect to incur consulting fees in connection with the review of Molina Medicaid Solutions’ core operating processes.

The following table illustrates our estimates of the total costs, by segment and major type of cost, that we expect to incur under the Restructuring Plan, and includes costs incurred inthrough September 30, 2017. We expect the ~~six months ended June 30, 2017, are reported in “Restructuring and separation costs” in~~Restructuring Plan to be completed by the ~~accompanying consolidated statements~~end of 2018.



Estimated Costs Expected to be Incurred by Reportable Segment	Health Plans	Molina Medicaid Solutions	Other	Total
	(In millions)
Termination benefits	$30 to $35	—	$30 to $35	$60 to $70
Other restructuring costs	$40 to $45	$10	$110 to $115	$160 to $170
	$70 to $80	$10	$140 to $150	$220 to $240

Costs Incurred

Restructuring Plan

Restructuring costs incurred to date consist primarily of termination benefits, write-offs of capitalized software due to the re-design of our core operating processes, restructuring of our direct delivery operations, and ~~are included in the Other segment because they represent corporate costs not allocated to the other reportable segments.~~consulting fees.

Separation Costs

~~Separation costs–ongoing benefit arrangements for former executives.~~ ~~We entered into amended and restated~~On May 2, 2017, we terminated the employment ~~agreements with~~of our former CEO and ~~former~~ CFO ~~in 2016. On May 2, 2017, their employment was terminated~~ without cause. Under ~~the~~their amended and restated employment agreements, they were each entitled to receive 400% of their base salary, a prorated termination bonus (150% of base salary for the former CEO and 125% of base salary for the former CFO), full vesting of equity compensation, and a cash payment for health and welfare benefits. ~~During the second quarter of 2017, we~~We recorded ~~charges~~separation costs of $35 million ~~for severance~~ primarily related to these former ~~executives.~~executives under FASB ASC Topic 712, Nonretirement and Postemployment Benefits. Of this total, $23 million related to the acceleration of their share-based compensation, as further discussed in Note 9, “Stockholders' Equity.” Employee separation costs were insignificant in 2016.

Restructuring and separation costs are reported in “Restructuring and separation costs” in the accompanying consolidated statements of operations. The following tables present the major types of such costs by segment. Long-lived assets include capitalized software, intangible assets and furniture, fixtures and equipment.



	Three Months Ended September 30, 2017
	Separation Costs - Former Executives		One-Time Termination Benefits		Other Restructuring Costs						Total
	Separation Costs - Former Executives		One-Time Termination Benefits		Write-offs of Long-lived Assets		Consulting Fees		Contract Termination Costs		Total
	(In millions)
Health Plans	$	—	$	27	$	6	$	—	$	—	$	33
Molina Medicaid Solutions	—		—		8		—		—		8
Other	—		23		35		16		3		77
	$	—	$	50	$	49	$	16	$	3	$	118



	Nine Months Ended September 30, 2017
	Separation Costs - Former Executives		One-Time Termination Benefits		Other Restructuring Costs						Total
	Separation Costs - Former Executives		One-Time Termination Benefits		Write-offs of Long-lived Assets		Consulting Fees		Contract Termination Costs		Total
	(In millions)
Health Plans	$	—	$	27	$	6	$	—	$	—	$	33
Molina Medicaid Solutions	—		—		8		—		—		8
Other	35		23		35		24		3		120
	$	35	$	50	$	49	$	24	$	3	$	161

Reconciliation of Liability

~~Separation costs–one-time benefit arrangement for workforce reduction.~~ ~~As part~~For those restructuring and separation costs that require cash settlement (primarily separation costs, termination benefits and consulting fees), the following table presents a roll-forward of the Restructuring Plan, we are reducing our corporate and health plans workforce by approximately 10%, or 1,500 full-time-equivalent employees. This workforce rightsizing, which represents 7% of the total number of our employees, is expected to be completed by the end of 2017. Affected employees will be offered severance and outplacement assistance. Our board of

~~directors approved the reduction in our workforce under the Restructuring Plan effective July 27, 2017; as such no amounts were~~ accrued ~~for this termination plan as of June 30, 2017.~~

~~Other Restructuring Costs~~

In the six months ended June 30, 2017, we incurred approximately $8 million in other restructuring costs including primarily consulting fees relating to the operational assessment and restructuring initiatives described above.

~~The following table summarizes the year-to-date activities related to our Restructuring Plan, the reserve for~~liability, which is reported in “Accounts payable and accrued liabilities” in the accompanying consolidated balance sheets:

Separation Costs–Former Executives
Other Restructuring Costs Total
(In millions)
Accrued restructuring and separation costs as of December 31, 2016 $ —
$ —
$ —
Costs recognized 35
8
43
Cash payments (1 ) (2 ) (3 )
Other adjustments–acceleration of share-based compensation
(23 ) —
(23 )
Accrued restructuring and separation costs as of June 30, 2017 $ 11
$ 6
$ 17

~~Expected Costs~~

We estimate that total pre-tax costs associated with the Restructuring Plan will be approximately $130 million to $150 million for the second half of 2017, with an additional $40 million to be incurred in 2018. We expect these costs to relate only to the Health Plans and Other segments. Other restructuring costs will include primarily consulting fees; costs associated with the restructuring of our direct delivery operations including lease terminations and accelerated depreciation and amortization; and restructuring of various corporate business functions.

~~The following table illustrates our estimates of costs associated with the Restructuring Plan, which we expect to be completed by the end of 2018, by segment and major type of cost:~~



~~Estimated Costs Expected to be Incurred by Reportable Segment~~	~~Health Plans~~	~~Other~~	~~Total~~
	~~(In millions)~~
~~Separation costs–one-time benefit arrangement for a workforce reduction~~	~~$25 to $30~~	~~$35 to $40~~	~~$60 to $70~~
~~Other restructuring costs~~	~~$55 to $60~~	~~$55 to $60~~	~~$110 to $120~~
	~~$80 to $90~~	~~$90 to $100~~	~~$170 to $190~~



	Separation Costs - Former Executives			One-Time Termination Benefits			Other Restructuring Costs			Total
	(In millions)
Accrued as of December 31, 2016	$	—		$	—		$	—		$	—
Charges	12			50			27			89
Cash payments	(1		)	(9		)	(14		)	(24		)
Accrued as of September 30, 2017	$	11		$	41		$	13		$	65

12. Segment Information

We have three reportable segments. These segments consist of our Health Plans segment, which constitutes the vast majority of our operations; our Molina Medicaid Solutions segment; and our Other segment. Our reportable segments are consistent with how we currently manage the business and view the markets we serve.

Gross margin is the appropriate earnings measure for our reportable segments, based on how our chief operating decision maker currently reviews results, assesses performance, and allocates resources.

Gross margin for our Health Plans segment is referred to as “Medical margin,” and for our Molina Medicaid Solutions and Other segments, as “Service margin.” Medical margin represents the amount earned by the Health Plans segment after medical costs are deducted from premium revenue. The medical care ratio represents medical care costs as a percentage of premium revenue, and is one of the key metrics used to assess the performance of the Health Plans segment. Therefore, the underlying medical margin is the most important measure of earnings reviewed by the chief operating decision maker. The service margin is equal to service revenue minus cost of service revenue.


	Health Plans			Molina Medicaid Solutions		Other			Consolidated			Health Plans				Molina Medicaid Solutions			Other			Consolidated

			(In millions)												(In millions)
Three Months Ended June 30, 2017
Three Months Ended September 30, 2017
Total revenue ⁽¹⁾	$	4,868		$	47	$	84		$	4,999		$	4,899			$	47		$	85		$	5,031
Gross margin	249			4		1			254			557				5			2			564
Impairment losses	—			—		(72		)	(72		)	—				(28		)	(101		)	(129		)
Restructuring and separation costs	—			—		(43		)	(43		)	(33		)		(8		)	(77		)	(118		)

Six Months Ended June 30, 2017
Nine Months Ended September 30, 2017
Total revenue ⁽¹⁾	9,639			93		171			9,903			$	14,538			$	140		$	256		$	14,934
Gross margin	786			8		6			800			1,343				13			8			1,364
Impairment losses	—			—		(72		)	(72		)	—				(28		)	(173		)	(201		)
Restructuring and separation costs	—			—		(43		)	(43		)	(33		)		(8		)	(120		)	(161		)

Three Months Ended June 30, 2016
Three Months Ended September 30, 2016
Total revenue ⁽¹⁾	4,223			46		90			4,359			$	4,412			$	48		$	86		$	4,546
Gross margin	435			5		14			454			443				6			8			457
Impairment losses	—			—		—			—			—				—			—			—
Restructuring and separation costs	—			—		—			—			—				—			—			—

Six Months Ended June 30, 2016
Nine Months Ended September 30, 2016
Total revenue ⁽¹⁾	8,424			98		180			8,702			$	12,835			$	146		$	267		$	13,248
Gross margin	842			11		21			874			1,285				17			29			1,331
Impairment losses	—			—		—			—			—				—			—			—
Restructuring and separation costs	—			—		—			—			—				—			—			—

Total Assets
June 30, 2017	6,732			240		1,611			8,583
Total assets
September 30, 2017												$	7,031			$	233		$	1,690		$	8,954
December 31, 2016	5,897			267		1,285			7,449			5,897				267			1,285			7,449

Goodwill, and Intangible Assets, Net
June 30, 2017	498			72		101			671
Goodwill and intangible assets, net
September 30, 2017												$	488			$	43		$	—		$	531
December 31, 2016	513			72		175			760			513				72			175			760

______________________


(1)	Total revenue consists primarily of premium revenue, premium tax revenue and health insurer fee revenue for the Health Plans segment, and service revenue for the Molina Medicaid Solutions and Other segments. Inter-segment revenue is insignificant for all periods presented.

The following table reconciles gross margin by segment to consolidated income before income tax expense:


	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016			2017			2016			2017			2016
	(In millions)												(In millions)
Gross margin:
Health Plans	$	249		$	435		$	786		$	842		$	557		$	443		$	1,343		$	1,285
Molina Medicaid Solutions	4			5			8			11			5			6			13			17
Other	1			14			6			21			2			8			8			29
Total gross margin	254			454			800			874			564			457			1,364			1,331
Add: other operating revenues ⁽¹⁾	130			195			255			403			124			222			379			625
Less: other operating expenses ⁽²⁾	(671		)	(544		)	(1,260		)	(1,083		)	(769		)	(561		)	(2,029		)	(1,644		)
Operating (loss) income	(287		)	105			(205		)	194			(81		)	118			(286		)	312
Other expenses (income), net	27			25			(22		)	50
Other expenses, net													32			26			10			76
(Loss) income before income taxes	$	(314	)	$	80		$	(183	)	$	144		$	(113	)	$	92		$	(296	)	$	236

______________________


(1)	Other operating revenues include premium tax revenue, health insurer fee revenue, investment income and other revenue.


(2)	Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fee expenses, depreciation and amortization, impairment losses, and restructuring and separation costs.

13. Commitments and Contingencies

Regulatory Capital Requirements and Dividend Restrictions

Our health plans, which are operated by our ~~respective~~ wholly owned subsidiaries in ~~those~~the states in which our health plans operate, are subject to state laws and regulations that, among other things, require the maintenance of minimum levels of statutory capital, as defined by each state. Regulators in some states may also attempt to enforce capital requirements that require the retention of net worth in excess of amounts formally required by statute or regulation. Such statutes, regulations and informal capital requirements also restrict the timing, payment, and amount of dividends and other distributions that may be paid to us as the sole stockholder. To the extent our subsidiaries must comply with these regulations, they may not have the financial flexibility to transfer funds to us. Based on current statutes and regulations, the net assets in these subsidiaries (after intercompany eliminations) which may not be transferable to us in the form of loans, advances, or cash dividends was approximately ~~$1,526~~$1,696 million at ~~June~~September 30, 2017, and $1,492 million at December 31, 2016. Because of the statutory restrictions that inhibit the ability of our health plans to transfer net assets to us, the amount of retained earnings readily available to pay dividends to our stockholders is generally limited to cash, cash equivalents and investments (excluding restricted investments) held by the parent company – Molina Healthcare, Inc. Such cash, cash equivalents and investments (excluding restricted investments) amounted to ~~$165~~$391 million and $264 million as of ~~June~~September 30, 2017 and December 31, 2016, respectively.

The National Association of Insurance Commissioners (NAIC) adopted rules effective December 31, 1998, which, if implemented by the states, set minimum capitalization requirements for insurance companies, HMOs, and other entities bearing risk for health care coverage. The requirements take the form of risk-based capital (RBC) rules which may vary from state to state. All of the states in which our health plans operate, except California, Florida and New York, have adopted these rules. Such requirements, if adopted by California, Florida and New York, may increase the minimum capital required for those states.

As of ~~June~~September 30, 2017, our health plans had aggregate statutory capital and surplus of approximately ~~$1,662~~$1,828 million compared with the required minimum aggregate statutory capital and surplus of approximately ~~$1,118~~$1,113 million. ~~Primarily as a result of the recognition of Marketplace-related premium deficiency reserves discussed in Note 2, “Significant Accounting Policies,” certain~~All of our health plans ~~did not meet~~were in compliance with the minimum capital requirements ~~on June~~at September 30, ~~2017. We intend to remedy the deficiencies to the satisfaction of our departments of insurance prior to the filing of the statutory financial statements on August 15,~~ 2017. We have the ability, and have committed to provide, additional capital to each of our health plans as necessary to ensure compliance with statutory capital and surplus requirements.

Legal Proceedings

The health care and Medicaid-related business process outsourcing industries are subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. Penalties

associated with violations of these laws and regulations include significant fines, ~~and penalties,~~ exclusion from participating in publicly funded programs, and the repayment of previously billed and collected revenues.

We are involved in legal actions in the ordinary course of business, some of which seek monetary damages, including claims for punitive damages, which are not covered by insurance. We have accrued liabilities for certain matters for which we deem the loss to be both probable and ~~estimable. Although we believe that~~reasonably estimable, but the outcome of legal actions is inherently uncertain and our estimates of such losses ~~are reasonable, these estimates~~ could change as a result of further developments of these matters. ~~The outcome of legal actions is inherently uncertain and such~~For certain pending matters, ~~for which~~ accruals have not been established because such matters have not progressed sufficiently through discovery, and/or development of important factual information and legal issues is insufficient to enable us to estimate a range of possible loss, if any. ~~While it is not possible to accurately predict or determine the eventual outcomes of these items, an~~An adverse determination in one or more of these pending matters could have a material adverse effect on our consolidated financial position, results of operations, or cash flows.

Marketplace Risk Corridor Program. On January 19, 2017, we filed suit against the United States of America in the United States Court of Federal Claims, Case Number 1:55-cv-01000-UNJ, on behalf of our health plans seeking recovery from the federal government of approximately $52 million in Marketplace risk corridor payments for calendar year 2015. Based upon current estimates, we believe our health plans are also owed approximately $76 million in Marketplace risk corridor payments from the federal government for calendar year ~~2016, and a further nominal amount for calendar year 2014. Our lawsuit seeks recovery of all of these unpaid amounts.~~2016. We have not recognized revenue, nor have we recorded a receivable, for any amount due from the federal government for unpaid Marketplace risk corridor payments as of ~~June~~September 30, 2017. We have fully recognized all liabilities due to the federal government that we have incurred under the Marketplace risk corridor program, and have paid all amounts due to the federal government as required.

Rodriguez v. Providence Community Corrections. On October 1, 2015, seven individuals, on behalf of themselves and all others similarly situated, filed a complaint in the District Court for the Middle District of Tennessee, Nashville Division, Case No. 3:15-cv-01048 (the Rodriquez Litigation), against Providence Community Corrections, Inc. (now known as Pathways Community Corrections, Inc., or PCC). Rutherford County, Tennessee formerly contracted with PCC for the administration of misdemeanor probation, which involved the collection of court costs and fees from probationers. The complaint alleges, among other things, that PCC illegally assessed fees and surcharges against probationers and made improper threats of arrest and probation revocation if the probationers did not pay such amounts. The plaintiffs in the Rodriguez Litigation seek alleged compensatory, treble, and punitive damages, plus attorneys’ fees, for alleged federal and state constitutional violations, as well as alleged violations of the Racketeer Influenced and Corrupt Organization Act. PCC’s agreement with Rutherford County terminated effective March 31, 2016. On November 1, 2015, one month after the Rodriguez Litigation commenced, we acquired PCC from The Providence Service Corporation (Providence) pursuant to a membership interest purchase agreement. In September 2016, the parties to the Rodriguez Litigation accepted a mediation proposal for settlement pursuant to which PCC and Rutherford County would pay the plaintiffs $14 million and $3 million, respectively. The parties are in the process of finalizing the settlement agreement. We expect to recover the full amount of the settlement under the indemnification provisions of the membership interest purchase agreement with Providence.

United States of America, ex rel., Anita Silingo v. Mobile Medical Examination Services, Inc., et al. On or around October 14, 2014, Molina Healthcare of California, Molina Healthcare of California Partner Plan, Inc., Mobile Medical Examination Services, Inc. (MedXM), and other health plan defendants were served with a ~~Complaint~~complaint previously filed under seal in the Central District Court of California by Relator, Anita Silingo, Case No. SACV13-1348-FMO(SHx). The ~~Complaint~~complaint alleges that MedXM improperly modified medical records and otherwise took inappropriate steps to increase members’ risk adjustment scores, and that the defendants, including Molina Healthcare of California and Molina Healthcare of California Partner Plan, Inc., purportedly turned a “blind eye” to these unlawful practices. On October 22, 2015, the Relator filed a third amended complaint, seeking general and compensatory damages, treble damages, civil penalties, plus interest and attorneys’ fees. On July 11, 2016, the District Court dismissed with prejudice the third amended complaint, without leave to amend. On September 23, 2016, the plaintiff filed an appeal with the Ninth Circuit Court of Appeals. The appeal has been fully briefed by the parties and we are awaiting the Court’s decision.

States’ Budgets

From time to time, the states in which our health plans operate may experience financial difficulties, which could lead to delays in premium payments. Until July 4, 2017, the state of Illinois operated without a budget for its current fiscal year. As of ~~June~~September 30, 2017, our Illinois health plan served approximately 163,000 members, and recognized premium revenue of approximately ~~$310~~$447 million in the ~~first half of~~nine months ended September 30, 2017. As of ~~July 28,~~September 30, 2017, the state of Illinois owed us approximately ~~$116~~$220 million for certain March ~~April, May and June~~through September 2017 premiums.

On May 3, 2017, Puerto Rico’s financial oversight board filed for a form of bankruptcy in the U.S. District Court in Puerto Rico under Title III of PROMESA. The Title III provision allows for a court debt restructuring process similar to U.S. bankruptcy protection. To the extent such bankruptcy results in our failure to receive payment of amounts due under our Medicaid contract with the Commonwealth or the inability of the Commonwealth to extend our Medicaid contract at the end of its current term, such bankruptcy could have a material adverse effect on our business, financial condition, cash flows, or results of operations. As of ~~June~~September 30, 2017, the plan served approximately ~~322,000~~306,000 members and recorded premium revenue of approximately ~~$362~~$553 million in the ~~first half of~~nine months ended September 30, 2017. As of ~~July 28,~~October 27, 2017, the Commonwealth was current with its premium payments.

14. Related Party Transactions

Our California health plan has entered into a provider agreement with Pacific Healthcare IPA (Pacific), which is 50% owned by the brother-in-law of Dr. J. Mario Molina and John C. Molina, who are members of our board of directors. Under the terms of this provider agreement, the California health plan pays Pacific for medical care Pacific provides to health plan members. For the three and ~~six~~nine months ended ~~June~~September 30, 2017 and 2016, the amounts paid to Pacific were insignificant.

Refer to Note 15, “Variable Interest Entities (VIEs),” for a discussion of the Joseph M. Molina, M.D. Professional Corporations.

15. Variable Interest Entities (VIEs)

The Joseph M. Molina, M.D. Professional Corporations (JMMPC) were created to further advance our direct delivery business. ~~On August 2,~~Effective September 30, 2017, we ~~announced~~terminated our relationship with JMMPC in Florida, Michigan, Washington, and Utah. Therefore, the agreements described below, for all of our health plans ~~to restructure our direct delivery operations.~~other than those in California and New Mexico, were terminated effective September 30, 2017.

JMMPC’s primary shareholder is Dr. J. Mario Molina, who is a member of our board of directors. Dr. Molina is paid no salary and receives no dividends in connection with his work for, or ownership of, JMMPC. JMMPC provides primary care medical services through its employed physicians and other medical professionals. JMMPC also provides certain specialty referral services to our California health plan members through a contracted provider network. ~~Substantially all of the individuals served by JMMPC are members of our California, Florida, New Mexico, Utah, and Washington health plans. These~~The health plans had entered into primary care services agreements with JMMPC, under which the health plans paid $29 million and $31 million to JMMPC for health care services provided in the three months ended ~~June~~September 30, 2017 and 2016, ~~respectively. For~~respectively, and $89 million and $92 million for the ~~six~~nine months ended ~~June~~September 30, 2017 and 2016, ~~the health plans paid JMMPC $60 million and $61 million,~~ respectively. JMMPC does not have agreements to provide professional medical services with any other entities.

Our wholly owned subsidiary, Molina Medical Management, Inc. (MMM), had also entered into services agreements with JMMPC to provide clinic facilities, clinic administrative support staff, patient scheduling services and medical supplies to JMMPC. The services agreements were designed such that JMMPC operated at break even, ensuring the availability of quality care and access for our health plan members. The services agreements further provided that the administrative fees charged to JMMPC by MMM were reviewed annually to assure the achievement of this goal. For ~~each of~~ the three months ended ~~June~~September 30, 2017 and 2016, JMMPC paid $12 million and $13 million to MMM for clinic administrative ~~services.~~services, respectively. For the ~~six~~nine months ended ~~June~~September 30, 2017 and 2016, JMMPC paid ~~$26~~$38 million and ~~$27~~$40 million, respectively, to MMM for clinic administrative services.

As of ~~June~~September 30, 2017, we determined that JMMPC is a VIE, and that we are its primary beneficiary. We reached this conclusion under the power and benefits criterion model according to GAAP. Specifically, we had the power to direct the activities (excluding clinical decisions) that most significantly affected JMMPC’s economic performance, and the obligation to absorb losses or right to receive benefits that were potentially significant to the VIE, under the agreements described above. Because we were its primary beneficiary, we consolidated JMMPC. JMMPC’s assets may be used to settle only JMMPC’s obligations, and JMMPC’s creditors have no recourse to the general credit of

Molina Healthcare, Inc. As of ~~June~~September 30, 2017, JMMPC had total assets of ~~$17~~$20 million, and total liabilities of ~~$18~~$24 million. As of December 31, 2016, JMMPC had total assets of $18 million, and total liabilities of $18 million.

Our maximum exposure to loss as a result of our involvement with JMMPC ~~was~~is generally limited to the amounts needed to fund JMMPC’s ongoing payroll, employee benefits and medical care costs associated with JMMPC’s specialty referral activities.

16. Supplemental Condensed Consolidating Financial Information

The 5.375% Notes described in Note 7, “Debt,” are fully and unconditionally guaranteed by certain of our 100% owned subsidiaries on a joint and several basis, with certain exceptions considered customary for such guarantees. The 5.375% Notes and the guarantees are effectively subordinated to all of our and our guarantors’ existing and future secured debt to the extent of the assets securing such debt. In addition, the 5.375% Notes and the guarantees are structurally subordinated to all indebtedness and other liabilities and preferred stock, if any, of our subsidiaries that do not guarantee the 5.375% Notes.

As discussed in Note 7, “Debt,” the First Amendment to the Credit Facility provided that all guarantors immediately prior to January 3, 2017, other than Molina Information Systems, LLC, d/b/a Molina Medicaid Solutions, Molina Pathways, LLC, and Pathways Health and Community Support LLC, were automatically and unconditionally released from their obligations as guarantors under the Credit Facility and the 5.375% Notes.

The following condensed consolidating financial statements present Molina Healthcare, Inc. (as parent guarantor), the subsidiary guarantors, the subsidiary non-guarantors and eliminations, according to the guarantor structure as assessed at the most recent balance sheet date, ~~June~~September 30, 2017.

CONDENSED CONSOLIDATING STATEMENTS OF OPERATIONS


	Three Months Ended June 30, 2017															Three Months Ended September 30, 2017
	Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations			Consolidated			Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations			Consolidated
	(In millions)															(In millions)
Revenue:
Total revenue	$	289		$	51		$	4,952		$	(293	)	$	4,999		$	380		$	47		$	4,983		$	(379	)	$	5,031
Expenses:
Medical care costs	3			—			4,488			—			4,491			3			—			4,217			—			4,220
Cost of service revenue	—			43			81			—			124			—			42			81			—			123
General and administrative expenses	258			7			433			(293		)	405			244			(1		)	519			(379		)	383
Premium tax expenses	—			—			114			—			114			—			—			106			—			106
Depreciation and amortization	25			—			12			—			37			23			1			9			—			33
Impairment losses	—			—			72			—			72			—			28			101			—			129
Restructuring and separation costs	43			—			—			—			43			77			8			33			—			118
Total operating expenses	329			50			5,200			(293		)	5,286			347			78			5,066			(379		)	5,112
Operating (loss) income	(40		)	1			(248		)	—			(287		)
Operating income (loss)																33			(31		)	(83		)	—			(81		)
Interest expense	27			—			—			—			27			32			—			—			—			32
(Loss) income before income taxes	(67		)	1			(248		)	—			(314		)
Income tax benefit	(14		)	—			(70		)	—			(84		)
Net (loss) income before equity in net losses of subsidiaries	(53		)	1			(178		)	—			(230		)
Income (loss) before income taxes																1			(31		)	(83		)	—			(113		)
Income tax expense (benefit)																9			(10		)	(15		)	—			(16		)
Net loss before equity in net losses of subsidiaries																(8		)	(21		)	(68		)	—			(97		)
Equity in net losses of subsidiaries	(177		)	(64		)	—			241			—			(89		)	(77		)	—			166			—
Net loss	$	(230	)	$	(63	)	$	(178	)	$	241		$	(230	)	$	(97	)	$	(98	)	$	(68	)	$	166		$	(97	)

CONDENSED CONSOLIDATING STATEMENTS OF COMPREHENSIVE LOSS


	Three Months Ended June 30, 2017														Three Months Ended September 30, 2017
	Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations		Consolidated			Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations		Consolidated
	(In millions)														(In millions)
Net loss	$	(230	)	$	(63	)	$	(178	)	$	241	$	(230	)	$	(97	)	$	(98	)	$	(68	)	$	166	$	(97	)
Other comprehensive loss, net of tax	—			—			—			—		—			—			—			—			—		—
Comprehensive loss	$	(230	)	$	(63	)	$	(178	)	$	241	$	(230	)	$	(97	)	$	(98	)	$	(68	)	$	166	$	(97	)

CONDENSED CONSOLIDATING STATEMENTS OF INCOME


	Three Months Ended June 30, 2016													Three Months Ended September 30, 2016
	Parent Guarantor			Other Guarantors			Non-Guarantors		Eliminations			Consolidated		Parent Guarantor			Other Guarantors			Non-Guarantors		Eliminations			Consolidated
	(In millions)													(In millions)
Revenue:
Total revenue	$	261		$	47		$	4,311	$	(260	)	$	4,359	$	274		$	48		$	4,498	$	(274	)	$	4,546
Expenses:
Medical care costs	19			—			3,575		—			3,594		19			—			3,730		(1		)	3,748
Cost of service revenue	—			23			93		—			116		—			42			77		—			119
General and administrative expenses	219			24			368		(260		)	351		223			(4		)	397		(273		)	343
Premium tax expenses	—			—			109		—			109		—			—			127		—			127
Health insurer fee expenses	—			—			50		—			50		—			—			55		—			55
Depreciation and amortization	23			1			10		—			34		25			2			9		—			36
Total operating expenses	261			48			4,205		(260		)	4,254		267			40			4,395		(274		)	4,428
Operating (loss) income	—			(1		)	106		—			105
Operating income														7			8			103		—			118
Interest expense	25			—			—		—			25		26			—			—		—			26
(Loss) income before income taxes	(25		)	(1		)	106		—			80		(19		)	8			103		—			92
Income tax (benefit) expense	(12		)	(1		)	60		—			47
Income tax expense														4			—			46		—			50
Net (loss) income before equity in net earnings of subsidiaries	(13		)	—			46		—			33		(23		)	8			57		—			42
Equity in net earnings of subsidiaries	46			1			—		(47		)	—		65			—			—		(65		)	—
Net income	$	33		$	1		$	46	$	(47	)	$	33	$	42		$	8		$	57	$	(65	)	$	42

CONDENSED CONSOLIDATING STATEMENTS OF COMPREHENSIVE INCOME


	Three Months Ended June 30, 2016											Three Months Ended September 30, 2016
	Parent Guarantor		Other Guarantors		Non-Guarantors		Eliminations			Consolidated		Parent Guarantor			Other Guarantors		Non-Guarantors			Eliminations			Consolidated

	(In millions)											(In millions)
Net income	$	33	$	1	$	46	$	(47	)	$	33	$	42		$	8	$	57		$	(65	)	$	42
Other comprehensive income, net of tax	2		—		2		(2		)	2
Other comprehensive loss, net of tax												(1		)	—		(1		)	1			(1		)
Comprehensive income	$	35	$	1	$	48	$	(49	)	$	35	$	41		$	8	$	56		$	(64	)	$	41

CONDENSED CONSOLIDATING STATEMENTS OF OPERATIONS


	Six Months Ended June 30, 2017															Nine Months Ended September 30, 2017
	Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations			Consolidated			Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations			Consolidated
	(In millions)															(In millions)
Revenue:
Total revenue	$	630		$	99		$	9,809		$	(635	)	$	9,903		$	1,010		$	146		$	14,792		$	(1,014	)	$	14,934
Expenses:
Medical care costs	7			—			8,595			—			8,602			10			—			12,812			—			12,822
Cost of service revenue	—			85			161			—			246			—			127			242			—			369
General and administrative expenses	555			14			910			(635		)	844			799			13			1,429			(1,014		)	1,227
Premium tax expenses	—			—			225			—			225			—			—			331			—			331
Depreciation and amortization	52			—			24			—			76			75			1			33			—			109
Impairment losses	—			—			72			—			72			—			28			173			—			201
Restructuring and separation costs	43			—			—			—			43			120			8			33			—			161
Total operating expenses	657			99			9,987			(635		)	10,108			1,004			177			15,053			(1,014		)	15,220
Operating loss	(27		)	—			(178		)	—			(205		)
Operating income (loss)																6			(31		)	(261		)	—			(286		)
Interest expense	53			—			—			—			53			85			—			—			—			85
Other income, net	(75		)	—			—			—			(75		)	(75		)	—			—			—			(75		)
Loss before income taxes	(5		)	—			(178		)	—			(183		)	(4		)	(31		)	(261		)	—			(296		)
Income tax expense (benefit)	17			—			(47		)	—			(30		)	26			(10		)	(62		)	—			(46		)
Net loss before equity in net losses of subsidiaries	(22		)	—			(131		)	—			(153		)	(30		)	(21		)	(199		)	—			(250		)
Equity in net losses of subsidiaries	(131		)	(66		)	—			197			—			(220		)	(143		)	—			363			—
Net loss	$	(153	)	$	(66	)	$	(131	)	$	197		$	(153	)	$	(250	)	$	(164	)	$	(199	)	$	363		$	(250	)

CONDENSED CONSOLIDATING STATEMENTS OF COMPREHENSIVE LOSS


	Six Months Ended June 30, 2017															Nine Months Ended September 30, 2017
	Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations			Consolidated			Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations			Consolidated
	(In millions)															(In millions)
Net loss	$	(153	)	$	(66	)	$	(131	)	$	197		$	(153	)	$	(250	)	$	(164	)	$	(199	)	$	363		$	(250	)
Other comprehensive income, net of tax	1			—			1			(1		)	1			1			—			1			(1		)	1
Comprehensive loss	$	(152	)	$	(66	)	$	(130	)	$	196		$	(152	)	$	(249	)	$	(164	)	$	(198	)	$	362		$	(249	)

CONDENSED CONSOLIDATING STATEMENTS OF INCOME


	Six Months Ended June 30, 2016													Nine Months Ended September 30, 2016
	Parent Guarantor			Other Guarantors			Non-Guarantors		Eliminations			Consolidated		Parent Guarantor			Other Guarantors			Non-Guarantors		Eliminations			Consolidated
	(In millions)													(In millions)
Revenue:
Total revenue	$	512		$	99		$	8,601	$	(510	)	$	8,702	$	786		$	147		$	13,099	$	(784	)	$	13,248
Expenses:
Medical care costs	31			—			7,151		—			7,182		50			—			10,881		(1		)	10,930
Cost of service revenue	—			88			155		—			243		—			130			232		—			362
General and administrative expenses	436			9			756		(510		)	691		659			5			1,153		(783		)	1,034
Premium tax expenses	—			—			218		—			218		—			—			345		—			345
Health insurer fee expenses	—			—			108		—			108		—			—			163		—			163
Depreciation and amortization	45			3			18		—			66		70			5			27		—			102
Total operating expenses	512			100			8,406		(510		)	8,508		779			140			12,801		(784		)	12,936
Operating (loss) income	—			(1		)	195		—			194
Operating income														7			7			298		—			312
Interest expense	50			—			—		—			50		76			—			—		—			76
(Loss) income before income taxes	(50		)	(1		)	195		—			144		(69		)	7			298		—			236
Income tax (benefit) expense	(28		)	(1		)	116		—			87		(24		)	(1		)	162		—			137
Net (loss) income before equity in earnings of subsidiaries	(22		)	—			79		—			57		(45		)	8			136		—			99
Equity in net earnings of subsidiaries	79			3			—		(82		)	—		144			3			—		(147		)	—
Net income	$	57		$	3		$	79	$	(82	)	$	57	$	99		$	11		$	136	$	(147	)	$	99

CONDENSED CONSOLIDATING STATEMENTS OF COMPREHENSIVE INCOME


	Six Months Ended June 30, 2016											Nine Months Ended September 30, 2016
	Parent Guarantor		Other Guarantors		Non-Guarantors		Eliminations			Consolidated		Parent Guarantor		Other Guarantors		Non-Guarantors		Eliminations			Consolidated
	(In millions)											(In millions)
Net income	$	57	$	3	$	79	$	(82	)	$	57	$	99	$	11	$	136	$	(147	)	$	99
Other comprehensive income, net of tax	8		—		7		(7		)	8		7		—		6		(6		)	7
Comprehensive income	$	65	$	3	$	86	$	(89	)	$	65	$	106	$	11	$	142	$	(153	)	$	106

CONDENSED CONSOLIDATING BALANCE SHEETS


	June 30, 2017													September 30, 2017
	Parent Guarantor		Other Guarantors			Non-Guarantors			Eliminations			Consolidated		Parent Guarantor		Other Guarantors			Non-Guarantors			Eliminations			Consolidated
	(In millions)													(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	109	$	32		$	2,838		$	—		$	2,979	$	356	$	58		$	3,520		$	—		$	3,934
Investments	56		—			2,136			—			2,192		35		—			1,752			—			1,787
Restricted investments	325		—			—			—			325		326		—			—			—			326
Receivables	2		30			974			—			1,006		2		25			975			—			1,002
Income taxes refundable	7		1			60			—			68		2		—			58			—			60
Due from (to) affiliates	137		(6		)	(131		)	—			—		203		(5		)	(198		)	—			—
Prepaid expenses and other current assets	70		21			68			—			159		65		20			89			—			174
Derivative asset	440		—			—			—			440		425		—			—			—			425
Total current assets	1,146		78			5,945			—			7,169		1,414		98			6,196			—			7,708
Property, equipment, and capitalized software, net	297		47			105			—			449		261		37			99			—			397
Deferred contract costs	—		93			—			—			93		—		97			—			—			97
Goodwill and intangible assets, net	56		72			543			—			671		55		43			433			—			531
Restricted investments	—		—			118			—			118		—		—			117			—			117
Investment in subsidiaries, net	2,597		181			—			(2,778		)	—		2,625		95			—			(2,720		)	—
Deferred income taxes	10		(43		)	79			(10		)	36		10		—			96			(44		)	62
Other assets	55		2			6			(16		)	47		50		2			6			(16		)	42
	$	4,161	$	430		$	6,796		$	(2,804	)	$	8,583	$	4,415	$	372		$	6,947		$	(2,780	)	$	8,954

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Medical claims and benefits payable	$	—	$	—		$	2,077		$	—		$	2,077	$	—	$	—		$	2,478		$	—		$	2,478
Amounts due government agencies	—		—			1,844			—			1,844		—		—			1,324			—			1,324
Accounts payable and accrued liabilities	170		35			170			—			375		227		40			218			—			485
Deferred revenue	—		49			235			—			284		—		52			416			—			468
Current portion of long-term debt	773		—			—			—			773		782		—			—			—			782
Derivative liability	440		—			—			—			440		425		—			—			—			425
Total current liabilities	1,383		84			4,326			—			5,793		1,434		92			4,436			—			5,962
Long-term debt	1,215		—			16			(16		)	1,215		1,515		—			16			(16		)	1,515
Deferred income taxes	10		—			—			(10		)	—		12		32			—			(44		)	—
Other long-term liabilities	32		1			21			—			54		25		1			22			—			48
Total liabilities	2,640		85			4,363			(26		)	7,062		2,986		125			4,474			(60		)	7,525
Total stockholders’ equity	1,521		345			2,433			(2,778		)	1,521		1,429		247			2,473			(2,720		)	1,429
	$	4,161	$	430		$	6,796		$	(2,804	)	$	8,583	$	4,415	$	372		$	6,947		$	(2,780	)	$	8,954

CONDENSED CONSOLIDATING BALANCE SHEETS



	December 31, 2016
	Parent Guarantor		Other Guarantors			Non-Guarantors			Eliminations			Consolidated
	(In millions)
ASSETS
Current assets:
Cash and cash equivalents	$	86	$	6		$	2,727		$	—		$	2,819
Investments	178		—			1,580			—			1,758
Receivables	2		34			938			—			974
Income tax refundable	17		4			18			—			39
Due from (to) affiliates	104		(5		)	(99		)	—			—
Prepaid expenses and other current assets	58		30			43			—			131
Derivative asset	267		—			—			—			267
Total current assets	712		69			5,207			—			5,988
Property, equipment, and capitalized software, net	301		46			107			—			454
Deferred contract costs	—		86			—			—			86
Goodwill and intangible assets, net	58		73			629			—			760
Restricted investments	—		—			110			—			110
Investment in subsidiaries, net	2,609		246			—			(2,855		)	—
Deferred income taxes	10		—			—			—			10
Other assets	48		3			6			(16		)	41
	$	3,738	$	523		$	6,059		$	(2,871	)	$	7,449

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Medical claims and benefits payable	$	1	$	—		$	1,928		$	—		$	1,929
Amounts due government agencies	—		—			1,202			—			1,202
Accounts payable and accrued liabilities	146		34			205			—			385
Deferred revenue	—		40			275			—			315
Current portion of long-term debt	472		—			—			—			472
Derivative liability	267		—			—			—			267
Total current liabilities	886		74			3,610			—			4,570
Long-term debt	1,173		—			16			(16		)	1,173
Deferred income taxes	11		39			(35		)	—			15
Other long-term liabilities	19		1			22			—			42
Total liabilities	2,089		114			3,613			(16		)	5,800
Total stockholders’ equity	1,649		409			2,446			(2,855		)	1,649
	$	3,738	$	523		$	6,059		$	(2,871	)	$	7,449

CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS


	Six Months Ended June 30, 2017														Nine Months Ended September 30, 2017
	Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations		Consolidated			Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations		Consolidated
	(In millions)														(In millions)
Operating activities:
Net cash provided by operating activities	$	90		$	44		$	538		$	—	$	672		$	215		$	81		$	661		$	—	$	957
Investing activities:
Purchases of investments	(330		)	—			(1,306		)	—		(1,636		)	(333		)	—			(1,563		)	—		(1,896		)
Proceeds from sales and maturities of investments	127			—			747			—		874			150			—			1,388			—		1,538
Purchases of property, equipment and capitalized software	(45		)	(9		)	(6		)	—		(60		)	(67		)	(10		)	(8		)	—		(85		)
Increase in restricted investments held-to-maturity	—			—			(10		)	—		(10		)	—			—			(10		)	—		(10		)
Capital contributions to/from subsidiaries	(238		)	2			236			—		—			(363		)	2			361			—		—
Dividends to/from subsidiaries	120			—			(120		)	—		—			136			—			(136		)	—		—
Change in amounts due to/from affiliates	(34		)	2			32			—		—			(100		)	—			100			—		—
Other, net	—			(13		)	—			—		(13		)	—			(21		)	—			—		(21		)
Net cash used in investing activities	(400		)	(18		)	(427		)	—		(845		)
Net cash (used in) provided by investing activities															(577		)	(29		)	132			—		(474		)
Financing activities:
Proceeds from senior notes offerings, net of issuance costs	325			—			—			—		325
Proceeds from senior notes offering, net of issuance costs															325			—			—			—		325
Proceeds from borrowings under credit facility															300			—			—			—		300
Proceeds from employee stock plans	11			—			—			—		11			11			—			—			—		11
Other, net	(3		)	—			—			—		(3		)	(4		)	—			—			—		(4		)
Net cash provided by financing activities	333			—			—			—		333			632			—			—			—		632
Net increase in cash and cash equivalents	23			26			111			—		160			270			52			793			—		1,115
Cash and cash equivalents at beginning of period	86			6			2,727			—		2,819			86			6			2,727			—		2,819
Cash and cash equivalents at end of period	$	109		$	32		$	2,838		$	—	$	2,979		$	356		$	58		$	3,520		$	—	$	3,934

CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS


	Six Months Ended June 30, 2016														Nine Months Ended September 30, 2016
	Parent Guarantor			Other Guarantors			Non-Guarantors			Eliminations		Consolidated			Parent Guarantor			Other Guarantors				Non-Guarantors			Eliminations		Consolidated
	(In millions)														(In millions)
Operating activities:
Net cash (used in) provided by operating activities	$	(21	)	$	20		$	279		$	—	$	278
Net cash provided by operating activities															$	43		$	34			$	556		$	—	$	633
Investing activities:
Purchases of investments	(67		)	—			(907		)	—		(974		)	(114		)	—				(1,330		)	—		(1,444		)
Proceeds from sales and maturities of investments	67			—			745			—		812			103			—				1,409			—		1,512
Purchases of property, equipment and capitalized software	(73		)	(19		)	(10		)	—		(102		)	(102		)	(23		)		(18		)	—		(143		)
Decrease in restricted investments held-to-maturity	—			—			5			—		5			—			—				4			—		4
Net cash paid in business combinations	—			(1		)	(7		)	—		(8		)	—			(5		)		(43		)	—		(48		)
Capital contributions to/from subsidiaries	(106		)	2			104			—		—			(221		)	7				214			—		—
Dividends to/from subsidiaries	50			—			(50		)	—		—			50			—				(50		)	—		—
Change in amounts due to/from affiliates	(13		)	2			11			—		—			(12		)	4				8			—		—
Other, net	5			(12		)	1			—		(6		)	6			(19		)		1			—		(12		)
Net cash used in investing activities	(137		)	(28		)	(108		)	—		(273		)
Net cash (used in) provided by investing activities															(290		)	(36		)		195			—		(131		)
Financing activities:																					��
Proceeds from employee stock plans	10			—			—			—		10			10			—				—			—		10
Other, net	2			—			(1		)	—		1			2			—				(1		)	—		1
Net cash provided by (used in) financing activities	12			—			(1		)	—		11			12			—				(1		)	—		11
Net (decrease) increase in cash and cash equivalents	(146		)	(8		)	170			—		16			(235		)	(2		)		750			—		513
Cash and cash equivalents at beginning of period	360			13			1,956			—		2,329			360			13				1,956			—		2,329
Cash and cash equivalents at end of period	$	214		$	5		$	2,126		$	—	$	2,345		$	125		$	11			$	2,706		$	—	$	2,842

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (MD&A)

~~FORWARD LOOKING~~FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains forward-looking statements regarding our business, financial condition, and results of operations within the meaning of Section 27A of the Securities Act of 1933, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, or Securities Exchange Act. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we are including this statement for purposes of complying with these safe harbor provisions. All statements, other than statements of historical facts, included in this quarterly report may be deemed to be forward-looking statements for purposes of the Securities Act and the Securities Exchange Act. Without limiting the foregoing, we use the words “anticipate(s),” “believe(s),” “estimate(s),” “expect(s),” “intend(s),” “may,” “plan(s),” “project(s),” “will,” “would,” “could,” “should” and similar expressions to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we will actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and, accordingly, you should not place undue reliance on our forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from the forward-looking statements that we make. You should read these factors and the other cautionary statements as being applicable to all related forward-looking statements wherever they appear in this quarterly report. We caution you that we do not undertake any obligation to update forward-looking statements made by us. Forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected, estimated, expected, or contemplated. Those known risks and uncertainties include, but are not limited to, the following:

the success of ~~the Restructuring Plan,~~our previously announced restructuring plan, including the timing and amounts of the benefits realized;

the numerous political and market-based uncertainties associated with the Affordable Care Act (the “ACA”) or “Obamacare,” including any potential repeal and replacement of the law, amendment of the law, or move to state block grants for Medicaid;

the market dynamics surrounding the ACA Marketplaces, including but not limited to uncertainties associated with risk transfer requirements, the potential for disproportionate enrollment of higher acuity members, the ~~withdrawal~~discontinuation of ~~cost sharing subsidies and/or~~ premium tax credits, the adequacy of agreed rates, and potential disruption associated with market ~~withdrawal;~~withdrawal from Utah, Wisconsin, or other states;

subsequent adjustments to reported premium revenue based upon subsequent developments or new information, including changes to estimated amounts payable or receivable related to Marketplace risk adjustment/risk transfer, risk corridors, and reinsurance;

effective management of our medical costs;

our ability to predict with a reasonable degree of accuracy utilization rates, including utilization rates associated with seasonal flu patterns or other newly emergent diseases;

significant budget pressures on state governments and their potential inability to maintain current rates, to implement expected rate increases, or to maintain existing benefit packages or membership eligibility thresholds or criteria, including the payment of all amounts due to our Illinois health plan following the resolution of the Illinois budget impasse;

the success of our efforts to retain existing ~~government~~managed care contracts, including those in Florida, ~~Illinois,~~ New Mexico, Puerto Rico, and Texas, and to obtain new government contracts in connection with state requests for proposals (RFPs) in both existing and new states;

any adverse impact resulting from the significant changes to our executive leadership team and the rightsizing of our workforce;

the impact of our decision to exit the Utah and Wisconsin ACA Marketplace markets effective December 31, 2017;

our ability to manage our operations, including maintaining and creating adequate internal systems and controls relating to authorizations, approvals, provider payments, and the overall success of our care management initiatives;

our ability to consummate and realize benefits from acquisitions or divestitures;

our receipt of adequate premium rates to support increasing pharmacy costs, including costs associated with specialty drugs and costs resulting from formulary changes that allow the option of higher-priced non-generic drugs;

our ability to operate profitably in an environment where the trend in premium rate increases lags behind the trend in increasing medical costs;

the interpretation and implementation of federal or state medical cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit sharing arrangements, and risk adjustment provisions;

our estimates of amounts owed for such cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions;

the Medicaid expansion cost corridors in California, New Mexico, and Washington, and any other retroactive adjustment to revenue where methodologies and procedures are subject to interpretation or dependent upon information about the health status of participants other than Molina members;

the interpretation and implementation of at-risk premium rules and state contract performance requirements regarding the achievement of certain quality measures, and our ability to recognize revenue amounts associated therewith;

cyber-attacks or other privacy or data security incidents resulting in an inadvertent unauthorized disclosure of protected health information;

the success of our health plan in Puerto Rico, including the resolution of the Puerto Rico debt crisis, payment of all amounts due under our Medicaid contract, the effect of the PROMESA law, the impact of Hurricane Maria and our efforts to better manage the health care costs of our Puerto Rico health plan;

the success and renewal of our duals demonstration programs in California, Illinois, Michigan, Ohio, South Carolina, and Texas;

the accurate estimation of incurred but not reported or paid medical costs across our health plans;

efforts by states to recoup previously paid and recognized premium amounts;

~~the continuation and renewal of the government contracts of our health plans, Molina Medicaid Solutions, and Pathways, and the terms under which such contracts are renewed;~~

complications, member confusion, or enrollment backlogs related to the annual renewal of Medicaid coverage;

government audits and reviews, or potential investigations, and any fine, sanction, enrollment freeze, monitoring program, or premium recovery that may result therefrom, including any potential demand by the state of New Mexico to recover purportedly underpaid premium taxes;

changes with respect to our provider contracts and the loss of providers;

approval by state regulators of dividends and distributions by our health plan subsidiaries;

changes in funding under our contracts as a result of regulatory changes, programmatic adjustments, or other reforms;

high dollar claims related to catastrophic illness;

the favorable resolution of litigation, arbitration, or administrative proceedings;

the relatively small number of states in which we operate health plans;

the availability of adequate financing on acceptable terms to fund and capitalize our expansion and growth, repay our outstanding indebtedness at maturity and meet our liquidity needs, including the interest expense and other costs associated with such financing;

our failure to comply with the financial or other covenants in our credit agreement or the indentures governing our outstanding notes;

the sufficiency of our funds on hand to pay the amounts due upon conversion or maturity of our outstanding notes;

the failure of a state in which we operate to renew its federal Medicaid waiver;

changes generally affecting the managed care or Medicaid management information systems industries;

increases in government surcharges, taxes, and assessments, including but not limited to the deductibility of certain compensation costs;

newly emergent viruses or widespread epidemics, public catastrophes or terrorist attacks, and associated public alarm; and

increasing competition and consolidation in the Medicaid industry;

~~Investors~~Readers should refer to the section entitled “Risk Factors” in each of our Annual Report on Form 10-K for the year ended December 31, 2016, our Quarterly ~~Report~~Reports on Form 10-Q for the ~~quarter~~quarters ended March 31, 2017 and June 30, 2017, and this Quarterly Report on Form 10-Q, for a discussion of certain risk factors that could materially affect our business, financial condition, cash flows, or results of operations. Given these risks and uncertainties, we can give no assurance that any results or events projected or contemplated by our forward-looking statements will in fact occur.

This ~~document~~quarterly report and the following discussion of our financial condition and results of operations should be read in conjunction with the accompanying consolidated financial statements and the notes to those statements appearing elsewhere in this report, and the audited financial statements and Management’s Discussion and Analysis appearing in our Annual Report on Form 10-K for the year ended December 31, 2016.

ABOUT MOLINA HEALTHCARE

OUR MISSION IS TO PROVIDE QUALITY HEALTHCARE TO PEOPLE RECEIVING GOVERNMENT ASSISTANCE.

~~OUR GOAL IS TO ACHIEVE OUR MISSION WHILE IMPROVING THE FINANCIAL STRENGTH OF OUR ORGANIZATION.~~

KEY PERFORMANCE INDICATORS

Non-GAAP Financial Measures

We use non-GAAP financial measures as supplemental metrics in evaluating our financial performance, making financing and business decisions, and forecasting and planning for future periods. For these reasons, management believes such measures are useful supplemental measures to investors in comparing our performance to the performance of other public companies in the health care industry. These non-GAAP financial measures should be considered as supplements to, and not as substitutes for or superior to, GAAP measures.

See further information regarding non-GAAP measures in the “Supplemental Information” section of this MD&A, including the reconciliations to U.S. GAAP. Non-GAAP financial measures referred to in this report are designated with an asterisk (*).


	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016			2017			2016			2017			2016
	(Dollar amounts in millions, except per-share amounts)												(Dollar amounts in millions, except per-share amounts)
Net (loss) income	$	(230	)	$	33		$	(153	)	$	57		$	(97	)	$	42		$	(250	)	$	99
Net (loss) income per diluted share	$	(4.10	)	$	0.58		$	(2.74	)	$	1.01		$	(1.70	)	$	0.76		$	(4.44	)	$	1.77
MCR ⁽¹⁾	94.8		%	89.2		%	91.6		%	89.5		%	88.3		%	89.4		%	90.5		%	89.5		%
G&A ratio ⁽²⁾	8.1		%	8.1		%	8.5		%	7.9		%	7.6		%	7.6		%	8.2		%	7.8		%
Premium tax ratio ⁽¹⁾	2.4		%	2.6		%	2.3		%	2.6		%	2.2		%	2.9		%	2.3		%	2.7		%
Effective tax rate	26.8		%	59.8		%	16.0		%	60.7		%	14.6		%	54.0		%	15.5		%	58.0		%
Net profit margin ⁽²⁾	(4.6		)%	0.7		%	(1.5		)%	0.7		%	(1.9		)%	0.9		%	(1.7		)%	0.7		%
EBITDA*	$	(243	)	$	144		$	(40	)	$	270		$	(42	)	$	160		$	(82	)	$	430
Adjusted net (loss) income*	$	(225	)	$	38		$	(142	)	$	67		$	(93	)	$	47		$	(235	)	$	114
Adjusted net (loss) income per diluted share*	$	(4.01	)	$	0.67		$	(2.55	)	$	1.18		$	(1.62	)	$	0.85		$	(4.17	)	$	2.03

________________________


(1)	MCR represents medical care costs as a percentage of premium revenue; premium tax ratio represents premium tax expenses as a percentage of premium revenue plus premium tax revenue.


(2)	G&A ratio represents general and administrative expenses as a percentage of total revenue. Net profit margin represents net income as a percentage of total revenue.

CONSOLIDATED RESULTS

Three Months Ended ~~June~~September 30, 2017 Compared with Three Months Ended ~~June~~September 30, ~~2017~~2016

Net loss per diluted share was ~~$4.10 in~~$1.70 for the ~~second~~third quarter of 2017 compared with net income per diluted share of ~~$0.58~~$0.76 reported for the ~~second~~third quarter of 2016. Adjusted net loss per diluted share* was ~~$4.01~~$1.62 in the ~~second~~third quarter of 2017, compared with adjusted net income per diluted ~~share~~share* of ~~$0.67~~$0.85 in the ~~second~~third quarter of 2016. Loss before income tax benefit for the ~~second~~third quarter of 2017 was ~~$314~~$113 million.

~~Certain significant items contributed $330 million~~

Medical care costs measured as a percentage of premium revenue (the “medical care ratio”) declined to ~~the loss before income tax benefit. See further discussion of these items~~88.3% in the ~~table below,~~third quarter of 2017 from 89.4% in ~~“Health Plans—Financial Performance by Program,”~~the third quarter of 2016 and ~~“Other Consolidated Information.”~~

~~The medical care ratio increased to~~ from 94.8% in the second quarter of 2017. Improved medical cost performance in the third quarter of 2017 ~~compared to~~ ~~89.2%~~was the result of:


◦	Improved sequential performance at our Illinois, New Mexico, Ohio, Puerto Rico, Texas, and Washington health plans, exclusive of the Marketplace program.


◦	Improved performance of our Marketplace program, including a reduction to the premium deficiency reserve of $30 million ($0.33 per diluted share, net of tax). The reserve, which was $100 million at June 30, 2017, decreased to $70 million as of September 30, 2017.

General and administrative costs, measured as a percentage of total revenue (the “administrative cost ratio”), were 7.6% in the third quarter of 2017, consistent with the third quarter of 2016, and 50 basis points lower than the second quarter of 2017. Excluding Marketplace broker commission and exchange fees, the administrative cost ratio decreased 30 basis points from the third quarter of 2016. ~~See further discussion below~~

Restructuring costs and the impairment of certain purchased intangible assets increased loss before income tax benefit in ~~“Reportable Segments—Health Plans—Financial Overview.”~~the third quarter of 2017 by approximately $247 million. Specifically:

We recorded $118 million ($1.39 per diluted share, net of tax) of restructuring costs in the third quarter of 2017. Restructuring costs incurred to date consist primarily of termination benefits, write-offs of capitalized software due to the re-design of our core operating processes, restructuring of our direct delivery operations, and consulting fees.

We recorded $129 million ($1.77 per diluted share, net of tax) in non-cash goodwill impairment losses for our Pathways behavioral health subsidiary and our Molina Medicaid Solutions (MMS) segment. In the third quarter of 2017, management determined that neither business will provide future benefits relating to the integration of their operations with the Health Plans segment to the extent previously expected.

The ~~following~~ table below summarizes the impact of certain items significant to our financial performance in the ~~significant items:~~periods presented.

Summary of Significant Items Affecting 2017 Financial Results
Three Months Ended Six Months Ended
June 30, 2017 June 30, 2017
(In millions, except per diluted share amounts)
Amount
Per Diluted Share ⁽¹⁾
Amount
Per Diluted Share ⁽¹⁾
Impairment losses $ 72
$ 1.01
$ 72
$ 1.02
Losses at behavioral health subsidiary exclusive of impairment 8
0.09
12
0.14
Medical care costs related to prior year service dates that were in excess of historical expectations 85
0.95
74
0.84
Marketplace adjustments related to risk transfer, cost sharing subsidies, and other items for 2016 service dates 44
0.49
47
0.53
Marketplace premium deficiency reserve for 2017 service dates 78
0.87
70
0.79
Restructuring and separation costs 43
0.68
43
0.68
Termination fee received for Terminated Medicare acquisition —
—
(75 ) (0.84 )
$ 330
$ 4.09
$ 243
$ 3.16



Summary of Significant Items Affecting 2017 Financial Results
	Three Months Ended						Nine Months Ended
	September 30, 2017						September 30, 2017
	(In millions, except per diluted share amounts)
	Amount			Per Diluted Share ⁽¹⁾			Amount			Per Diluted Share ⁽¹⁾
Restructuring and separation costs	$	118		$	1.39		$	161		$	1.92
Impairment losses	129			1.77			201			2.77
Change in Marketplace premium deficiency reserve for 2017 service dates	(30		)	(0.33		)	40			0.45
Termination fee received for terminated Medicare acquisition	—			—			(75		)	(0.84		)
	$	217		$	2.83		$	327		$	4.30

________________________


(1)	Except for certain items that are not deductible for tax purposes, per diluted share amounts are generally calculated at our statutory income tax rate of 37%, which is in excess of the effective tax rate recorded in our consolidated statements of operations.

~~Certain significant items increased loss~~

Marketplace Cost Share Reduction (CSR) Update

basis of CSR subsidies paid to all health plans against the actual costs incurred by the health plans. Were such a reconciliation to be performed for the full calendar year of 2017—consistent with past practice—we would be able to offset nearly all of the $85 million expense incurred in the fourth quarter against the excess amounts received prior to September 30, 2017. However, should CMS transition to a nine month reconciliation period ending September 30, 2017—the last month for which CSR subsidies have been paid—the absence of CSR subsidy reimbursement would reduce income before income tax ~~benefit in the second quarter of 2017~~expense by ~~approximately $330 million. Specifically:~~

We recorded $72 million in non-cash impairment losses for goodwill and intangibles, primarily relating to our Pathways subsidiary. In the course of developing our restructuring and profitability improvement plan, we determined that future benefits to be derived from Pathways (including integration with our health plans) will be less than previously anticipated. While such impairment losses have a short-term impact on profitability, there is no impact to our cash flows. Pathways experienced operating losses of $8 million for the quarter ended June 30, 2017 and $12 million for the six months ended June 30, 2017.

Medical care costs related to 2016 service dates were significantly in excess of what the Company usually experiences for out-of-period claims development, particularly at the Florida, Illinois, New Mexico, and Puerto Rico health plans. In total, we experienced out-of-period claims development that was approximately $85 million ~~higher than expected at December 31, 2016.~~

~~We recorded $44 million for Marketplace changes~~ in estimates, including risk transfer and cost sharing subsidies, related to 2016 service dates. Liabilities for risk transfer payments and cost sharing subsidies that were estimated at December 31, 2016 were finalized during the ~~second~~fourth quarter of 2017.

Loss before income tax benefit increased by $78 million as a result of an increase to the premium deficiency reserve established for the Marketplace program. The reserve, which was $22 million at March 31, 2017, increased to $100 million as of June 30, 2017. Based upon revenue and cost trends observed in the second quarter of 2017, we now believe that Marketplace performance in the second half of 2017 will fall substantially short of previous expectations. Marketplace performance has been most disappointing in Florida, Utah, Washington, and Wisconsin.

We recorded $43 million in restructuring and separation costs in the second quarter of 2017 related primarily to contractually required termination benefits paid to our former chief executive officer and chief financial officer. Also included in these costs are consulting fees incurred for the development and implementation of our corporate restructuring initiatives. See below in “Liquidity and Financial Condition—Future Sources and Uses of Liquidity,” and Notes to Consolidated Financial Statements, Note 11, “~~Restructuring and Separation Costs,” for further information.~~

~~Six~~Nine Months ended ~~June~~September 30, 2017 Compared with ~~Six~~Nine Months Ended ~~June~~September 30, 2016

Net loss per diluted share was ~~$2.74~~$4.44 in the ~~first half of~~nine months ended September 30, 2017 compared with net income per diluted share of ~~$1.01~~$1.77 reported for the ~~first half of~~nine months ended September 30, 2016. Adjusted net loss per diluted share* was ~~$2.55~~$4.17 in the ~~first half of~~nine months ended September 30, 2017, compared with adjusted net income per diluted share* of ~~$1.18~~$2.03 in the ~~first half of~~nine months ended September 30, 2016. Loss before income tax benefit for the ~~first half of~~nine months ended September 30, 2017 was ~~$153~~$296 million. ~~These results~~Results for the nine months ended September 30, 2017, were affected by ~~several out-of-period adjustments as~~the significant items presented in the table, and as further described, above. In total, these adjustments increased pretax loss in the ~~first half of~~nine months ended September 30, 2017 by ~~$243 million~~.

$327 million.

RESTRUCTURING AND PROFIT IMPROVEMENT PLAN UPDATE

As ~~a result~~previously disclosed, we estimate that our restructuring plan will reduce annualized run-rate expenses by approximately $300 million to $400 million when completed by the end of ~~our poor operating performance and catalyzed by our change~~2018. We have already achieved $200 million of these run-rate reductions on an annualized basis, which will take full effect no later than January 1, 2018. Our third quarter results include approximately $10 million of these reductions. All savings targets discussed in management, we accelerated the implementation of a comprehensive restructuring and profitability improvement plan (the Restructuring Plan). Under the Restructuring Plan, we are taking the following actions:


1.	We are streamlining our organizational structure, including the elimination of redundant layers of management, the consolidation of regional support services, and other reductions to our workforce, to improve efficiency as well as the speed and quality of our decision-making.


2.	We are re-designing core operating processes such as provider payment, utilization management, quality monitoring and improvement, and information technology to achieve more effective and cost efficient outcomes.


3.	~~We are remediating high cost provider contracts and building around high quality, cost-effective networks.~~


4.	~~We are restructuring our existing direct delivery operations.~~


5.	~~We are reviewing our vendor base to ensure that we are partnering with the lowest-cost, most-effective vendors.~~


6.	Throughout this process, we are taking precautions to ensure that our actions do not impede our ability to continue to deliver quality health care, retain existing managed care contracts, and to secure new managed care contracts.

~~ACTION PLAN—2018 MARKETPLACE PERFORMANCE~~

~~In addition~~regards to the ~~Restructuring Plan,~~restructuring plan represent annualized run-rate savings that we ~~are taking these further steps~~expect to ~~improve profitability~~achieve during the year following the indicated implementation date. We expect one-time costs associated with the restructuring plan to exceed the benefits realized in ~~2018:~~2017 due to the upfront payment of implementation costs and the delayed benefit of full savings until the beginning of 2018.


1.	We are exiting the Utah and Wisconsin ACA Marketplaces effective December 31, 2017. For the three months ended June 30, 2017, these two health plans reported a total of $127 million in Marketplace premium revenue (16% of consolidated Marketplace premium revenue), and a combined Marketplace medical care ratio of 128%.


2.	In our remaining Marketplace plans, we are increasing 2018 premiums by 55%. The increase takes into account the absence of cost sharing reduction subsidies. Had we assumed that cost sharing reduction subsidies would be funded for 2018, the premium increase would have been 30%.


3.	~~We are also reducing the scope of our 2018 participation in the Washington Marketplace.~~


4.	We continue to closely monitor the current political and programmatic developments pertaining to our 2018 participation in other Marketplace states, and subject to those developments, will withdraw from 2018 participation as may be necessary.

TRENDS AND UNCERTAINTIES

ACA and the Marketplace

The future of the Affordable Care Act (ACA) and its underlying programs, including the Marketplace, are subject to substantial uncertainty. We ~~continue~~have taken the following steps in regards to ~~advocate for federal policies to stabilize~~our participation in the ACA Marketplace ~~program.~~in 2018:


1.	As previously announced, we will exit the Utah and Wisconsin ACA Marketplaces effective December 31, 2017.


2.	In our remaining Marketplace plans, we are increasing 2018 premiums by 55% to take into account the absence of cost sharing reduction (CSR) subsidies and other risks related to ACA Marketplace uncertainties.


3.	We have reduced the scope of our 2018 participation in the state of Washington Marketplace.


4.	We continue to monitor the current political and programmatic developments pertaining to the ACA Marketplace.

Medicaid Contract Re-Procurement

The following table illustrates Health Plans segment Medicaid contracts scheduled for re-procurement in the near term. While we have been notified of the Medicaid regulators’ intention to re-procure the contracts, the anticipated award dates and effective dates are management’s current best ~~estimates. Such~~estimates; such dates are subject to ~~change and, in some cases, not yet known to us.~~change. Premium revenue is stated in millions.

Premium Revenue

Membership as of

Six Months Ended

Anticipated

Membership as of

Nine Months Ended

Anticipated

State Health Plan

Medicaid Program(s)

June 30, 2017

Award Date

Effective Date

Medicaid Program(s)

September 30, 2017

Award Date

Effective Date

Florida

All

359,000

726

Q1 2018

1/1/2019

All

355,000

1,105

Q2 2018

1/1/2019

Illinois

All

159,000

259

Q3 2017

1/1/2018

New Mexico

All

234,000

605

Q1 2018

1/1/2019

All

225,000

893

Q1 2018

1/1/2019

Puerto Rico

All

322,000

362

Q1 2018

7/1/2018

Texas

All

191,000

920

Q3 2018

9/1/2019

ABD

87,000

1,065

Q3 2018

9/1/2019

Texas

CHIP

25,000

Q4 2017

9/1/2018

CHIP

24,000

Q4 2017

9/1/2018

Illinois Health Plan. In August 2017, Molina Healthcare of Illinois, Inc. was awarded a statewide Medicaid managed care contract by the Illinois Department of Healthcare and Family Services. This Medicaid contract further integrates behavioral health and physical health by combining the State’s three current managed care programs into one program. The contract begins January 1, 2018, for four years with options to renew annually for up to four additional years.

Washington Health Plan. ~~As discussed in Notes to Consolidated Financial Statements, Note 1, “Basis of Presentation,” in~~In May 2017, Molina Healthcare of Washington, Inc. was selected by the Washington State Health Care Authority to negotiate and enter into managed care contracts for the North Central region of the state’s Apple Health Integrated Managed Care Program. The start date for the new contract is scheduled for January 1, 2018.

REPORTABLE SEGMENTS

How We Assess Performance

We derive our revenues primarily from health insurance premiums, and our primary customers are state Medicaid agencies and the federal government.

One of the key metrics used to assess the performance of our most significant segment, the Health Plans segment, is the medical care ratio, or MCR. The medical care ratio represents medical care costs as a percentage of premium revenue. Therefore, the underlying gross margin, or the amount earned by the Health Plans segment after medical costs are deducted from premium revenue, is the most important measure of earnings reviewed by management.

Gross margin for our Health Plans segment is referred to as “Medical margin,” and for our Molina Medicaid Solutions and Other segments, as “Service margin.” The service margin is equal to service revenue minus cost of service revenue. Management’s discussion and analysis of the changes in the individual components of gross

margin, by reportable segment, is presented in the “Health Plans—Financial Overview,” “Molina Medicaid Solutions—Financial Overview,” and “Other—Financial Overview” sections ~~respectively,~~ of this MD&A.

SEGMENT SUMMARY


	Three Months Ended June 30,						Six Months Ended June 30,						Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016			2017			2016			2017			2016
	(In millions)												(In millions)
Segment gross margin:
Health Plans medical margin ⁽¹⁾	$	249		$	435		$	786		$	842		$	557		$	443		$	1,343		$	1,285
Molina Medicaid Solutions service margin ⁽²⁾	4			5			8			11			5			6			13			17
Other ⁽²⁾	1			14			6			21			2			8			8			29
Total segment gross margin	254			454			800			874			564			457			1,364			1,331
Other operating revenues ⁽³⁾	130			195			255			403			124			222			379			625
Other operating expenses ⁽⁴⁾	(671		)	(544		)	(1,260		)	(1,083		)	(769		)	(561		)	(2,029		)	(1,644		)
Operating (loss) income	(287		)	105			(205		)	194			(81		)	118			(286		)	312
Other expenses (income), net	27			25			(22		)	50
Other expenses, net													32			26			10			76
(Loss) income before income tax expense	(314		)	80			(183		)	144			(113		)	92			(296		)	236
Income tax (benefit) expense	(84		)	47			(30		)	87			(16		)	50			(46		)	137
Net (loss) income	$	(230	)	$	33		$	(153	)	57			$	(97	)	$	42		$	(250	)	99

_______________________


(1)	Represents premium revenue minus medical care costs.


(2)	Represents service revenue minus cost of service revenue.


(3)	Other operating revenues include premium tax revenue, health insurer fee revenue, investment income and other revenue.


(4)	Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fee expenses, depreciation and amortization, impairment losses, and restructuring and separation costs.

HEALTH PLANS

BUSINESS OVERVIEW

Recent Developments — Health Plans Segment

Refer to Notes to Consolidated Financial Statements, Note 1, “Basis of Presentation.”

Health Plans Membership

The following tables set forth our Health Plans membership as of the dates indicated:


	June 30, 2017	December 31, 2016	June 30, 2016	September 30, 2017	December 31, 2016	September 30, 2016
Ending Membership by Program:
Temporary Assistance for Needy Families (TANF) and Children’s Health Insurance Program (CHIP)	2,517,000	2,536,000	2,500,000	2,451,000	2,536,000	2,529,000
Marketplace	949,000	526,000	597,000	877,000	526,000	568,000
Medicaid Expansion	678,000	673,000	654,000	662,000	673,000	658,000
Aged, Blind or Disabled (ABD)	408,000	396,000	387,000	411,000	396,000	395,000
Medicare-Medicaid Plan (MMP) – Integrated ⁽¹⁾	54,000	51,000	51,000	58,000	51,000	51,000
Medicare Special Needs Plans (Medicare)	44,000	45,000	44,000	44,000	45,000	45,000
	4,650,000	4,227,000	4,233,000	4,503,000	4,227,000	4,246,000
Ending Membership by Health Plan:
California	766,000	683,000	680,000	751,000	683,000	683,000
Florida	672,000	553,000	565,000	641,000	553,000	563,000
Illinois	163,000	195,000	201,000	163,000	195,000	195,000
Michigan	414,000	391,000	393,000	399,000	391,000	387,000
New Mexico	266,000	254,000	251,000	256,000	254,000	253,000
New York ⁽²⁾	34,000	35,000	—	33,000	35,000	37,000
Ohio	351,000	332,000	341,000	343,000	332,000	339,000
Puerto Rico	322,000	330,000	336,000	306,000	330,000	331,000
South Carolina	112,000	109,000	105,000	113,000	109,000	109,000
Texas	465,000	337,000	367,000	444,000	337,000	352,000
Utah	167,000	146,000	151,000	160,000	146,000	150,000
Washington	788,000	736,000	709,000	770,000	736,000	716,000
Wisconsin	130,000	126,000	134,000	124,000	126,000	131,000
	4,650,000	4,227,000	4,233,000	4,503,000	4,227,000	4,246,000

_________________________


(1)	MMP members receive both Medicaid and Medicare coverage from Molina Healthcare.


~~(2)~~	~~The New York health plan was acquired on August 1, 2016.~~

Premiums by Program

The amount of the premiums paid to our health plans may vary substantially between states and among various government programs. The following table sets forth the ranges of premiums paid to our state health plans by program on a per member per month (PMPM) basis, for the ~~six~~nine months ended ~~June~~September 30, 2017. The “Consolidated” column represents the weighted-average amounts for our total membership by program.


	PMPM Premiums						PMPM Premiums
	Low		High		Consolidated		Low		High		Consolidated
TANF and CHIP	$	120.00	$	320.00	$	180.00	$	120.00	$	310.00	$	180.00
Marketplace	180.00		440.00		270.00		190.00		470.00		280.00
Medicaid Expansion	320.00		510.00		390.00		320.00		510.00		390.00
ABD	370.00		1,490.00		1,030.00		380.00		1,480.00		1,030.00
MMP – Integrated	1,220.00		3,250.00		2,150.00		1,250.00		3,280.00		2,190.00
Medicare	910.00		1,240.00		1,100.00		960.00		1,260.00		1,140.00

FINANCIAL OVERVIEW

In the ~~second~~third quarter of 2017, premium revenue increased approximately ~~18%~~14%, or ~~$711~~$586 million, when compared with the ~~second~~third quarter of 2016. Member months grew 8% while revenue PMPM increased 6%. Medical care costs as a percent of premium revenue decreased to 88.3% in the third quarter of 2017 from 89.4% in the third quarter of 2016. Medical margin increased 26% in the third quarter of 2017 from the third quarter of 2016.

In the nine months ended September 30, 2017, premium revenue increased approximately 16%, or $1,950 million, when compared with the nine months ended September 30, 2016. Member months grew 11% while revenue PMPM increased 7%5%. Medical care costs as a percent of premium revenue increased to ~~94.8%~~90.5% in the ~~second quarter of 2017 from 89.2% in the second quarter of 2016. Medical margin decreased 43% in the second quarter of 2017 from the second quarter of 2016.~~

~~In the six~~nine months ended June 30, 2017, premium revenue increased approximately 17%, or $1,364 million, when compared with the six months ended June 30, 2016. Member months grew 13% while revenue PMPM increased 4%. Medical care costs as a percent of premium revenue increased to 91.6% in the six months ended JuneSeptember 30, 2017 from 89.5% in the ~~six~~nine months ended ~~June~~September 30, 2016. Medical margin ~~decreased 7%~~increased 5% in the ~~six~~nine months ended ~~June~~September 30, 2017 from the ~~six~~nine months ended ~~June~~September 30, 2016.

FINANCIAL PERFORMANCE BY PROGRAM

The following tables summarize member months, premium revenue, medical care costs, medical care ratio and medical margin by program for the periods indicated (PMPM amounts are in whole dollars; member months and other dollar amounts are in millions):


	Three Months Ended June 30, 2017															Three Months Ended September 30, 2017
	Member Months ⁽¹⁾	Premium Revenue				Medical Care Costs				MCR ⁽²⁾			Medical Margin			Member Months ⁽¹⁾			Premium Revenue								Medical Care Costs							MCR ⁽²⁾			Medical Margin
	Member Months ⁽¹⁾	Total		PMPM		Total		PMPM					Medical Margin			Member Months ⁽¹⁾		Total				PMPM				Total				PMPM				MCR ⁽²⁾			Medical Margin
TANF and CHIP	7.6	$	1,391	$	182.47	$	1,315	$	172.48	MCR ⁽²⁾	94.5	%		$	76		7.5			$	1,392			$	185.95			$	1,242			$	165.76		89.1	%		$	150
Medicaid Expansion	2.1	786		383.07		689		335.26		87.5			97			2.0			773				385.58				667				332.99			86.4			106
ABD	1.2	1,285		1,053.89		1,245		1,020.85		96.9			40			1.2			1,288				1,038.85				1,259				1,016.06			97.8			29
Total Medicaid	10.9	3,462		317.79		3,249		298.10		93.8			213			10.7			3,453				321.77				3,168				295.23			91.8			285
MMP	0.1	361		2,217.44		333		2,050.20		92.5			28			0.2			378				2,263.07				336				2,013.67			89.0			42
Medicare	0.2	148		1,126.14		126		963.34		85.5			22			0.1			163				1,231.61				126				951.01			77.2			37
Total Medicare	0.3	509		1,730.91		459		1,565.65		90.5			50			0.3			541				1,806.26				462				1,543.05			85.4			79
Excluding Marketplace	11.2	3,971		354.87		3,708		331.36		93.4			263			11.0			3,994				362.04				3,630				329.08			90.9			364
Marketplace	2.8	769		267.37		783		272.37		101.9			(14		)	2.7			783				301.72				590				227.22			75.3			193
	14.0	$	4,740	$	336.98	$	4,491	$	319.29	94.8	%		$	249		13.7			$	4,777			$	350.55			$	4,220			$	309.68		88.3	%		$	557


	Three Months Ended June 30, 2016															Three Months Ended September 30, 2016
	Member Months ⁽¹⁾	Premium Revenue				Medical Care Costs				MCR ⁽²⁾			Medical Margin			Member Months ⁽¹⁾			Premium Revenue								Medical Care Costs							MCR ⁽²⁾			Medical Margin
	Member Months ⁽¹⁾	Total		PMPM		Total		PMPM					Medical Margin			Member Months ⁽¹⁾		Total				PMPM				Total				PMPM				MCR ⁽²⁾			Medical Margin
TANF and CHIP	7.5	$	1,302	$	173.57	$	1,202	$	160.26	MCR ⁽²⁾	92.3	%		$	100		7.6			$	1,373			$	180.74			$	1,246			$	164.04		90.8	%		$	127
Medicaid Expansion	1.9	742		378.19		634		323.56		85.6			108			2.0			763				386.98				642				325.68			84.2			121
ABD	1.2	1,168		991.38		1,038		881.80		88.9			130			1.1			1,186				1,008.28				1,094				929.93			92.2			92
Total Medicaid	10.6	3,212		301.86		2,874		270.27		89.5			338			10.7			3,322				309.19				2,982				277.55			89.8			340
MMP	0.2	315		2,093.29		270		1,792.78		85.6			45			0.2			334				2,165.26				280				1,818.75			84.0			54
Medicare	0.2	129		997.44		127		974.30		97.7			2			0.1			136				1,019.19				134				1,003.85			98.5			2
Total Medicare	0.4	444		1,584.77		397		1,412.96		89.2			47			0.3			470				1,633.62				414				1,440.73			88.2			56
Excluding Marketplace	11.0	3,656		334.86		3,271		299.67		89.5			385			11.0			3,792				343.68				3,396				307.84			89.6			396
Marketplace	1.8	373		206.88		323		178.79		86.4			50			1.7			399				238.86				352				210.38			88.1			47
	12.8	$	4,029	$	316.72	$	3,594	$	282.54	89.2	%		$	435		12.7			$	4,191			$	329.88			$	3,748			$	295.01		89.4	%		$	443


	Six Months Ended June 30, 2017															Nine Months Ended September 30, 2017
	Member Months ⁽¹⁾	Premium Revenue				Medical Care Costs				MCR ⁽²⁾			Medical Margin			Member Months ⁽¹⁾			Premium Revenue								Medical Care Costs							MCR ⁽²⁾			Medical Margin
	Member Months ⁽¹⁾	Total		PMPM		Total		PMPM					Medical Margin			Member Months ⁽¹⁾		Total				PMPM				Total				PMPM				MCR ⁽²⁾			Medical Margin
TANF and CHIP	15.3	$	2,793	$	182.58	$	2,619	$	171.25	MCR ⁽²⁾	93.8	%		$	174		22.8			$	4,185			$	183.69			$	3,861			$	169.44		92.2	%		$	324
Medicaid Expansion	4.1	1,603		390.88		1,378		335.88		85.9			225			6.1			2,376				389.14				2,045				334.93			86.1			331
ABD	2.4	2,481		1,030.68		2,375		986.54		95.7			106			3.6			3,769				1,033.45				3,634				996.58			96.4			135
Total Medicaid	21.8	6,877		315.39		6,372		292.22		92.7			505			32.5			10,330				317.49				9,540				293.21			92.4			790
MMP	0.3	705		2,152.75		640		1,954.15		90.8			65			0.5			1,083				2,189.96				976				1,974.22			90.1			107
Medicare	0.3	286		1,097.36		243		933.20		85.0			43			0.4			449				1,142.68				369				939.21			82.2			80
Total Medicare	0.6	991		1,685.72		883		1,502.36		89.1			108			0.9			1,532				1,726.39				1,345				1,516.09			87.8			187
Excluding Marketplace	22.4	7,868		351.35		7,255		323.98		92.2			613			33.4			11,862				354.88				10,885				325.66			91.8			977
Marketplace	5.7	1,520		264.77		1,347		234.62		88.6			173			8.4			2,303				276.27				1,937				232.31			84.1			366
	28.1	$	9,388	$	333.68	$	8,602	$	305.74	91.6	%		$	786		41.8			$	14,165			$	339.19			$	12,822			$	307.03		90.5	%		$	1,343


	Six Months Ended June 30, 2016															Nine Months Ended September 30, 2016
	Member Months ⁽¹⁾	Premium Revenue				Medical Care Costs				MCR ⁽²⁾			Medical Margin			Member Months ⁽¹⁾			Premium Revenue								Medical Care Costs							MCR ⁽²⁾			Medical Margin
	Member Months ⁽¹⁾	Total		PMPM		Total		PMPM					Medical Margin			Member Months ⁽¹⁾		Total				PMPM				Total				PMPM				MCR ⁽²⁾			Medical Margin
TANF and CHIP	14.9	$	2,626	$	176.00	$	2,400	$	160.85	MCR ⁽²⁾	91.4	%		$	226		22.5			$	3,999			$	177.60			$	3,646			$	161.93		91.2	%		$	353
Medicaid Expansion	3.8	1,421		371.82		1,208		316.13		85.0			213			5.8			2,184				376.98				1,850				319.38			84.7			334
ABD	2.4	2,280		976.58		2,079		890.71		91.2			201			3.5			3,466				987.20				3,173				903.85			91.6			293
Total Medicaid	21.1	6,327		300.19		5,687		269.86		89.9			640			31.8			9,649				303.23				8,669				272.46			89.9			980
MMP	0.3	655		2,157.55		587		1,932.73		89.6			68			0.5			989				2,160.14				867				1,894.38			87.7			122
Medicare	0.3	260		1,013.04		251		977.35		96.5			9			0.4			396				1,015.14				385				986.40			97.2			11
Total Medicare	0.6	915		1,633.08		838		1,494.92		91.5			77			0.9			1,385				1,633.26				1,252				1,476.57			90.4			133
Excluding Marketplace	21.7	7,242		334.74		6,525		301.61		90.1			717			32.7			11,034				337.76				9,921				303.72			89.9			1,113
Marketplace	3.4	782		228.19		657		191.62		84.0			125			5.1			1,181				231.69				1,009				197.77			85.4			172
	25.1	$	8,024	$	320.17	$	7,182	$	286.57	89.5	%		$	842		37.8			$	12,215			$	323.44			$	10,930			$	289.41		89.5	%		$	1,285

_______________________


(1)	A member month is defined as the aggregate of each month’s ending membership for the period presented.


(2)	“MCR” represents medical costs as a percentage of premium revenue.

Medicaid: TANF/CHIP, Medicaid Expansion and ABD

The medical care ratios of the combined TANF/CHIP, Medicaid Expansion and ABD programs increased to ~~93.8%~~91.8% in the ~~second~~third quarter of 2017, from ~~89.5%~~89.8% in the ~~second~~third quarter of 2016.

~~As noted above, medical care costs recognized in~~ Margin pressures at the second quarter of 2017 for services delivered in 2016 were significantly in excess of what we usually experience for out-of-period claims development. Favorable run-out of our reported in “Medical claimsCalifornia health plan (primarily due to reduced Medicaid Expansion premium rates effective July 1, 2017), the Florida health plan; and ~~benefits payable” as of December 31, 2016, was $85 million less~~the Illinois health plan more than ~~our typical experience, and was reflected in higher medical care costs for~~offset improved performance at the ~~quarter. This development was most notable at our Florida, Illinois, New Mexico, and Puerto Rico~~Washington health ~~plans. Additionally, those same health plans experienced higher than expected current period medical care costs.~~plan.

The medical care ratios of the combined TANF/CHIP, Medicaid Expansion and ABD programs increased to ~~92.7%~~92.4% in the ~~six~~nine months ended ~~June~~September 30, 2017, from 89.9% in the ~~six~~nine months ended ~~June~~September 30, ~~2016, primarily due to~~2016. For the ~~reasons noted above~~nine months ended September 30, 2017, margin pressures at the Florida, Illinois, New Mexico and Texas health plans more than offset improved performance at the Washington health plan. Financial results for the ~~increased medical care ratio~~Texas health plan in 2016 benefited from the ~~second quarter~~recognition of ~~2017.~~$44 million of quality revenue related to 2015 and 2014.

MMP and Medicare

The medical care ratio for these programs, in the aggregate, ~~increased~~decreased in the ~~second~~third quarter of 2017 when compared with the ~~second~~third quarter of ~~2016. However, for~~2016, and also in the ~~six~~nine months ended ~~June~~September 30, 2017, compared with the ~~six~~nine months ended ~~June~~September 30, ~~2016,~~2016. Utilization of inpatient and pharmacy services among our Medicare members has been subdued for the ~~aggregated medical care ratio for these two programs decreased.~~

first nine months of 2017.

Marketplace

~~The medical care ratio for the~~ Marketplace ~~program~~member months increased ~~to 101.9%~~64% in the ~~second quarter of 2017, from 86.4% in the second quarter of 2016.~~

~~The medical care ratio for the Marketplace program increased to 88.6% in the six~~nine months ended ~~June~~September 30, ~~2017, from 84.0% in the six months ended June 30, 2016.~~

In the second quarter of 2017, we recorded an increase to the premium deficiency reserve established for the Marketplace program. The reserve, which was $22 million at March 31, 2017, increased to $100 million as of June 30, 2017. In addition, we recorded $44 million for Marketplace changes in estimates, including risk transfer and cost sharing subsidies, related to 2016 service dates. Liabilities for risk transfer payments and cost sharing subsidies that were estimated at December 31, 2016 were finalized during the second quarter of 2017.

~~In the first half of 2016, adjustments related to 2015 dates of service reduced Marketplace pretax income by approximately $68 million.~~

~~Member months increased 68% in the second quarter of~~ 2017, when compared with the ~~second quarter of~~nine months ended September 30, 2016, as a result of membership growth primarily in California, Florida and Texas.

The medical care ratio for the Marketplace program decreased to 75.3% in the third quarter of 2017, from 88.1% in the third quarter of 2016. Absent a $30 million reduction to a previously established premium deficiency reserve, the medical care ratio for our Marketplace program would have been approximately 79% in the third quarter of 2017. The medical care ratio of the Marketplace program for the nine months ended September 30, 2017 was 84.1%, and generally consistent with the medical care ratio reported for the same period in 2016.

FINANCIAL PERFORMANCE BY STATE

~~The ongoing poor performance at our Florida, Illinois, New Mexico and Puerto Rico health plans in 2017 all contributed to our disappointing financial performance in the second quarter of 2017.~~ The following tables summarize member months, premium revenue, medical care costs, medical care ratio, and medical margin by state health plan for the periods indicated (PMPM amounts are in whole dollars; member months and other dollar amounts are in millions):

Health Plans Segment Financial Data — Non-Marketplace



	Three Months Ended September 30, 2017
	Member Months	Premium Revenue				Medical Care Costs				MCR		Medical Margin
	Member Months	Total		PMPM		Total		PMPM		MCR		Medical Margin
California	1.9	$	601	$	322.97	$	563	$	302.67	93.7	%	$	38
Florida	1.0	388		355.59		390		356.83		100.3		(2		)
Illinois	0.5	137		287.69		138		289.36		100.6		(1		)
Michigan	1.2	390		337.17		345		298.83		88.6		45
New Mexico	0.7	304		429.07		277		390.91		91.1		27
New York (3)	0.1	43		435.00		41		413.02		94.9		2
Ohio	0.9	549		560.06		483		492.61		88.0		66
Puerto Rico	1.0	191		202.59		159		168.25		83.1		32
South Carolina	0.3	113		332.48		101		297.74		89.6		12
Texas	0.7	541		778.50		506		728.19		93.5		35
Utah	0.2	89		318.98		71		254.99		79.9		18
Washington	2.3	612		276.73		522		236.11		85.3		90
Wisconsin	0.2	34		175.77		27		141.78		80.7		7
Other (4)	—	2		—		7		—		—		(5		)
	11.0	$	3,994	$	362.04	$	3,630	$	329.08	90.9	%	$	364



	Three Months Ended September 30, 2016
	Member Months	Premium Revenue				Medical Care Costs				MCR		Medical Margin
	Member Months	Total		PMPM		Total		PMPM		MCR		Medical Margin
California	1.8	$	575	$	310.64	$	493	$	266.81	85.9	%	$	82
Florida	1.0	335		323.98		317		305.71		94.4		18
Illinois	0.6	163		275.26		145		244.86		89.0		18
Michigan	1.2	385		335.34		335		291.69		87.0		50
New Mexico	0.7	323		451.06		293		409.24		90.7		30
New York (3)	0.1	32		427.40		30		403.71		94.5		2
Ohio	1.0	492		497.08		417		421.95		84.9		75
Puerto Rico	1.0	184		183.46		167		167.44		91.3		17
South Carolina	0.3	102		312.28		94		285.97		91.6		8
Texas	0.7	534		728.84		484		662.79		90.9		50
Utah	0.3	83		288.59		71		242.77		84.1		12
Washington	2.0	546		264.01		500		241.49		91.5		46
Wisconsin	0.3	35		166.82		26		125.86		75.4		9
Other (4)	—	3		—		24		—		—		(21		)
	11.0	$	3,792	$	343.68	$	3,396	$	307.84	89.6	%	$	396



	Nine Months Ended September 30, 2017
	Member Months	Premium Revenue				Medical Care Costs				MCR		Medical Margin
	Member Months	Total		PMPM		Total		PMPM		MCR		Medical Margin
California	5.6	$	1,771	$	316.83	$	1,586	$	283.82	89.6	%	$	185
Florida	3.2	1,132		347.41		1,112		341.15		98.2		20
Illinois	1.6	447		284.18		492		312.54		110.0		(45		)
Michigan	3.5	1,162		332.60		1,035		296.28		89.1		127
New Mexico	2.2	933		431.70		887		410.24		95.0		46
New York (3)	0.3	135		444.77		128		421.58		94.8		7
Ohio	2.9	1,598		541.56		1,434		486.02		89.7		164
Puerto Rico	2.9	553		190.99		513		177.01		92.7		40
South Carolina	1.0	329		325.43		301		298.43		91.7		28
Texas	2.1	1,592		760.76		1,468		701.32		92.2		124
Utah	0.8	267		315.35		219		258.64		82.0		48
Washington	6.7	1,835		275.60		1,603		240.83		87.4		232
Wisconsin	0.6	101		170.64		80		136.04		79.7		21
Other (4)	—	7		—		27		—		—		(20		)
	33.4	$	11,862	$	354.88	$	10,885	$	325.66	91.8	%	$	977



	Nine Months Ended September 30, 2016
	Member Months	Premium Revenue				Medical Care Costs				MCR		Medical Margin
	Member Months	Total		PMPM		Total		PMPM		MCR		Medical Margin
California	5.5	$	1,603	$	291.20	$	1,411	$	256.41	88.1	%	$	192
Florida	3.0	974		322.69		892		295.43		91.6		82
Illinois	1.8	466		266.11		414		236.39		88.8		52
Michigan	3.6	1,136		323.08		1,013		288.13		89.2		123
New Mexico	2.1	974		460.71		873		412.92		89.6		101
New York (3)	0.1	32		427.40		30		403.71		94.5		2
Ohio	2.9	1,444		489.63		1,286		435.99		89.0		158
Puerto Rico	3.0	535		176.44		516		170.46		96.6		19
South Carolina	0.9	273		288.93		232		245.13		84.8		41
Texas	2.2	1,650		744.71		1,466		662.01		88.9		184
Utah	0.9	255		293.33		221		253.79		86.5		34
Washington	6.0	1,576		261.23		1,431		237.20		90.8		145
Wisconsin	0.7	107		165.53		78		120.82		73.0		29
Other (4)	—	9		—		58		—		—		(49		)
	32.7	$	11,034	$	337.76	$	9,921	$	303.72	89.9	%	$	1,113

Health Plans Segment Financial Data — Marketplace


	Three Months Ended June 30, 2017															Three Months Ended September 30, 2017
	Member Months	Premium Revenue				Medical Care Costs				MCR			Medical Margin			Member Months			Premium Revenue								Medical Care Costs							MCR			Medical Margin
	Member Months	Total		PMPM		Total		PMPM					Medical Margin			Member Months		Total				PMPM				Total				PMPM				MCR			Medical Margin
California	2.4	$	679	$	294.09	$	606	$	262.34	MCR	89.2	%		$	73		0.3			$	88			$	208.19			$	63			$	147.87		71.0	%		$	25
Florida	2.0	649		318.21		687		337.39		106.0			(38		)	0.9			260				313.36				235				283.13			90.4			25
Illinois	0.5	149		289.51		174		336.76		116.3			(25		)
Michigan	1.2	406		325.38		368		295.06		90.7			38			—			14				212.08				10				150.24			70.8			4
New Mexico	0.8	352		435.34		334		411.83		94.6			18			0.1			29				383.58				20				269.28			70.2			9
New York ⁽¹⁾	0.1	46		457.96		45		442.16		96.5			1
Ohio	1.0	553		527.14		516		490.75		93.1			37			0.1			23				386.09				20				364.31			94.4			3
Puerto Rico	0.9	179		184.28		189		194.42		105.5			(10		)
South Carolina	0.4	111		326.57		102		304.14		93.1			9
Texas	1.4	701		495.93		602		426.41		86.0			99			0.7			183				291.14				109				172.70			59.3			74
Utah	0.5	130		258.10		129		255.00		98.8			1			0.3			49				241.65				31				155.13			64.2			18
Washington	2.4	662		279.21		595		251.16		90.0			67			0.1			42				327.40				33				256.52			78.3			9
Wisconsin	0.4	120		303.59		135		342.43		112.8			(15		)	0.2			95				527.17				70				385.65			73.2			25
Other ⁽²⁾	—	3		—		9		—		—			(6		)
Other ⁽³⁾																—			—				—				(1		)		—			—			1
	14.0	$	4,740	$	336.98	$	4,491	$	319.29	94.8	%		$	249		2.7			$	783			$	301.72			$	590			$	227.22		75.3	%		$	193



	Three Months Ended September 30, 2016
	Member Months	Premium Revenue				Medical Care Costs					MCR		Medical Margin
	Member Months	Total		PMPM		Total			PMPM		MCR		Medical Margin
California	0.3	$	37	$	185.04	$	30		$	140.10	75.7	%	$	7
Florida	0.6	159		253.16		145			231.78		91.6		14
Michigan	—	2		221.84		2			132.62		59.8		—
New Mexico	0.1	15		290.63		11			220.32		75.8		4
Ohio	—	9		307.24		7			215.01		70.0		2
Texas	0.4	63		189.85		41			121.06		63.8		22
Utah	0.1	23		142.10		33			208.48		146.7		(10		)
Washington	0.1	23		307.55		21			300.71		97.8		2
Wisconsin	0.1	68		375.60		64			357.60		95.2		4
Other (3)	—	—		—		(2		)	—		—		2
	1.7	$	399	$	238.86	$	352		$	210.38	88.1	%	$	47



	Nine Months Ended September 30, 2017
	Member Months	Premium Revenue				Medical Care Costs					MCR		Medical Margin
	Member Months	Total		PMPM		Total			PMPM		MCR		Medical Margin
California	1.2	$	241	$	193.33	$	156		$	124.32	64.3	%	$	85
Florida	2.8	821		296.14		758			273.55		92.4		63
Michigan	0.2	41		187.96		27			126.76		67.4		14
New Mexico	0.2	82		338.18		62			256.05		75.7		20
Ohio	0.2	68		365.35		64			346.93		95.0		4
Texas	2.1	517		252.32		351			171.57		68.0		166
Utah	0.7	135		209.43		135			209.13		99.9		—
Washington	0.4	123		315.95		128			327.51		103.7		(5		)
Wisconsin	0.6	275		469.44		260			443.41		94.5		15
Other (3)	—	—		—		(4		)	—		—		4
	8.4	$	2,303	$	276.27	$	1,937		$	232.31	84.1	%	$	366


	Three Months Ended June 30, 2016															Nine Months Ended September 30, 2016
	Member Months	Premium Revenue				Medical Care Costs				MCR			Medical Margin			Member Months			Premium Revenue								Medical Care Costs							MCR			Medical Margin
	Member Months	Total		PMPM		Total		PMPM					Medical Margin			Member Months		Total				PMPM				Total				PMPM				MCR			Medical Margin
California	2.0	$	554	$	268.95	$	493	$	239.63	MCR	89.1	%		$	61		0.6			$	104			$	177.57			$	74			$	124.29		70.0	%		$	30
Florida	1.8	464		273.90		426		251.69		91.9			38			2.0			473				237.37				409				205.37			86.5			64
Illinois	0.6	154		256.17		137		227.71		88.9			17
Michigan	1.2	369		312.18		334		282.86		90.6			35			—			7				213.35				5				138.37			64.9			2
New Mexico	0.8	342		451.72		305		403.52		89.3			37			0.2			42				264.76				32				201.73			76.2			10
New York ⁽¹⁾	—	—		—		—		—		—			—
Ohio	1.0	483		473.91		433		424.87		89.7			50			0.1			28				322.36				20				232.44			72.1			8
Puerto Rico	1.0	170		169.04		175		173.49		102.6			(5		)
South Carolina	0.3	87		277.22		71		226.27		81.6			16
Texas	1.1	635		571.14		499		448.23		78.5			136			1.1			202				196.45				133				128.97			65.7			69
Utah	0.5	110		240.26		106		233.12		97.0			4			0.4			75				160.33				91				194.78			121.5			(16		)
Washington	2.1	559		264.40		500		236.32		89.4			59			0.2			58				281.80				48				235.78			83.7			10
Wisconsin	0.4	99		244.88		96		235.88		96.3			3			0.5			192				357.80				200				373.94			104.5			(8		)
Other ⁽²⁾	—	3		—		19		—		—			(16		)
Other (3)																—			—				—				(3		)		—			—			3
	12.8	$	4,029	$	316.72	$	3,594	$	282.54	89.2	%		$	435		5.1			$	1,181			$	231.69			$	1,009			$	197.77		85.4	%		$	172

Health Plans Segment Financial Data — Total


	Six Months Ended June 30, 2017															Three Months Ended September 30, 2017
	Member Months	Premium Revenue				Medical Care Costs				MCR			Medical Margin			Member Months			Premium Revenue								Medical Care Costs							MCR			Medical Margin
	Member Months	Total		PMPM		Total		PMPM					Medical Margin			Member Months		Total				PMPM				Total				PMPM				MCR			Medical Margin
California	4.6	$	1,323	$	290.56	$	1,116	$	245.02	MCR	84.3	%		$	207		2.2			$	689			$	301.64			$	626			$	273.90		90.8	%		$	63
Florida	4.1	1,305		317.53		1,245		303.09		95.5			60			1.9			648				337.40				625				325.09			96.4			23
Illinois	1.1	310		282.66		354		322.63		114.1			(44		)	0.5			137				287.69				138				289.36			100.6			(1		)
Michigan	2.5	799		321.10		707		284.24		88.5			92			1.2			404				330.27				355				290.63			88.0			49
New Mexico	1.6	682		421.11		652		402.27		95.5			30			0.8			333				424.61				297				378.98			89.3			36
New York ⁽¹⁾	0.2	92		449.48		87		425.72		94.7			5			0.1			43				435.00				41				413.02			94.9			2
Ohio	2.1	1,094		521.57		995		473.95		90.9			99			1.0			572				550.75				503				485.61			88.2			69
Puerto Rico	1.9	362		185.40		354		181.24		97.8			8			1.0			191				202.59				159				168.25			83.1			32
South Carolina	0.7	216		321.85		200		298.79		92.8			16			0.3			113				332.48				101				297.74			89.6			12
Texas	2.8	1,385		491.46		1,204		427.48		87.0			181			1.4			724				546.57				615				463.83			84.9			109
Utah	1.0	264		261.42		252		248.77		95.2			12			0.5			138				286.39				102				212.91			74.3			36
Washington	4.7	1,304		276.99		1,176		249.79		90.2			128			2.4			654				279.52				555				237.23			84.9			99
Wisconsin	0.8	247		307.50		243		302.95		98.5			4			0.4			129				345.63				97				259.66			75.1			32
Other ⁽²⁾	—	5		—		17		—		—			(12		)	—			2				—				6				—			—			(4		)
	28.1	$	9,388	$	333.68	$	8,602	$	305.74	91.6	%		$	786		13.7			$	4,777			$	350.55			$	4,220			$	309.68		88.3	%		$	557


	Six Months Ended June 30, 2016															Three Months Ended September 30, 2016
	Member Months	Premium Revenue				Medical Care Costs				MCR			Medical Margin			Member Months			Premium Revenue								Medical Care Costs							MCR			Medical Margin
	Member Months	Total		PMPM		Total		PMPM					Medical Margin			Member Months		Total				PMPM				Total				PMPM				MCR			Medical Margin
California	4.0	$	1,095	$	271.14	$	962	$	238.30	MCR	87.9	%		$	133		2.1			$	612			$	298.05			$	523			$	254.11		85.3	%		$	89
Florida	3.4	953		284.53		839		250.58		88.1			114			1.6			494				297.24				462				277.79			93.5			32
Illinois	1.2	303		261.43		269		232.06		88.8			34			0.6			163				275.26				145				244.86			89.0			18
Michigan	2.4	756		316.18		681		285.13		90.2			75			1.2			387				334.25				337				290.16			86.8			50
New Mexico	1.5	678		450.62		601		399.17		88.6			77			0.8			338				440.12				304				396.35			90.1			34
New York ⁽¹⁾	—	—		—		—		—		—			—			0.1			32				427.40				30				403.71			94.5			2
Ohio	2.0	971		481.44		882		437.35		90.8			89			1.0			501				491.51				424				415.87			84.6			77
Puerto Rico	2.0	351		172.98		349		171.95		99.4			2			1.0			184				183.46				167				167.44			91.3			17
South Carolina	0.6	171		276.61		138		223.58		80.8			33			0.3			102				312.28				94				285.97			91.6			8
Texas	2.2	1,255		575.87		1,074		492.65		85.5			181			1.1			597				559.98				525				493.07			88.1			72
Utah	0.9	224		252.08		208		234.46		93.0			16			0.4			106				236.31				104				230.53			97.6			2
Washington	4.1	1,065		260.05		958		233.84		89.9			107			2.1			569				265.48				521				243.49			91.7			48
Wisconsin	0.8	196		247.57		188		236.92		95.7			8			0.4			103				262.32				90				231.86			88.4			13
Other ⁽²⁾	—	6		—		33		—		—			(27		)	—			3				—				22				—			—			(19		)
	25.1	$	8,024	$	320.17	$	7,182	$	286.57	89.5	%		$	842		12.7			$	4,191			$	329.88			$	3,748			$	295.01		89.4	%		$	443



	Nine Months Ended September 30, 2017
	Member Months	Premium Revenue				Medical Care Costs				MCR		Medical Margin
	Member Months	Total		PMPM		Total		PMPM		MCR		Medical Margin
California	6.8	$	2,012	$	294.26	$	1,742	$	254.67	86.5	%	$	270
Florida	6.0	1,953		323.86		1,870		310.09		95.7		83
Illinois	1.6	447		284.18		492		312.54		110.0		(45		)
Michigan	3.7	1,203		324.12		1,062		286.35		88.3		141
New Mexico	2.4	1,015		422.25		949		394.66		93.5		66
New York ⁽¹⁾	0.3	135		444.77		128		421.58		94.8		7
Ohio	3.1	1,666		531.17		1,498		477.81		90.0		168
Puerto Rico	2.9	553		190.99		513		177.01		92.7		40
South Carolina	1.0	329		325.43		301		298.43		91.7		28
Texas	4.2	2,109		509.09		1,819		439.11		86.3		290
Utah	1.5	402		269.48		354		237.20		88.0		48
Washington	7.1	1,958		277.83		1,731		245.62		88.4		227
Wisconsin	1.2	376		319.57		340		289.24		90.5		36
Other ⁽²⁾	—	7		—		23		—		—		(16		)
	41.8	$	14,165	$	339.19	$	12,822	$	307.03	90.5	%	$	1,343



	Nine Months Ended September 30, 2016
	Member Months	Premium Revenue				Medical Care Costs				MCR		Medical Margin
	Member Months	Total		PMPM		Total		PMPM		MCR		Medical Margin
California	6.1	$	1,707	$	280.21	$	1,485	$	243.64	86.9	%	$	222
Florida	5.0	1,447		288.74		1,301		259.60		89.9		146
Illinois	1.8	466		266.11		414		236.39		88.8		52
Michigan	3.6	1,143		322.08		1,018		286.77		89.0		125
New Mexico	2.3	1,016		447.07		905		398.22		89.1		111
New York ⁽¹⁾	0.1	32		427.40		30		403.71		94.5		2
Ohio	3.0	1,472		484.82		1,306		430.14		88.7		166
Puerto Rico	3.0	535		176.44		516		170.46		96.6		19
South Carolina	0.9	273		288.93		232		245.13		84.8		41
Texas	3.3	1,852		570.65		1,599		492.79		86.4		253
Utah	1.3	330		246.78		312		233.14		94.5		18
Washington	6.2	1,634		261.91		1,479		237.15		90.5		155
Wisconsin	1.2	299		252.45		278		235.25		93.2		21
Other ⁽²⁾	—	9		—		55		—		—		(46		)
	37.8	$	12,215	$	323.44	$	10,930	$	289.41	89.5	%	$	1,285


(1)	The New York health plan was acquired on August 1, 2016.


(2)	“Other” medical care costs include primarily medically related administrative costs of the parent company, and direct delivery costs.

MEDICAL CARE COSTS BY TYPE

The following table provides the details of consolidated medical care costs by category for the periods indicated (dollars in millions except PMPM amounts):


	Three Months Ended June 30,												Three Months Ended September 30,
	2017						2016						2017						2016
	Amount		PMPM		% of Total		Amount		PMPM		% of Total		Amount		PMPM		% of Total		Amount		PMPM		% of Total
Fee for service	$	3,348	$	238.04	74.5	%	$	2,620	$	206.01	72.9	%	$	3,196	$	234.51	75.8	%	$	2,799	$	220.29	74.7	%
Pharmacy	650		46.23		14.5		529		41.59		14.7		638		46.85		15.1		567		44.65		15.1
Capitation	356		25.29		7.9		304		23.87		8.5		342		25.07		8.1		302		23.83		8.1
Direct delivery	22		1.54		0.5		18		1.39		0.5		18		1.37		0.4		21		1.66		0.5
Other	115		8.19		2.6		123		9.68		3.4		26		1.88		0.6		59		4.58		1.6
	$	4,491	$	319.29	100.0	%	$	3,594	$	282.54	100.0	%	$	4,220	$	309.68	100.0	%	$	3,748	$	295.01	100.0	%


	Six Months Ended June 30,												Nine Months Ended September 30,
	2017						2016						2017						2016
	Amount		PMPM		% of Total		Amount		PMPM		% of Total		Amount		PMPM		% of Total		Amount		PMPM		% of Total
Fee for service	$	6,434	$	228.68	74.8	%	$	5,357	$	213.77	74.6	%	$	9,630	$	230.58	75.1	%	$	8,156	$	215.96	74.6	%
Pharmacy	1,266		45.00		14.7		1,054		42.05		14.7		1,904		45.60		14.8		1,621		42.93		14.8
Capitation	680		24.17		7.9		599		23.87		8.3		1,022		24.47		8.0		901		23.86		8.3
Direct delivery	44		1.56		0.5		34		1.36		0.5		62		1.50		0.5		55		1.46		0.5
Other	178		6.33		2.1		138		5.52		1.9		204		4.88		1.6		197		5.20		1.8
	$	8,602	$	305.74	100.0	%	$	7,182	$	286.57	100.0	%	$	12,822	$	307.03	100.0	%	$	10,930	$	289.41	100.0	%

PREMIUM TAXES

The premium tax ratio (premium tax expense as a percentage of premium revenue plus premium tax revenue) was ~~2.4%~~2.2% in the ~~second~~third quarter of 2017 compared with ~~2.6%~~2.9% in the ~~second~~third quarter of 2016 and 2.3% in the ~~six~~nine months

ended ~~June~~September 30, 2017, compared with ~~2.6%~~2.7% in the ~~six~~nine months ended ~~June~~September 30, 2016. This decline was primarily due to the temporary suspension of a Michigan HMO use tax effective January 1, 2017, which was partially offset by a higher California premium tax rate effective July 1, 2016, and significant revenue growth at our Florida health plan, which operates in a state with no premium tax.

HEALTH INSURER FEE (HIF) REVENUE AND EXPENSES

The Consolidated Appropriations Act of 2016 provided for a HIF moratorium in 2017. Therefore, there are no HIF revenues or expenses in 2017.

MOLINA MEDICAID SOLUTIONS

FINANCIAL OVERVIEW

The Molina Medicaid Solutions segment service margin for the ~~second~~third quarter of 2017 and 2016, and for the ~~six~~nine months ended ~~June~~September 30, 2017 and 2016, was insignificant.

As discussed further in Notes to Consolidated Financial Statements, Note 10, “Impairment Losses,” we recorded a goodwill impairment charge of $28 million, reported in our consolidated statements of operations as “Impairment losses.”

OTHER

The Other segment includes primarily our Pathways behavioral health and social services provider, and corporate amounts not allocated to other reportable segments.

Substantially all of Pathways’ revenue is derived from contracts with state or local government agencies and government intermediaries, the majority of which are negotiated fee-for-service arrangements. A significant number of these contracts allow the payer to terminate the contract immediately with or without cause.

FINANCIAL OVERVIEW

The Other segment service margin for the ~~second~~third quarter of 2017 and 2016, and for the ~~six~~nine months ended ~~June~~September 30, 2017 and 2016, was insignificant.

~~In the course of developing the Restructuring Plan, as~~As discussed further in Notes to Consolidated Financial Statements, Note ~~11, “Restructuring and Separation Costs,~~10, “Impairment Losses,” we determined that future benefits to be derived from Pathways, including integration with our health plans, would be less than previously anticipated. In addition, poorer than expected year-to-date operating results and lower projections of operating results for periods in the near term led us to conclude that a triggering event for an interim impairment analysis had occurred in the second quarter of ~~2017.~~

~~For the Other segment in total,~~2017 we recorded impairment ~~charges~~losses, primarily relating to our Pathways subsidiary, of $61 million for goodwill and $11 million for intangible assets, or $72 million in the ~~aggregate, reported in our consolidated statements~~aggregate. In the third quarter of ~~operations as “Impairment losses.”~~2017, we recorded a further goodwill impairment loss relating to the Pathways subsidiary, of $101 million.

OTHER CONSOLIDATED INFORMATION

GENERAL AND ADMINISTRATIVE EXPENSES

The G&A ratio was ~~8.1% in~~7.6% for both the ~~second~~third quarter of 2017 and 2016. The G&A ratio increased to ~~8.5%~~8.2% for the ~~six~~nine months ended ~~June~~September 30, 2017, compared with ~~7.9%~~7.8% for the ~~six~~nine months ended ~~June~~September 30, 2016. ~~The year~~Refer to ~~date G&A ratio increased over 2016 primarily due to costs associated with increased Marketplace enrollment~~discussion above, in ~~2017 and the reduction to revenue as a result of the 2017 Health Insurer Fee (HIF) moratorium.~~“Consolidated Results.”

DEPRECIATION AND AMORTIZATION

Depreciation and amortization, as a percentage of total revenue, was 0.7% and 0.8% in the ~~six~~nine months ended ~~June~~September 30, 2017 and ~~2016.~~2016, respectively.

IMPAIRMENT LOSSES

See Notes to Consolidated Financial Statements, Note 10, “Impairment Losses.”

RESTRUCTURING AND SEPARATION COSTS

See Notes to Consolidated Financial Statements, Note 11, “Restructuring and Separation Costs.”

INTEREST EXPENSE

Interest expense was ~~$27~~$32 million for the ~~second~~third quarter of 2017, compared with ~~$25~~$26 million for the ~~second~~third quarter of 2016. Interest expense ~~increased to $53~~was $85 million for the ~~six~~nine months ended ~~June~~September 30, 2017, ~~from $50~~compared with $76 million for the ~~six~~nine months ended ~~June~~September 30, 2016. Interest expense includes non-cash interest expense relating primarily to the amortization of the discount on convertible senior notes, which amounted to $8 million ~~and $7 million~~ for ~~second~~both the third quarter of 2017 and 2016, ~~respectively~~ and ~~$16~~$24 million and ~~$15~~$23 million in the ~~six~~nine months ended ~~June~~September 30, 2017 and 2016, respectively. We expect interest expense to continue to increase in future periods as a result of our recent $330 million offering of 4.875% ~~Notes.~~Notes, and borrowings under the Credit Facility. See further discussion in Notes to Consolidated Financial Statements, Note 7, “Debt.”

OTHER INCOME, NET

As described in Notes to Consolidated Financial Statements, Note 1, “Basis of Presentation,” in February 2017, we received an aggregate termination fee of $75 million for the ~~Terminated~~terminated Medicare Acquisition. This amount is reported in “Other income, net” in our consolidated statements of operations.

INCOME TAXES

The (benefit) provision for income taxes was recorded at an effective rate of ~~26.8%~~14.6% for the ~~second~~third quarter of 2017, compared with ~~59.8%~~54.0% for the ~~second~~third quarter of 2016, and an effective rate of ~~16.0%~~15.5% for the ~~six~~nine months ended ~~June~~September 30, 2017 compared with ~~60.7%~~58.0% for the ~~six~~nine months ended ~~June~~September 30, 2016. The significant change in the effective tax rate was primarily a result of pretax losses in 2017 combined with significant nondeductible expenses (primarily, ~~compensation~~separation costs and goodwill impairment) and the 2017 HIF moratorium as described above in “Health Plans—Health Insurer Fee (HIF) Revenue and Expenses.”

LIQUIDITY AND FINANCIAL CONDITION

INTRODUCTION

We manage our cash, investments, and capital structure to meet the short- and long-term obligations of our business while maintaining liquidity and financial flexibility. We forecast, analyze, and monitor our cash flows to enable prudent investment management and financing within the confines of our financial strategy.

A majority of the assets held by our Health Plans segment regulated subsidiaries is in the form of cash, cash equivalents, and investments. After considering expected cash flows from operating activities, we generally invest

cash of regulated subsidiaries that exceeds our expected short-term obligations in longer term, investment-grade, and marketable debt securities to improve our overall investment return. These investments are made pursuant to board-approved investment policies that conform to applicable state laws and regulations.

Our investments are classified as current assets, except for our held-to-maturity restricted investments, which are classified as non-current assets, and which are not included in the totals below. Our held-to-maturity restricted investments are invested principally in certificates of deposit and U.S. treasury securities.

Investment income increased to ~~$22~~$37 million for the ~~six~~nine months ended ~~June~~September 30, 2017, compared with ~~$16~~$25 million for the ~~six~~nine months ended ~~June~~September 30, 2016, primarily due to the increase in invested assets.

MARKET RISK

Our earnings and financial position are exposed to financial market risk relating to changes in interest rates, and the resulting impact on investment income and interest expense.

Substantially all of our investments and restricted investments are subject to interest rate risk and will decrease in value if market interest rates increase. Assuming a hypothetical and immediate 1% increase in market interest rates at ~~June~~September 30, 2017, the fair value of our fixed income investments would decrease by approximately ~~$27~~$25 million. Declines in interest rates over time will reduce our investment income.

For further information on fair value measurements and our investment portfolio, please refer to Notes to Consolidated Financial Statements, Note 4, “Fair Value Measurements,” and Note 5, “Investments.”

Borrowings under our Credit Facility bear interest based, at our election, on a base rate or an adjusted London Interbank Offered Rate (LIBOR), plus in each case the applicable margin. As of ~~June~~September 30, 2017, ~~no amounts were~~$300 million was outstanding under the Credit Facility.

LIQUIDITY

A condensed schedule of cash flows to facilitate our discussion of liquidity follows:


	Six Months Ended June 30,									Nine Months Ended September 30,
	2017			2016			Change			2017			2016			Change
	(In millions)									(In millions)
Net cash provided by operating activities	$	672		$	278		$	394		$	957		$	633		$	324
Net cash used in investing activities	(845		)	(273		)	(572		)	(474		)	(131		)	(343		)
Net cash provided by financing activities	333			11			322			632			11			621
Net increase in cash and cash equivalents	$	160		$	16		$	144		$	1,115		$	513		$	602

Operating Activities

Cash provided by operating activities increased ~~$394~~$324 million in the ~~six~~nine months ended ~~June~~September 30, 2017 compared with the ~~six~~nine months ended ~~June~~September 30, 2016. The change in net (loss) income, ~~plus~~partially offset by the effect of adjustments to reconcile net loss to net cash provided by operating activities, reduced cash provided by operating activities by ~~$195~~$169 million. This change was more than offset by the aggregate of the following changes:

Medical claims and benefits payable. In 2017, the change in medical claims and benefits payable increased cash flows from operations by $381 million, primarily due to additional accruals relating to increased membership in 2017.

Receivables and deferred revenue. In 2017, the aggregate change in receivables and deferred revenue increased cash flows from operations by ~~$470~~$395 million. Cash flows from operations in each period were impacted by the timing of premium revenues receipts. In general, state or federal payors may delay our premium payments, which we record as a receivable, or they may prepay the following month’s premium payment, which we record as deferred revenue. We typically receive capitation payments monthly; however, state or federal payors may decide to adjust their payment schedules which could positively or negatively impact our reported cash flows from operating activities in a any given period. In 2017, the year-over-year effect of the timing of premiums received at our California, Florida, Michigan, Ohio, Texas and Washington health plans positively impacted our cash flows from operating activities.

Amounts due government agencies. In 2017, the change in amounts due government agencies ~~increased cash flows from operations by $133 million, due primarily to additional accruals for ACA Marketplace risk transfer payments.~~

~~Accounts payable and accrued liabilities.~~ ~~In 2017, the change in accounts payable and accrued liabilities~~ decreased cash flows from operations by ~~$165 million. In 2016, accounts payable and accrued liabilities increased $147~~$381 million, primarily due to payments in the ~~HIF payable at June 30, 2016. As~~third quarter of ~~June 30, 2017, there is no comparable accrual because of the HIF moratorium.~~2017.

Investing Activities

Net cash used in investing activities increased ~~$572~~$343 million in the ~~six~~nine months ended ~~June~~September 30, 2017 compared with the ~~six~~nine months ended ~~June~~September 30, 2016, primarily due to higher purchases of investments, net of sales and maturities, in the current year.

Financing Activities

Net cash provided by financing activities increased ~~$322~~$621 million in the ~~six~~nine months ended ~~June~~September 30, 2017 compared with the ~~six~~nine months ended ~~June~~September 30, 2016, due to proceeds received from the 4.875% Notes ~~offering.~~offering and borrowings under the Credit Facility.

FINANCIAL CONDITION

We believe that our cash resources, combined with borrowing capacity available under our Credit Facility, as discussed further below in “~~Future~~“Future Sources and Uses of ~~Liquidity — Sources~~”Liquidity—Sources”, and internally generated funds will be sufficient to support costs under the Restructuring Plan, operations, regulatory requirements, and capital expenditures for at least the next 12 months.

On a consolidated basis, at ~~June~~September 30, 2017, our working capital was ~~$1,376~~$1,746 million, compared with $1,418 million at December 31, 2016. At ~~June~~September 30, 2017, our cash and investments amounted to ~~$5,616~~$6,166 million, compared with $4,689 million at December 31, 2016.

Debt Ratings. Our 5.375% Notes are rated “BB” by Standard & Poor’s, and ~~“Ba3”~~“B2” by Moody’s Investor Service, Inc. A significant downgrade in our ratings could adversely affect our borrowing capacity and costs.

Financial Covenants. Our Credit Facility contains customary non-financial and financial covenants, including a net leverage ratio and an interest coverage ~~ratio,~~ratio. Such ratios, presented below, are computed as ~~follows:~~defined by the terms of the Credit Facility.



Credit Facility Financial Covenants	Required Per Agreement	As of ~~June~~September 30, 2017

Net leverage ratio	<4.0x	~~3.3x~~2.5x
Interest coverage ratio	>3.5x	~~4.5x~~8.8x

In addition, the terms of our 4.875% Notes, 5.375% Notes and each of the 1.125% and 1.625% Convertible Notes contain cross-default provisions with the Credit Facility that are triggered upon an event of default under the Credit Facility, and when borrowings under the Credit Facility equal or exceed certain amounts as defined in the related indentures. As of ~~June~~September 30, 2017, we were in compliance with all covenants under the Credit Facility.

FUTURE SOURCES AND USES OF LIQUIDITY

Sources

Our Health Plans segment regulated subsidiaries generate significant cash flows from premium revenue, which we generally receive a short time before we pay for the related health care services. Such cash flows are our primary source of liquidity. Thus, any future decline in our profitability may have a negative impact on our liquidity.

Dividends from Subsidiaries. When available and as permitted by applicable regulations, cash in excess of the capital needs of our regulated health plans is generally paid in the form of dividends to our unregulated parent company to be used for general corporate purposes. In the ~~six~~nine months ended ~~June~~September 30, 2017 and 2016, we received ~~$120~~$100 million and $50 million, respectively, in dividends from our regulated health plan subsidiaries. We received $36 million in dividends from our unregulated subsidiaries in the nine months ended September 30, 2017. See further discussion in Notes to Consolidated Financial Statements, Note 13, “Commitments and Contingencies—Regulatory Capital Requirements and Dividend Restrictions.”

Restructuring Plan. ~~In total,~~As previously disclosed, we estimate that ~~the Restructuring Plan~~our restructuring plan will reduce annualized run-rate expenses by approximately $300 million to $400 million ~~upon its completion in late~~when completed by the end of 2018. We have already achieved $200 million of these run-rate reductions on an annualized basis, which ~~are a result of staff reductions,~~ will be in place by December 2017, and therefore will fully contribute to our 2018 results. Since the close of the second quarter, we have already achieved $55 million of our annualized run-rate reduction target as a result of staff reductions taken on July 27th.take full effect no later than January 1, 2018. All savings targets discussed in regards to the ~~Restructuring Plan~~restructuring plan represent annualized run-rate savings that we expect to achieve during the year following the indicated implementation date. ~~One-time~~We expect one-time costs associated with the ~~Restructuring Plan are expected~~restructuring plan to exceed the benefits realized in 2017 due to the upfront payment of implementation costs and the delayed benefit of full savings until the beginning of 2018. We expect the cost savings to reduce both “General and administrative expenses” and “Medical care costs” reported on our consolidated statements of operations.

The following table illustrates our estimates of run-rate savings associated with the ~~Restructuring Plan.~~restructuring plan. Such savings will be offset, through the end of 2018, by the costs noted below in “~~Future Sources and Uses of Liquidity—~~Uses.” Following 2018, the savings will be offset by approximately $20 million in run-rate expenses resulting from the implementation of ~~Restructuring Plan~~restructuring plan initiatives.



Estimated Savings Expected to be Realized by Reportable Segment	Health Plans	Other		Total
	(In millions)
General and administrative expenses	$50	$120 to $140		$170 to $190
Medical care costs	$110 to $190	$20		$130 to $210
	$160 to $240	$140 to $160	��	$300 to $400

Credit Facility. Refer to Notes to Consolidated Financial Statements, Note 7, “Debt,” for a detailed discussion of our Credit Facility. ~~We intend to borrow approximately $300 million under~~In August 2017, we drew against the Credit Facility in ~~early August 2017.~~the amount of $300 million.

4.875% Notes. The 4.875% Notes contain a limitation on the use of proceeds which required us to deposit the net proceeds from their issuance into a segregated deposit account, a current asset reported as “Restricted investments” in our consolidated balance sheets. See further discussion in Notes to Consolidated Financial Statements, Note 7, “Debt.”

Shelf Registration Statement. We have a shelf registration statement on file with the Securities and Exchange Commission to register an unlimited amount of any combination of debt or equity securities in one or more

offerings. Specific information regarding the terms and securities being offered will be provided at the time of an offering. Proceeds from future offerings are expected to be used for general corporate purposes, including, but not limited to, the repayment of debt, investments in or extensions of credit to our subsidiaries and the financing of possible acquisitions or business expansion.

Uses

Restructuring. We recorded $118 million of restructuring costs in the third quarter of 2017. Restructuring costs incurred to date consist primarily of termination benefits, write-offs of capitalized software due to the re-design of our core operating processes, restructuring of our direct delivery operations, and consulting fees. Under the restructuring plan, and also including separation costs to former executives, we have made cash payments of $24 million in the nine months ended September 30, 2017, and have accrued a liability of $65 million for future payments as of September 30, 2017.

We estimate that total pre-tax costs associated with the ~~Restructuring Plan~~restructuring plan will be approximately ~~$130~~$70 million to ~~$150~~$90 million ~~for~~in the ~~second half~~fourth quarter of 2017, with an additional $20 million to $40 million to be incurred in 2018. We currently estimate that a majority of the costs we expect to incur in the fourth quarter of 2017 will be settled in cash. The costs we incur associated with the ~~Restructuring Plan will be~~restructuring plan are reported in “Restructuring and separation costs” in our consolidated statements of operations.



Estimated Costs Expected to be Incurred by Reportable Segment	Health Plans	Molina Medicaid Solutions	Other	Total
	(In millions)
~~Separation costs–one-time benefit arrangement for a workforce reduction~~Termination benefits	$2530 to ~~$30~~$35	—	$3530 to ~~$40~~$35	$60 to $70
Other restructuring costs	$5540 to ~~$60~~$45	$~~55 to $60~~10	$110 to ~~$120~~$115	$160 to $170
	$8070 to ~~$90~~$80	$~~90 to $100~~10	$~~170~~140 to ~~$190~~$150	$220 to $240

Regulatory Capital Requirements and Dividend Restrictions. For more information on our regulatory capital requirements and dividend restrictions, refer to Notes to Consolidated Financial Statements, Note 13, “Commitments and Contingencies.”

States’ Budgets. From time to time, the states in which our health plans operate may experience financial difficulties, which could lead to delays in premium payments. Until July 4, 2017, the state of Illinois operated without a budget for its current fiscal year. As of ~~June~~September 30, 2017, our Illinois health plan served approximately 163,000 members, and recognized premium revenue of approximately ~~$310~~$447 million in the ~~first half of~~nine months ended September 30, 2017. As of ~~July 28,~~October 27, 2017, the state of Illinois owed us approximately ~~$116~~$220 million for certain March ~~April, May and June~~through September 2017 premiums.

Convertible Notes. We have outstanding $550 million aggregate principal amount of 1.125% cash convertible senior notes due January 15, 2020, unless earlier repurchased or converted. We refer to these notes as our 1.125% Convertible Notes. We also have outstanding $302 million aggregate principal amount of 1.625% convertible senior notes due August 14, 2044, unless earlier repurchased, redeemed, or converted. We refer to these notes as our 1.625% Convertible Notes. We refer to the 1.125% Convertible Notes and 1.625% Convertible Notes collectively as the Convertible Notes. The 1.125% Convertible Notes are convertible entirely tointo cash, and the 1.625% Convertible Notes are convertible partially tointo cash, each prior to their respective maturity dates under certain circumstances, one of which relates to the closing price of our common stock over a specified period. We refer to this conversion trigger as the stock price trigger.

For economic reasons related to the trading market for our Convertible Notes, we believe that the amount of the notes that may be converted over the next twelve months, if any, will not be significant. However, if the trading market for our Convertible Notes becomes closed or restricted due to market turmoil or other reasons such that the notes cannot be traded, or if the trading price of our Convertible Notes, which normally trade at a marginal premium to the underlying composite stock-and-interest economic value, no longer includes that marginal premium, holders of our Convertible Notes may elect to convert the notes to cash.

We currently have sufficient available cash, combined with borrowing capacity available under our Credit Facility, to fund such conversions.

CONTRACTUAL OBLIGATIONS

A summary of future obligations under our various contractual obligations and commitments as of December 31, 2016, was disclosed in our 2016 Annual Report on Form 10-K. ~~There~~

As described further in the Notes to Consolidated Financial Statements, Note 7 “Debt,” on June 6, 2017, we completed the private offering of $330 million aggregate principal amount of senior notes (4.875% Notes) due June 15, 2025. In addition, in the third quarter of 2017, we borrowed $300 million under our Credit Facility.

Other than the transactions described above, there were no material changes to this previously filed information outside the ordinary course of business during the ~~six~~nine months ended ~~June~~September 30, 2017. ~~For additional information regarding our long-term debt, including maturity dates, refer to Notes to Consolidated Financial Statements, Note 7, “Debt.”~~

CRITICAL ACCOUNTING ESTIMATES

When we prepare our consolidated financial statements, we use estimates and assumptions that may affect reported amounts and disclosures; actual results could differ from these estimates. Our critical accounting estimates relate to:

Health Plans segment medical claims and benefits payable. Refer to Notes to Consolidated Financial Statements, Note 6, “Medical Claims and Benefits Payable,” for a table that presents the components of the change in medical claims and benefits payable, and for additional information regarding the factors used to determine our changes in estimates for all periods presented in the accompanying consolidated financial statements. Other than the discussion as noted above, there have been no significant changes during the ~~six~~nine months ended ~~June~~September 30, 2017, to our disclosure reported in “Critical Accounting Estimates” in our Annual Report on Form 10-K for the year ended December 31, 2016.

Health Plans segment contractual provisions that may adjust or limit revenue or profit. For a discussion of this topic, including amounts recorded in our consolidated financial statements, refer to Notes to Consolidated Financial Statements, Note 2, “Significant Accounting Policies.”

Health Plans segment quality incentives. For a discussion of this topic, including amounts recorded in our consolidated financial statements, refer to Notes to Consolidated Financial Statements, Note 2, “Significant Accounting Policies.”

Molina Medicaid Solutions segment revenue and cost recognition. There have been no significant changes during the ~~six~~nine months ended ~~June~~September 30, 2017, to our disclosure reported in “Critical Accounting Estimates” in our Annual Report on Form 10-K for the year ended December 31, 2016.

Goodwill and intangible assets, net. Please refer to Notes to Consolidated Financial Statements, Note 2, “Significant Accounting Policies,” regarding our adoption of Accounting Standards Update No. 2017-04 as of June 30, 2017, which has simplified the test for goodwill impairment. WeIn the third quarter of 2017, we

recorded impairment charges of $129 million for goodwill, and in the second quarter of 2017, we recorded impairment charges of $61 million for goodwill and $11 million for intangible assets, or $72 million in the ~~aggregate,~~aggregate. Such charges are reported in the accompanying consolidated statements of operations as “Impairment losses.” At ~~June~~September 30, 2017, goodwill and intangible assets, net, represented approximately 8%6% of total assets and ~~44%~~37% of total stockholders’ equity, compared with 10% and 46%, respectively, at December 31, 2016. Refer to Notes to Consolidated Financial Statements, Note 10, “Impairment Losses.”

SUPPLEMENTAL INFORMATION

FINANCIAL MEASURES THAT SUPPLEMENT U.S. GAAP (NON-GAAP FINANCIAL MEASURES)

We use these non-GAAP financial measures as supplemental metrics in evaluating our financial performance, making financing and business decisions, and forecasting and planning for future periods. For these reasons, management believes such measures are useful supplemental measures to investors in comparing our performance to the performance of other public companies in the health care industry.

EBITDA*

We believe that earnings before interest, taxes, depreciation and amortization (EBITDA*) is helpful in assessing our ability to meet the cash demands of our operating units.


	Three Months Ended June 30,					Six Months Ended June 30,					Three Months Ended September 30,					Nine Months Ended September 30,
	2017			2016		2017			2016		2017			2016		2017			2016
	(In millions)										(In millions)
Net (loss) income	$	(230	)	$	33	$	(153	)	$	57	$	(97	)	$	42	$	(250	)	$	99
Adjustments:
Depreciation, and amortization of intangible assets and capitalized software	44			39		90			76		39			42		129			118
Interest expense	27			25		53			50		32			26		85			76
Income tax (benefit) expense	(84		)	47		(30		)	87		(16		)	50		(46		)	137
EBITDA*	$	(243	)	$	144	$	(40	)	$	270	$	(42	)	$	160	$	(82	)	$	430

ADJUSTED NET (LOSS) INCOME* AND ADJUSTED NET (LOSS) INCOME PER SHARE*

We believe that adjusted net (loss) income* and adjusted net (loss) income per diluted share* are helpful in assessing our financial performance exclusive of the non-cash impact of the amortization of purchased intangibles. The following table reconciles net income, which we believe to be the most comparable GAAP measure, to adjusted net (loss) income*.


	Three Months Ended June 30,												Six Months Ended June 30,												Three Months Ended September 30,												Nine Months Ended September 30,
	2017						2016						2017						2016						2017						2016						2017						2016
	(In millions, except diluted per-share amounts)																								(In millions, except diluted per-share amounts)
Net (loss) income	$	(230	)	$	(4.10	)	$	33		$	0.58		$	(153	)	$	(2.74	)	$	57		$	1.01		$	(97	)	$	(1.70	)	$	42		$	0.76		$	(250	)	$	(4.44	)	$	99		$	1.77
Adjustment:
Amortization of intangible assets	8			0.14			8			0.14			17			0.30			15			0.27			7			0.13			9			0.15			24			0.43			24			0.42
Income tax effect ⁽¹⁾	(3		)	(0.05		)	(3		)	(0.05		)	(6		)	(0.11		)	(5		)	(0.10		)	(3		)	(0.05		)	(4		)	(0.06		)	(9		)	(0.16		)	(9		)	(0.16		)
Amortization of intangible assets, net of tax effect	5			0.09			5			0.09			11			0.19			10			0.17			4			0.08			5			0.09			15			0.27			15			0.26
Adjusted net (loss) income*	$	(225	)	$	(4.01	)	$	38		$	0.67		$	(142	)	$	(2.55	)	$	67		$	1.18		$	(93	)	$	(1.62	)	$	47		$	0.85		$	(235	)	$	(4.17	)	$	114		$	2.03

__________________________


(1)	Income tax effect of adjustments calculated at the blended federal and state statutory tax rate of 37%.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures: Our management, with the participation of our interim chief executive officer and our chief financial officer, has concluded, based upon its evaluation as of the end of the period covered by this report, that the Company’s “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), were not effective at the reasonable assurance level because of the material weakness in our internal control over financial reporting described below. Notwithstanding the material weakness described below, management has concluded that our consolidated financial statements included in this interim report on Form 10-Q are fairly stated in all material

respects in accordance with U.S. generally accepted accounting principles (GAAP) for each of the periods presented herein.

Existence of a Material Weakness in Internal Control as of September 30, 2017

During the quarter ended September 30, 2017, we determined that a material weakness existed in our internal control over financial reporting relating to the design and operating effectiveness of our internal control for our interim goodwill impairment tests for our Pathways subsidiary and Molina Medicaid Solutions segment. Specifically, spreadsheet formula errors in our valuation model, and errors made in the calculation of impairment losses recorded, were not detected in our review procedures. As a result, we initially miscalculated the goodwill impairment in the three and nine months ended September 30, 2017. The impairment calculation was corrected prior to the filing of our unaudited consolidated financial statements as of and for the three and nine months ended September 30, 2017.

Remediation Plan for Material Weakness

We will implement a remediation plan developed to address this material weakness as of September 30, 2017. The remediation efforts we intend to implement include the enhancement of the design of the controls relating to the computation and rigor of review of the goodwill impairment tests. The enhancement of the controls will include the engagement of additional subject matter experts to support the valuation calculations, key assumptions and review process. In addition, we intend to develop new review controls that operate at an appropriate level of precision to prevent or detect potential material errors within the valuation calculations. We believe these measures will remediate the material weakness identified above and will strengthen our internal control over financial reporting for the computation of reporting unit fair value and potential consequent goodwill impairment. We are currently targeting to complete the implementation of the control enhancements during the fourth quarter of 2017. We will test the operating effectiveness of the control enhancements subsequent to implementation. If the remedial measures described above are insufficient to address the material weakness described above, or are not implemented timely, or additional deficiencies arise in the future, material misstatements in our interim or annual financial statements may occur in the future and could have the effects described in “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2016.

Changes in Internal Control Over Financial Reporting: Except as described above, management did not identify any change in our internal control over financial reporting during the fiscal quarter ended September 30, 2017 that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

Existence of a Material Weakness in Internal Control as of December 31, 2016

As disclosed in our Annual Report on Form 10-K for the year ended December 31, 2016, our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2016, based on the framework set forth in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.

We determined that a material weakness existed in our internal control over financial reporting relating to the operation of an element of our process for calculating the amount owed to California by our California health plan. More specifically, a Medicaid Expansion contract amendment executed in the fourth quarter of 2016 changed the medical loss ratio corridor formula and such amendment was not initially considered in determining the liability. As a result, we understated net income by $44 million for the year ended December 31, 2016, which was material to our consolidated results for the year ended December 31, 2016. This amount was corrected prior to the issuance of our consolidated financial statements as of and for the year ended December 31, 2016.

Because of this material weakness, management concluded that we did not maintain effective internal control over financial reporting as of December 31, 2016, based on criteria described in Internal Control - Integrated Framework (2013) issued by COSO.

Remediation Plan for Material Weakness

We are executing the remediation plan developed to address the material weakness reported as of December 31, 2016. The remediation efforts we have implemented include the development of robust protocols to ensure that the control, relating to the review of a contractual amendment affecting the computation of the Medicaid Expansion medical loss ratio corridor for our California health plan, is operating as designed. We believe these measures will remediate the material weakness identified above and will strengthen our internal control over financial reporting for the computation of our California Medicaid Expansion medical loss ratio corridor. We currently are targeting to complete the implementation of the control enhancements during 2017. We will test the ongoing operating effectiveness of the control enhancements subsequent to implementation, and consider the material weakness remediated after the applicable remedial control enhancements operate effectively for a sufficient period of time. If the remedial measures described above are insufficient to address the material weakness described above, or are not implemented timely, or additional deficiencies arise in the future, material misstatements in our interim or annual financial statements may occur in the future and could have the effects described in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2016.

~~Changes in Internal Control Over Financial Reporting:~~ Except as described above, management did not identify any change in our internal control over financial reporting during the fiscal quarter ended June 30, 2017 that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting.

LEGAL PROCEEDINGS

For information regarding legal proceedings, see Notes to Consolidated Financial Statements, Note 13, “Commitments and Contingencies.”

RISK FACTORS

Certain ~~risk factors~~risks may have a material adverse effect on our business, financial condition, cash flows, or results of operations, or stock price, and you should carefully consider ~~them.~~them before making an investment decision. In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2016 and our Quarterly ~~Report~~Reports on Form 10-Q for the ~~quarter~~quarters ended March 31, 2017 and June 30, 2017. The risk factors described ~~herein, and~~ in our 2016 Annual Report on Form 10-K and our Quarterly ~~Report~~Reports on Form 10-Q for the ~~quarter~~quarters ended March 31, 2017 and June 30, 2017, are not the only risks ~~facing our Company.~~that we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, cash flows, ~~or results of operations.~~

~~The Restructuring Plan may be disruptive, and we may not fully realize the anticipated benefits.~~

As discussed herein, we recently initiated a comprehensive Restructuring Plan to improve our profitability and operational efficiency. As part of that Restructuring Plan, we are re-designing core operating processes such as provider payment, utilization management, quality monitoring and improvement, and information technology. We are also streamlining our organization structure, including eliminating redundant layers of management. Finally, we are reducing our workforce by approximately 10%, or 1,400 full-time-equivalent positions. While we expect to benefit from the implementation of the Restructuring Plan, estimates of cost savings are inherently uncertain, and we may not be able to achieve these cost savings, or the expected operating efficiencies, within the periods we have projected, or at all. Restructuring activities may also result in a loss of continuity or institutional knowledge, inefficiency, depressed employee morale, and litigation during transitional periods and thereafter. Internal restructurings can also require a significant amount of time and focus from management and other employees, which may divert attention from our ongoing business operations. In addition, our implementation of the Restructuring Plan will require significant upfront costs. Our estimate of the costs necessary to achieve the cost savings we have identified may prove to be inaccurate, and any increase in such costs may affect our ability to achieve our anticipated cost savings within the period we have projected, or at all. If the Restructuring Plan fails to achieve all of the anticipated benefits, our business, financial condition, cash flows, or results of operations, ~~could be materially and adversely affected.~~ or stock price.

~~An impairment charge with respect to our recorded goodwill, or our finite-lived intangible assets, could have a material impact on our financial results.~~

As of December 31, 2016, the carrying amounts of goodwill and intangible assets, net, amounted to $620 million, and $140 million, respectively. Intangible assets are amortized generally on a straight-line basis over their estimated useful lives. For the reasons described below, as of June 30, 2017 the carrying amounts of goodwill and intangible assets, net, had declined to $559 million, and $112 million, respectively.

Goodwill represents the excess of the purchase price over the fair value of net assets acquired in business combinations. Goodwill is not amortized, but is subject to an annual impairment test. We are required to test at least annually for impairment, or more frequently if adverse events or changes in circumstances indicate that the asset may be impaired. We estimate the fair values of our reporting units using discounted cash flows.

Finite-lived, separately-identified intangible assets acquired in business combinations are assets that represent future expected benefits but lack physical substance (such as purchased contract rights and provider contracts). Following the identification of any potential impairment indicators, to determine whether an impairment exists, we would compare the carrying amount of a finite-lived intangible asset with the undiscounted cash flows that are expected to result from the use of the asset or related group of assets.

cash flow (including significant assumptions about operations, capital requirements and income taxes), long-term growth rates for determining terminal value beyond the discretely forecasted periods, and discount rates. If these assumptions differ from actual results, the outcome of our impairment tests could be adversely affected.

Based on our impairment tests, we recorded $72 million in non-cash impairment losses for goodwill and intangibles, primarily relating to our Pathways subsidiary. In the course of developing our restructuring and profitability improvement plan, we determined that future benefits to be derived from Pathways (including integration with our health plans) will be less than previously anticipated.

We cannot accurately predict the amount and timing of any future impairment charges. Additional events could occur that would cause us to further revise our estimates and assumptions used in analyzing the value of our goodwill, and intangible assets, net. For example, if the responsive bid of one or more of our health plans is not successful, we will lose our Medicaid contract in the applicable state or states. If such state health plans have recorded goodwill and intangible assets, net, the contract loss could result in a non-cash impairment charge. Additionally, if we are unable to procure new state MMIS contracts, the outcome of our goodwill impairment tests could be adversely affected and result in a non-cash impairment charge. Such a non-cash impairment charge could have a material adverse impact on our financial results.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

ISSUER PURCHASES OF EQUITY SECURITIES

Purchases of common stock made by us, or on our behalf during the quarter ended ~~June~~September 30, 2017, including shares withheld by us to satisfy our employees’ income tax obligations, are set forth below:

Total Number
of Shares
Purchased ⁽¹⁾

Average Price
Paid per Share

Total Number of Shares
Purchased as Part of
Publicly
Announced
Plans or
Programs

Approximate
Dollar Value
of Shares Authorized to Be Purchased Under the Plans or Programs
April 1 - April 30 12,389
$ 45.60
—
$ —
May 1 - May 31 223,661
$ 62.45
—
$ —
June 1 - June 30 —
$ —
—
$ —
Total 236,050
$ 61.56
—



	Total Number of Shares Purchased ⁽¹⁾	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares Authorized to Be Purchased Under the Plans or Programs
July 1 - July 31	665	$	69.18	—	$	—
August 1 - August 31	285	$	57.03	—	$	—
September 1 - September 30	—	$	—	—	$	—
Total	950	$	65.54	—

_______________________


(1)	During the three months ended ~~June~~September 30, 2017, we withheld ~~236,050~~950 shares of common stock under our 2011 Equity Incentive Plan to settle employee income tax obligations.

INDEX TO EXHIBITS



Exhibit No.		Title

~~4.1~~ 10.1		~~Indenture,~~Employment Agreement, dated ~~June 6,~~October 9, 2017, by and ~~among~~between Molina Healthcare, Inc.~~, the Guarantors party thereto~~ and ~~U.S. Bank National Association, as Trustee. Filed as Exhibit 1.1 to registrant’s Form 8-K filed June 6, 2017.~~

~~4.2~~		~~Form of 4.875% Senior Notes due 2025. Included in Exhibit 1.1 to registrant’s Form 8-K filed June 6, 2017.~~

~~4.3~~		~~Form of Guarantees in connection with Indenture dated June 6, 2017. Included in Exhibit 1.1 to registrant’s Form 8-K filed June 6, 2017.~~

~~10.1~~		Third Amendment to Credit Agreement dated as of May 19, 2017, by and among Molina Healthcare, Inc., the Guarantors party thereto, the Lenders party thereto and SunTrust Bank, in its capacities as Administrative Agent, Issuing Bank and Swingline Lender.Joseph M. Zubretsky. Filed as Exhibit 10.1 to registrant’s Form 8-K filed ~~May 22,~~October 10, 2017.

~~10.2~~31.1		~~Amended and Restated Employment Agreement with Joseph W. White, dated June 5, 2017, and effective as of May 2, 2017. Filed as Exhibit 10.1 to registrant’s Form 8-K filed June 7, 2017.~~

~~10.3~~		~~Waiver and Release Agreement, dated June 24, 2017, by and between J. Mario Molina and Molina Healthcare, Inc. Filed as Exhibit 10. 1 to registrant’s Form 8-K filed June 28, 2017.~~

~~10.4~~		~~Waiver and Release Agreement, dated June 26, 2017, by and between John Molina and Molina Healthcare, Inc. Filed as Exhibit 10.2 to registrant’s Form 8-K filed June 28, 2017.~~

~~10.5~~		Purchase Agreement, dated May 22, 2017, by and among the Company, the guarantors party thereto and SunTrust Robinson Humphrey, Inc., as representative of the several initial purchasers named in Schedule A thereto. Filed as Exhibit 1.1 to registrant’s Form 8-K filed May 23, 2017.

~~31.1~~		Certification of Interim Chief Executive Officer and Chief Financial Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended.

32.1		Certification of Interim Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS		XBRL Taxonomy Instance Document.

101.SCH		XBRL Taxonomy Extension Schema Document.

101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB		XBRL Taxonomy Extension Label Linkbase Document.

101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



		MOLINA HEALTHCARE, INC.
		(Registrant)

Dated:	~~August 2,~~November 5, 2017	/s/ JOSEPH W. WHITE
		Joseph W. White
		Interim Chief Executive Officer
		(Principal Executive Officer)

Dated:	~~August 2,~~November 5, 2017	/s/ JOSEPH W. WHITE
		Joseph W. White
		Chief Financial Officer and Treasurer
		(Principal Financial Officer)

Molina Healthcare, Inc. 2017 Form 10-Q | 6267



	Separation Costs–Former Executives			Other Restructuring Costs			Total
	(In millions)
Accrued restructuring and separation costs as of December 31, 2016	$	—		$	—		$	—
Costs recognized	35			8			43
Cash payments	(1		)	(2		)	(3		)
Other adjustments–acceleration of share-based compensation	(23		)	—			(23		)
Accrued restructuring and separation costs as of June 30, 2017	$	11		$	6		$	17